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Primary sensory neurons and their associated tissues are important targets for 
neurochemical study.  Disorders of the sensory system, including chronic pain and itch, 
can be extremely devastating and, in many cases, difficult to treat. Part of the difficulty of 
treating such disorders is the limited understanding that we have for the multitude of 
chemical players involved in the communication of sensation within the nervous system. 
One particular set of intercellular signaling molecules, neuropeptides, are known to play 
an important role in the transmission of pain and itch signals from the peripheral system 
to the spinal cord. While we have a basic understanding of how many of these molecules 
are involved in sensory transmission, further knowledge would be benefited by more 
accurate and spatially relevant sampling and characterization. However, due to their low 
concentration and dynamic presence, the detection of these molecules in a non-targeted 
manner poses a unique challenge.  
This dissertation focuses on characterizing the peptides found in the tissues of the 
sensory system and released from primary sensory neurons in culture as well as 
improving culturing and stimulation paradigms for future research. We have worked to 
characterize the full content of peptides within the dorsal root ganglia, which houses the 
cell bodies of the primary sensory neurons, as well as other related tissues of rat and to 
detect changes in the peptide content of the dorsal root ganglia and dorsal horn upon 
generation of an itch model in mice. We have also designed a physiologically relevant 
sensory neuron culturing system and made strides toward spatially relevant release 
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Introduction and Document Overview 
 
1.1 Introduction 
The primary sensory system is an important target for neurochemical study. Mainly 
composed of primary sensory neurons, their support cells, and the nerves and ganglia in 
which they reside, the system also interfaces with skin, viscera, and the spinal cord. 
Disorders of the sensory system, including chronic pain and chronic itch, can be 
extremely devastating and, in many cases, difficult to treat. Part of the difficulty of treating 
such disorders is the limit of understanding that we have for the multitude of chemical 
players involved in such disorders. Although there is much knowledge about chemical 
and molecular players involved in pain and itch sensation, most studies focus on one or 
a few molecular players rather than take a global approach.  As a lab with expertise in 
untargeted mass spectrometric techniques and a focus on neurochemistry, we have the 
unique opportunity to add more comprehensive information about the chemical players 
involved in the primary sensory system to the knowledge pool. While there are various 
molecules we could study using mass spectrometry, we decided to focus on 
neuropeptides. 
1.2 Neuropeptides and the Primary Sensory System 
Neuropeptides are short chains of amino acids processed from protein precursors which 
are synthesized in, stored by and released from neurons in order to influence a wide 
range of physiological systems through neurotransmission, neuromodulation, and 
hormonal affects [1, 2].  How the neuropeptide affects the function of the cell upon which 
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it is acting depends largely on the pattern of receptors for that peptide, their distance from 
the releasing neurons, and the various other signaling molecules involved. In relation to 
pain and itch (considered noxious stimuli), there are a variety of neuropeptides that are 
released in response to many distinct stimuli types, locations, and intensities while acting 
to either attenuate or facilitate the perception of pain or itch.  
Not surprisingly, the sensation and transmission of noxious stimuli within the body is quite 
complex [3]. Very basically, sensory information about the state of the periphery is 
brought in to the central nervous system (CNS) through the dorsal root and trigeminal 
ganglia. These ganglia are made up of sensory neurons categorized by what type of 
stimuli they are receiving. Of the four types of sensation, mechanosensation, 
proprioception, thermosensation, and nociception, it is the neurons that respond to 
noxious stimuli (including temperature, pH, and concentration of circulating factors that 
signal tissue damage) with which we are interested. Particularly, the Aδ and C nociceptive 
neurons are those carrying such information [3].  
The primary afferents of these sensory neurons terminate on second order neurons in the 
dorsal horn of the spinal cord, either superficially in laminae I and II or deeper in laminae 
IV and V.  The axons of the second order neurons then move through the lateral 
spinothalamic tract to innervate the medial and posterolateral thalamus or the anterior 
spinothalamic tract to innervate the lateral thalamus, respectively [3]. From the thalamus, 
signals are sent to both the primary and secondary somatosensory cortex as well as 
emotional processing centers [3]. The nervous system also modulates pain perception 
through a descending pathway consisting of white matter tracts moving through the 
periaqueductal gray (PAG) to the rostro-ventral medulla (RVM) and down through the 
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spinal cord [3, 4]. Neuropeptides are involved at all signaling levels of perception, from 
sensation transmission to descending modulatory mechanisms to mediation of emotional 
responses. 
1.2.1 Neuropeptides and Pain  
The roles of various neuropeptides in pain transmission are quite complex and can 
depend on the location, amount, and receptor type available as well as the responses of 
other neuropeptides in the system. A basic overview is that there are peptides such as 
substance P (SP), calcitonin gene related peptide (CGRP), somatostatin (STT), and 
vasoactive intestinal peptide (VIP) which facilitate hyperalgesia and sensitization upon 
noxious stimuli at the primary afferent or spinal cord levels [2, 3, 5, 6]. Then, there are 
peptides such as the opioids (enkephalins, endorphins, dynorphin), galanin, and 
neuropeptide Y (NPY), which induce analgesia by blocking the mechanisms of pain 
response induced by SP and CGRP [2, 5, 7, 8]. Further, there are peptides such as 
cholecystokinin (CCK), which reduce opioid action and, therefore, increase 
hypersensitivity, as well as those like neurotensin (NT), which act on various peptidergic 
systems and induce seemingly contradictory results [4, 5]. 
The major hyperalgesic peptide is SP.  A member of the tachykinin family, along with 
neuropeptides neurokinin A and neurokinin B, SP was first isolated in 1931, although its 
sensory transmission properties were not discovered until the 1950s and it was not 
sequenced until 1971. The tachykinins have multiple functions, with pain being one. SP 
and neurokinin A are the two tachykinins that are mostly expressed in sensory neurons 
[2]. SP is found in many primary sensory neurons, in both their peripheral and central 
terminals. It is also found throughout the CNS, including the superficial lamina (I and II) 
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of the spinal cord [5]. It is believed that the excitatory effects of tachykinins can be 
assumed by VIP in the spinal cord, especially following axotomy [2, 5].  
SP and another sensitizing peptide, CGRP, are colocalized in C-fiber primary sensory 
neurons and are released upon sensation of noxious stimuli, both centrally and 
peripherally. Both peptides induce slow, long-lasting depolarizations of the neurons on 
which they act, as well as inflammatory responses from blood vessels and immune cells 
in the vicinity of the injury [2, 3, 5]. Taken together, these changes induce hyperalgesia 
and sensitization of the affected neurons. The edema and inflammation caused by the 
release of SP and GCRP into the tissue may spread to the innervated areas of nearby 
nociceptors, acting as noxious stimuli, causing further release of SP and CGRP and 
continuing the cycle [2, 3]. In addition to the sensitizing effects of SP, CGRP, and VIP, 
STT is also included in the group of hyperalgesia inducing peptides. This peptide 
responds to noxious stimuli of a thermal nature and is not found to coexist with SP, 
although it can coexist with CGRP [6]. 
Opioid peptides, or endogenous opiates, were discovered in the mid-1970s in a search 
for morphine analogs [2]. Since then, much work has been done to understand their 
function in the hope to find a good alternative to morphine for the treatment of pain. 
Opioids are located both peripherally and centrally and influence both ascending and 
descending pain pathways through three main receptor types: µ (MOPR), δ (DOPR), and 
κ (KOPR), [2, 8]. Centrally, the opioids act either by hyperpolarizing their target cells via 
increased potassium ion currents or through neuromodulation and inhibition of 
neurotransmitter release [2, 8]. However, peripherally, they have been shown to inhibit 
calcium ion currents, blocking the excitability of peripheral neurons, induction of action 
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potentials, and release of neuropeptides like SP and CGRP [8]. To further confirm this 
action, Beaudry et al. have found that both MOPR and DOPRs are located on peptidergic 
primary neurons and that their agonists block SP release [7]. This inhibition of afferent 
neuron excitation upon injury reduces the inflammatory effects of SP and CGRP release 
mentioned previously. During chronic pain, opioid peptide receptors are upregulated in 
the spinal cord and periphery [7] and β-endorphin, met-enkephalin and dynorphin-A are 
upregulated in immune cells [8], indicating an effort by the body to control or alleviate the 
pain.  
1.2.2 Neuropeptides and Itch 
Chronic itch (pruritis) occurs in 25.5% of the population, with incidence increasing with 
age [9]. Associated with various medical conditions such as liver disease, asthma, 
eczema, elevated body mass index, and increased anxiety, pruritis can be quite 
debilitating [9, 10]. The neural processing pathways and the molecules involved in itch 
sensation are still being elucidated. Recent studies have shown that Mas-related G-
protein coupled receptors (Mrgprs) [11], specifically MrgprA3, MrgprC11, and MrgprD, 
are important players in the itch pathway [12, 13]. Although immunohistochemical, 
morphological, and functional characterizations of these neurons provide useful 
information, the in-depth characterization of the cell signaling molecules found within and 
released from these cells would improve our understanding of itch sensation. Performing 
peptidomics to determine their chemical content provides critical details on the 
contribution of these cells to itch. These studies can also provide clues into the functional 
relationship between individual molecules and the cells in which they are found. 
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The involvement of neuropeptides in pain response is extensive and we expect to find 
similar complexity in the neuropeptides involved in itch sensation. Already, SP [14], 
endothelin-1 [15, 16], neuromedin B (NMB) [17], CGRP [18], natriuretic peptide B and the 
kappa-opioid dynorphin [19] are implicated in the itch response. The transcriptomic data 
shows that natriuretic polypeptide b, agouti-related peptide, neurotensin, and adenylate 
cyclase activating polypeptide 1 are upregulated in itch sensing neurons [20]. However, 
we know that increased expression does not always translate to increased peptide 
content [21, 22]; therefore, it is important to characterize the changes in peptide content 
in the itch sensing neurons in the peripheral nervous system. 
1.3 Modeling Physiological Systems 
1.3.1 Primary Cell Culture 
One basic way to model a physiological system is through cell culture. Culturing cells 
taken directly from an organism, or primary cells, is an important tool for studying the 
chemical content of a cell type. Primary sensory neuron cell culture has provided 
important information about the growth conditions, chemical needs and susceptibilities, 
and expression changes within these cells under certain perturbations. In fact, much of 
the information already discussed about the neurochemical content of sensory neurons 
was elucidated using cell culture systems.  
While less reproducible than cell culture lines, primary cell culture is more relevant to the 
model organism from which the cells are obtained, and is therefore considered more 
physiologically relevant, especially when characterizing the behavior and chemical 
content of the cells. Additionally, while there is a cell line created out of a rat 
pheochromocytoma, PC12, that can be induced to differentiate into a neuron-like cells 
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[23, 24] and hybrid cell lines have been created for neuronal study [25, 26], neurons are 
inherently a non-dividing and non-passageable cell type. Therefore, we used primary cells 
isolated from the DRG of adult and neonatal rats as well as mice for our studies. 
Additionally, we did not purify the cultures to maintain only neuronal cells but instead 
included glial and support cells isolated from the ganglion within our culture system. 
1.3.2 Microfluidic Devices 
Microfluidic devices, as they are used in biology, are devices that rely on the physics of 
small-volume fluidics to create controlled microenvironments for cell growth [27, 28]. 
Generally created out of poly-dimethylsiloxane (PDMS), which is a breathable, non-toxic, 
optically clear material, microfluidic devices have been particularly useful in the study of 
neurobiology and neurochemistry [28, 29]. The use of microfluidic devices for 
compartmentalized growth [30], spatially controlled experiments [30, 31], specific 
chemical damage [31], chemical gradient generation [32, 33], controlled sampling [27], 
and even peptide quantitation [34] has been demonstrated by our group and others.  
For this project, the rationale for using microfluidic devices is three-fold. First, by using a 
device with cell culture compartments separated by microchannels, a more 
physiologically relevant structural growth scheme was provided for the sensory neurons. 
Second, by decreasing the amount of media used within the culture system, the relative 
concentration of the analytes was increased. Third, the structural specificity provided by 
the microfluidic device allows for the collection of sample in a spatially relevant manner, 
important for analysis of neuropeptide release from both the “skin” the “spinal cord” side 




1.3.3 Other Systems 
There are other types of systems that can be used to create physiologically relevant ex 
vivo or in vitro models, upon which this document will touch briefly. Generally, the systems 
include tools that can be used for creating viable three-dimensional cultures such as 
scaffolds [35, 36], fibers [37], hydrogels [36, 38], spheroid cultures [39-41] and more. This 
area of research is exciting and innovative and would be a good direction to take this 
project in the future. 
1.4 Detection and Characterization of Neuropeptide Content and Release using 
Mass Spectrometry 
Often, information about the expected neuropeptide content of a cell type or tissue is 
provided using transcriptomics and/or immunological techniques, such as 
radioimmunoassay [42, 43], enzyme-linked immunosorbent assay (ELISA) [44], or 
immunohistochemistry [45]. While transcriptomic information about the expected peptide 
content of a sample can be helpful, the genetic expression profile does not always 
translate to actual peptide content as there are various regulated processing, 
transportation, storage, and release steps involved in the peptide response to 
perturbations [2, 21, 22]. On the other hand, immune-based assays are targeted to one 
or a few pre-selected analytes and, therefore, miss much of the chemically complex 
information that can be gained from an untargeted detection approach. Also, chemical 
identification of a molecule cannot be performed using immune-based assays. Therefore, 
untargeted mass spectrometric analysis is an important tool for studying the complex 
peptide dynamics within a system. 
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Peptidomics, or the characterization of the peptides within a system with the goal of 
creating a list of peptide players, is an important first step toward understanding the 
multitude of peptide players within a sample and how they might change upon specific 
perturbations. Performing peptidomics on a whole tissue, such as the DRG, both allows 
us to gain insight into chemical content changes within the system and provides a 
comprehensive list of peptide masses to which we can match the masses from our 
released peptide samples.  
Peptide release studies, on the other hand, provide details on the release of certain 
peptides from individual cell types or locations. For example, CGRP and/or SP release 
from sensory neurons [42-44] and intact dorsal root and trigeminal ganglia [45] has been 
demonstrated, whereas ghrelin is released from gastrointestinal tract cells [46] and insulin 
and insulin-like peptides are released from cells of the liver, pancreas, and brain [47]. For 
full characterization of the peptide content, however, mass spectrometry (MS) is most 
helpful due to its ability to detect low amounts of analyte without pre-selection and has 
been used to characterize peptide release [27, 34].  
For the purposes of this project, two types of MS are particularly useful, especially when 
used together. Whole tissue measurements are performed using a liquid chromatography 
electrospray ionization (LC-ESI) MS and the cell release measurements as well as some 
single cell peptide measurements are performed using matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) MS. Combining these two methods is 
particularly effective in allowing us to assign identifications to signals detected in the 
release samples by MALDI-TOF through matching the masses with those of peptides 
characterized by LC-ESI MS, which is more efficient at identification but needs larger 
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amounts of sample [48-50]. More information about MS and its uses can be found in 
Chapters 2 and 3. 
1.5 Overview of Document 
Within this dissertation document, you will find the descriptions and results of my projects, 
as well as ideas for additional work. The document begins with two reviews followed by 
my co-first authored research publication, outlining the peptidomics and secretomics of 
the primary sensory system. The rest of the dissertation follows with the work resulting 
from that project.  
Chapter 2 consists of a published review (EG Tillmaand and JV Sweedler 
Microphysiological Systems June 2018, Volume 2, Issue 4, doi: 
10.21037/mps.2018.05.01) outlining the importance of using microphysiological systems 
in neurochemistry and ways that mass spectrometric analysis can be applied to such 
systems.  
Chapter 3 consists of an excerpt from a published review (Ong TH, Tillmaand EG, 
Makurath M, Rubakhin SS, Sweedler JV. Biochim Biophys Acta. 2015 Jul;1854(7):732-
40. doi: 10.1016/j.bbapap.2015.01.008). This chapter discusses methods for sampling 
from the extracellular environment for components of cellular release. 
Chapter 4 consists of published work outlining the peptidomics of the DRG and how it 
compares to the peptidomics of the dorsal and ventral root spinal nerves, as well as 
measurements of peptide release from all aspects of the intact sensory system, DRG 
explants, and cultured DRG cells ( Tillmaand EG, Yang N, Croushore-Kindt C, Rubakhin 
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SS, Sweedler JV. JASMS. December 2015, Volume 26, Issue 12, pp 2051–2061, doi: 
10.1007/S13361-015-1256-1). 
Chapter 5 consists of work performed toward understanding the peptide changes that 
occur in sensory system related tissues within models of itch-producing disorders. 
Chapter 6 outlines the work performed in the search for SP released from primary sensory 
neurons in our culture system. 
Chapter 7 is an investigation into a more physiologically relevant cell culture system and 
includes forays into extracellular matrix protein stamping, explant cultures, co-cultures, 
and the use of microfluidic devices. This chapter also includes a new primary sensory 
microphysiological system design that could be useful for future studies of the primary 
sensory system and which utilizes a cell culture material built off of work published with 
the Nuzzo group (Badea A, McCracken JM, Tillmaand EG, Kandel ME, Oraham AW, 
Mevis MB, Rubakhin SS, Popescu G, Sweedler JV, Nuzzo RG. ACS Appl Mater 
Interfaces. 2017 Sep 13;9(36):30318-30328. doi: 10.1021/acsami.7b06742). 
Chapter 8 consists of work toward characterizing primary sensory neuron subtypes. This 
project was born out of the complexity of the subtypes of neurons located in the DRG and 
an improved methodology for single cell peptide profiling developed in the lab.  
In summary, my dissertation research has focused on characterizing neuropeptides found 
in and released from primary sensory neurons. After characterizing the peptides found 
within both cultured DRG cells and intact DRG tissue (Chapter 4), I worked to 1) apply 
our current knowledge of the sensory system and ability to characterize peptides to 
explore the peptide changes in itch models (Chapter 5); 2) verify the validity of our cell 
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culture and stimulation paradigm (Chapter 6), and 3) develop a physiologically relevant 
system in which to culture the cells and perform more specific stimulations (Chapter 7).  
1.6 Conclusions 
Neuropeptides can be found in all aspects of sensory transmission, from sensation to 
facilitation to inhibition. They dynamically respond to injury and inflammation through a 
complex set of interactions to help central processing centers gain information about and 
respond to possible harm. However, sometimes this intricate system gets disrupted and 
chronic pain and itch symptoms prevail, even without obvious injury or after healing from 
injury appears to have occurred. Elucidating how the sensory system is affected on a 
molecular level and what the overall neuropeptide profiles of the system look like both in 
healthy and diseased states is an important area of study for gaining a better 
understanding of these chronic disorders. This document discusses the work performed 
toward accomplishing this goal.  
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Integrating Mass Spectrometry with Microphysiological Systems for 
Improved Neurochemical Studies 
2.1 Notes 
This chapter is an invited review co-authored by Emily Tillmaand and Jonathan Sweedler 
published in Microphysiological Systems (June 2018, Volume 2, Issue 4, doi: 
10.21037/mps.2018.05.01) and reproduced with permission. This work was supported by 
the National Institute on Drug Abuse under Award No. P30 DA018310, and the National 
Science Foundation under Award Nos. CHE-16-06791 and DGE- 17-35252. The content 
is solely the responsibility of the authors and does not necessarily represent the official 
views of the funding agencies. 
2.2 Abstract 
Microphysiological systems, often referred to as "organs-on-chips", are in vitro platforms 
designed to model the spatial, chemical, structural, and physiological elements of in vivo 
cellular environments. They enhance the evaluation of complex engineered biological 
systems and are a step between traditional cell culture and in vivo experimentation. As 
neurochemists and measurement scientists studying the molecules involved in 
intercellular communication in the nervous system, we focus here on recent advances in 
neuroscience using microneurological systems and their potential to interface with mass 
spectrometry. We discuss a number of examples – microfluidic devices, spheroid 
cultures, hydrogels, scaffolds, and fibers – highlighting those that would benefit from mass 





Until recently, scientists interested in examining cellular-level physiological responses to 
perturbations have used cultures of cells grown on dishes within a supportive medium. 
These cell cultures reduce the complexity of the living system to a level at which we can 
reasonably begin to understand the chemical, physical, and spatial influences affecting 
cellular behavior. Over the years, reductionist research strategies have advanced a broad 
range of scientific fields. However, it has become obvious that cells behave differently in 
cell culture than they do within the body. These differences may lead researchers to 
incorrect conclusions, with potentially detrimental effects on health-related research and 
scientific advancement. To solve this issue, and to gain more accurate insight into the 
physiologically based relationships among cells within the body, there has been a push 
to develop relevant microsystems in which cells are arranged in layers, cultured with other 
cells, or seeded onto various structures and geometries or within materials that more 
closely mimic those found in the body [1-3]. The goals are twofold: to improve the 
relevance of the cell culturing environment through the introduction of chemicals, 
gradients, cell types, and three-dimensional (3D) structures, and to create platforms that 
allow spatial and temporal specificity during sampling. 
While there are many benefits to using reductionist techniques, they tend to limit the 
amount of information that can be gained from cells removed from the context in which 
they develop, especially when investigating dynamic cellular processes. The actual 
chemical messengers, such as proteins, peptides, and metabolites, rather than genetic 
differences, are often the markers for change within a biological system. Traditional cell 
culture systems cannot reproduce the variety of chemical, structural, and mechanical 
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interactions that influence cellular growth, development, communication, and 
susceptibility to disorders and pathologies [3,4]. In fact, cells cultured in three-dimensional 
(3D) systems have been shown to have different morphologies [2,5], biochemical 
gradients and content [2,5-11], electrophysiological profiles (12), and responses to 
chemotherapeutics and irradiation [7,8,13], as compared to two- dimensional (2D) cell 
cultures. 
The relevance of the cell culture environment to the physiological system being 
investigated is particularly important in the study of neurochemistry. The nervous system 
uses a variety of intercellular messengers, including classical neurotransmitters, 
neuropeptides, metabolites, lipids, and even gases, to communicate important 
information throughout the body [14]. These intercellular signaling molecules and the 
information conveyed through them vary depending on their locations, amounts, and 
degradation pathways within the nervous system [15-17]. Additionally, the presence of 
these molecules and the responses of the target cells also depend on the surrounding 
environment, changing along with external perturbations [18,19], the presence or 
absence of other chemical or spatial signals [20,21], and the structural or geometric 
patterns in a growth system [22]. The goal of some neurochemical research is to gain a 
more complete understanding of the molecules involved in both healthy and diseased 
neurological systems in order to create better therapeutics for neurological disorders. This 
is a tall order that involves dynamic monitoring of intracellular, extracellular, signaling, and 
non-signaling molecules. We need to be able to understand specific relationships 
between perturbations in the nervous system and the resulting information flow via 
chemical messengers in both a temporal and spatial manner. While this is a daunting 
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task, the development of in vitro environments that mimic in vivo environments can bring 
us a step closer to realizing this goal. 
In addition to creating physiologically relevant environments through the introduction of 
chemicals, gradients, and 3D structures or geometries within a system, 
microphysiological devices also improve the ability to spatially and temporally define 
physical sampling steps within an experiment [23-28]. This is vital to neurochemical 
investigation in which the specific spatial localization of perturbations allows the study of 
neural damage and repair, release of cell signaling molecules, and even the specific cells 
involved in the response. Similarly, temporal relationships between cellular insults and 
signal transmission are central to gaining an improved understanding of the influence 
these molecules have on information transfer. 
As with advancements in any field, moving toward the development of more 
physiologically relevant microsystems comes with a need to apply emerging analytical 
toolsets to the new cell culture platforms and importantly, improve the chemical 
characterization of microneurological systems. Often, characterization of 
microphysiological systems is performed using morphological or physiological methods 
that provide little chemical information. In some cases, immunological techniques are 
used to target a few preselected molecules for analysis, and/or gene expression profiles 
are determined. However, to be confident that a newly developed system appropriately 
represents the chemical make-up of the tissue being mimicked, in-depth chemical 
characterization should be employed. After all, while transcriptomics provides information 
on the potential of a system, it is the molecules present that dictate its actual physiological 
state. The improved physiological relevance of microphysiological systems should lead 
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to important new discoveries, particularly in the neurochemical or cell signaling realm; 
therefore, we should be focusing on ways to better interrogate the systems for unique 
chemical information. Mass spectrometry (MS) is the single most information-rich 
chemical characterization technique available, allowing the detection and identification of 
a wide range of molecules in both a targeted and an untargeted manner. We expect that 
through the coupling of MS to these microsystems, we will be able to better characterize 
the dynamic chemical make-up of the cells involved, as well as the molecular messengers 
used in the information flow between cellular groups, both under physiological conditions 
and as a result of external perturbations. 
For those of us who are more accustomed to thinking about reductionist approaches, 
there are multiple examples of biologists and engineers working together to create 
innovative platforms for the development of relevant microsystems. In this review, we 
broadly outline MS approaches of relevance to these systems, discuss the use of 
microfluidic devices, spheroids, hydrogels, and scaffolds to create appropriate 
microsystems, and lastly, highlight the exciting progress and future potential of interfacing 
these approaches to obtain improved chemical information for advancing neurochemical 
research. 
2.4 MS as a chemical characterization approach 
2.4.1 Introduction to MS 
While the goal of many microsystem designs is to create an improved cell culturing 
environment and enhanced sampling system defined by the spatial and temporal aspects 
of the device, eventually the samples need to be characterized. If a preselected set of 
molecules are of interest, specific molecular or affinity probes can be used. However, for 
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more untargeted or less well-characterized analytes, MS remains the most chemically 
information-rich approach because it allows the characterization and quantitation of 
thousands of molecular species, usually without analyte preselection. There are a 
multitude of modern mass spectrometric techniques to choose from. The method selected 
depends on several factors, including sample properties and instrumental parameters, 
which together determine the compounds detected. Although detailed descriptions of all 
of the available hardware and operating procedures for MS are not within the scope of 
this review, a brief overview is provided to aid in the selection of the appropriate MS-
based characterization approach. Critical considerations include choosing the 
appropriate sample conditioning method (including a separation step), vaporization and 
ionization approaches, and mass analyzer. Readers interested in learning more about 
MS are referred to several recent reviews [29-31].  
2.4.2 Analysis of Small Sample Volumes via MS 
Researchers interested in characterizing a wide range of molecules using a 
microphysiological system, either present in the environment surrounding the system or 
found within the system, can efficiently couple the device to a mass spectrometer for the 
collection of small-volume samples. The most straightforward microphysiological systems 
for this type of sampling are those with direct inlet and outlet ports and/or direct access 
to the material that will be collected. The next steps depend on the desired information 
and the MS instrumentation available. The two most commonly employed MS 
characterization approaches are matrix-assisted laser desorption/ionization (MALDI) and 




For a dried sample, MALDI MS is a fast method that involves incorporating the analyte 
with an organic matrix, which when irradiated with a laser, vaporizes and ionizes the 
sample [34,37]. MALDI measurements have been performed from cellular releasates, 
individual cells, and even directly from tissue slices [38]. Basically, if a small-volume 
(picoliter to microliter) sample is dried and the appropriate chemical matrix added, efficient 
detection of a broad range of molecules becomes possible. MALDI has a high salt 
tolerance and requires nanoliter-volume samples [27,32,39], making it useful for the 
analysis of small-volume biological samples, and even individual cells [40-42]. 
Additionally, for precious samples, the recovery of leftover analytes is possible [43]. 
Sample conditioning can enhance MALDI analysis, for example, by desalting and 
concentration via solid phase extraction (SPE) [44,45]. After extraction, analytes of 
interest can be eluted onto a target plate (by SPE) or dried down, reconstituted in an 
appropriate amount of solvent, and then placed on the plate (by SPE or liquid extraction). 
In both situations, the sample is plated, mixed with a matrix, and dried in preparation for 
mass spectrometric analysis. 
While MALDI has a number of advantages, an issue with MALDI is that interfacing it to 
separations, such as liquid chromatography (LC) or capillary electrophoresis (CE), adds 
complexity as compared to ionization techniques that use samples in solution. Without a 
preseparation with MALDI, ion suppression can occur; thus, there are applications that 
are better suited to LC-ESI-MS. In ESI-MS, a liquid sample is sprayed from a capillary via 
the application of an electrical potential to the end of the capillary [35,46]. The 
electrosprayed droplets are desolvated and vaporized, resulting in multiply charged ions, 
which are introduced into the mass analyzer [35]. ESI works well as a characterization 
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approach after a liquid phase separation, and so often follows CE [44,47] or LC [48]. The 
figures of merit of ESI make it particularly useful for the identification and quantitation of 
a wide range of analytes within complex samples [35]. Researchers interested in 
evaluating the analytes within a microphysiological system would benefit from using these 
techniques, although other MS ionization approaches are available [49]. 
2.4.3 Analysis of Large, Complex Samples via MS 
At the other end of the volume scale, a number of metabolomics or proteomics 
approaches have evolved that take larger-volume samples, condition them, and then 
perform an LC separation followed by high performance MS, including tandem MS 
(MS/MS) [48]. As mentioned in the previous section, LC separation is important for the 
reduction of the chemical complexity and dynamic range inherent to biological samples, 
with the goal of separating the samples into chemically simpler fractions. LC-MS/MS 
generally requires larger amounts of sample than direct MALDI MS profiling, but is useful 
for peptidomic, metabolomic, or proteomic studies, as well as for quantitation.  
2.4.4 Direct Imaging of Samples using MS 
MALDI MS is increasingly being employed for spatially resolved tissue characterization 
in an approach termed mass spectrometry imaging (MSI). In a common embodiment of 
MSI, a laser samples the surface in a raster pattern, and at each point, a mass spectrum 
is acquired. The resulting spectra are then used to create images of ion intensity at 
specific locations within the sample [50]. Instead of interrogating a tissue with MS, one 
can use MSI to spatially measure the compounds within a microfabricated device [51,52]. 
Additionally, because microphysiological systems can contain complex 3D structures, 
these structures can be removed from the systems and processed as though they are 
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tissue through a series of stabilization and sectioning steps prior to analysis [38,53]. MSI 
can be performed using MALDI MS, secondary ion MS (SIMS), or desorption electrospray 
ionization MS [54]. Each ionization method has distinct figures of merit as well as different 
sample preparation requirements [50,54]. No matter which detection modality is used, 
MSI is useful for researchers who want to obtain spatial information on the molecular 
content of their samples, both for basic study and to determine how well the model 
systems compare to the in vivo systems they are mimicking. 
2.4.5 Single Cell Measurements via MS 
Understanding the chemical differences between cells is an important objective for 
neurochemical studies. Various MS methods can be employed for single cell 
measurements, including the aforementioned MALDI, ESI, and SIMS [38]. Single cells 
contain femtoliters to picoliters of liquid and, therefore, measurements require high 
sensitivity and low limits of detection. Additionally, cells contain a complex mixture of 
molecules, requiring wide analyte coverage and ionization of intact biomolecules. Direct 
sampling from specific cells using liquid microjunction extraction for CE-ESI MS [55], and 
direct MALDI profiling of individual cells sorted into microarrays [42] or dissociated onto 
slides [56], are methods that are currently employed to interrogate the chemical content 
of single cells, offering great potential for integration with microphysiological systems. 
2.4.6 Sample Preparation Considerations for MS  
We outline the factors that impact the selection of the sampling and measurement 
protocols. For sampling from a microphysiological system, we expect that cells, tissues, 
and extracellular fluid would be the most common types of samples obtained. The sample 
preparation method selected for an MS analysis depends on a variety of factors, including 
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the tissue or model the sample came from, the chemical information the researcher is 
trying to obtain, the instrument that will be used for the analysis, and how much time will 
elapse between sample preparation and analysis. In addition, a decision has to be made 
about whether it is important to the experimental objective to maintain structural, 
temporal, or location information, a choice that impacts how samples are collected and 
prepared. 
For example, if chemical characterization of different cellular populations is the goal, cells 
could be detached (or “dissected”) from the device, suspended in a liquid media, 
stabilized with glycerol or a similar substance so that they remain intact during a drying 
step, washed to remove the excess glycerol, dried under a nitrogen stream, and coated 
with a matrix in preparation for MALDI. Alternatively, the cells could be individually 
prepared for intracellular media sampling by CE. These sampling approaches would allow 
for intracellular chemical characterization of different cell types, but would not maintain 
the spatial relationships of the cells. In studies where retaining spatially relevant chemical 
information is more important, the system could instead be frozen, cryogenically sliced, 
and then the slices deposited onto MALDI target plates, stabilized, and covered in a matrix 
for MS analysis. This type of sample preparation maintains intra- and extracellular areas 
as well as spatial relationships between cells. On the other hand, if analysis of cell 
signaling molecules is the goal, extracellular fluid can be collected from the device in a 
temporal or spatially relevant manner, subjected to sample clean-up via SPE to remove 
the salts from the extracellular media, and then either mixed with a MALDI matrix or 
prepared with an appropriate solvent for LC-MS analysis. Finally, if the goal is to 
understand as much chemical information as possible about a certain system (at the 
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expense of spatial detail), the cells or tissues can be homogenized, the proteins, peptides, 
small molecules, or metabolites extracted, and the sample subjected to an SPE step and 
then prepared for LC prior to MS analysis. These are just a few examples of sample 
preparation methods that can be employed prior to MS analysis. 
2.5 Microphysiological Systems for Neurobiological Studies 
2.5.1 Microfluidic Systems 
Microfluidic systems for biological applications rely on the physics and chemistry of small- 
volume materials and fluidic interactions to create intricate platforms for the growth, 
analysis, and manipulation of cells on a micrometer scale [57]. When applied to biological 
systems, they have historically been used as a reductionist approach for single cell 
analyses, cell sorting, and compartmentalization; however, microfluidic devices are also 
used to create microphysiological systems [28,58-63]. The small-volume fluidic 
interactions allow for the formation of specially controlled microenvironments that can 
mimic the physiological milieu and structural relationships, while also providing 
opportunities for sampling, observation, and introduction of specific perturbations [64,65]. 
These attributes allow for the design of studies to provide a more accurate picture of 
cellular responses. Our research group has had success using microfluidic devices to 
sample from cells for mass spectrometric analysis [27,51,52,66], and we look forward to 
performing similar experiments utilizing microphysiological systems. 
The move away from traditional cell culture, and toward constructing a microphysiological 
system, can be facilitated by co-culturing different cell types in a microfluidic device. While 
many fields use the technology, the intricate relationships between neurons and their 
surrounding cells make co-culture for neurochemical investigation particularly relevant. 
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First and foremost, neurons and glia are interdependent, and studies have shown that 
neurons behave differently with and without glia in their cultures [28,58,61]. Therefore, 
both types of cells need to be incorporated into the microfluidic device. For example, 
Majumdar et al. [58] demonstrated a microfluidic device for the co-culture of primary 
hippocampal neurons and glial cells in which both types of cells were not physically in 
contact, but glial-conditioned media flowed directly from glia to the neurons. They found 
that the neurons co-cultured with glia had greater transfection efficiency than traditional 
cell cultures, demonstrating the influence of glial presence in the culture system. Li and 
Ren et al. [28] developed a microfluidic device in which axonal injury can be studied within 
a system that includes both neurons and glia. They showed that their system allowed re-
growth of axons when glial cells were introduced to the culture system. With the 
understanding that neuronal/glial interactions are important to study, Park et al. [59] kept 
the neuronal cell bodies physically separated but allowed interaction between 
oligodendrocytes and the neuronal axons for the study of myelination (Figure 2.1a). 
With microphysiological systems, it is important that target tissues are incorporated within 
the model system. Neurons develop, regenerate, and function based on their 
surroundings [14,28,67], supporting the need for functional neuromuscular junctions, 
sensory systems, and brain structures that can be studied. The neuromuscular junction 
consists of the spinal motor neurons, the cell bodies of which can be found in the ventral 
horn of the spinal cord, and their target organ, muscle. Recently, Kim et al. [60] 
demonstrated a microsystem in which spinal cord and muscle tissues were placed within 
channels located on opposing sides of the device, connected with microchannels. Axons 
from the spinal cord grew across the microchannels and innervated the muscle tissue. 
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Southam et al. [61] described the use of a commercial dual-chamber microfluidic device 
to culture motor neurons and glia on one side of the device and myocytes on the other. 
They demonstrated the growth of motor neuron axons through the microchannels and 
into the myotube side (Figure 2.1b) and discussed the importance of glial cells and target 
muscle tissue for the health of the motor neuron in culture.  
Perhaps more exciting is a system reported by the Perlson group [20,62], created using 
a slice of an embryonic spinal cord explant co-cultured with myotubes. In this microfluidic 
device, the axons from the motor neurons grew through grooves to innervate the 
myotubes. One of their studies revealed not only that the axons grew more quickly 
through the grooves when the myoblasts were present than when they are not, but also 
that the growth factor glial cell line-derived neurotrophic factor only promoted axonal 
growth and innervation when applied to the axons of the motor neurons, and not when 
applied to the cell body [20]. This outcome is a demonstration of the important new 
biochemical insights that can be gained from using microphysiological systems. 
For the peripheral sensory nervous system, there is one more “side” to account for within 
the microsystem. The cell body of the sensory neuron resides in the sensory ganglia 
located near the spinal cord [68,69]. Sensory neurons only have one outgrowth, an axon, 
which bifurcates, extending one branch to the skin or viscera and the other into the dorsal 
horn of the spinal cord. Using a popular microfluidic device design [70], Tsantoulas and 
colleagues [71] created the sensory ending side of this system by culturing primary 
sensory neurons from the dorsal root ganglion on one side of a two-chamber device and 
keratinocytes on the other, to resemble the skin (Figure 2.1c). They demonstrated the 
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successful innervation of the keratinocytes by the sensory neurons, as have other groups 
using separate two-compartment co-culture models [21,72,73].  
As for the side of the sensory neuron axon that extends to the spinal cord, a few groups 
have demonstrated functional cultures between neurons of the dorsal horn of the spinal 
cord and those of the dorsal root ganglia [74-77]. Additionally, Johnson et al. [26] 
demonstrated a 3D printed tri-chamber device within which they successfully cultured 
peripheral sensory neurons, Schwann cells and epithelial cells or hippocampal neurons, 
and peripheral sensory neurons and Schwann cells, in chambers 1, 2, and 3, respectively. 
While hippocampal neurons are not secondary sensory neurons, this is one of the only 
successful central nervous system (CNS) to peripheral nervous system micro-cultures. 
Unfortunately, there are not yet any microsystems that can mimic the peripheral sensory 
system from skin to spinal cord; however, work is being done in this area. 
Another important area of research for the design of microfluidic systems includes the re-
creation of the blood-brain barrier (BBB). Understanding the BBB is important to the study 
of neurochemistry because it is the gatekeeper of the brain, regulating which molecules 
are allowed to enter the CNS from the blood. Various groups have designed devices that 
mimic certain aspects of the BBB [78]. Two similar device designs, one created by the 
Sundaram group [63] and another by the Wikswo group [79], successfully modeled the 
neurovascular unit by using multiple layers, including a neural chamber, and a vascular 
chamber, and a microporous membrane separating the two (Figure 2.1d) [79]. The neural 
chamber consisted of a physiologically relevant mix of neurons and support cells such as 
astrocytes and microglia (for the Sundaram group) or pericytes (for the Wikswo group), 
and the vascular chamber contained microvascular endothelial cells. Both groups 
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reported the ability to include flow within their design, which is imperative for the 
appropriate function of endothelial cells and for mimicking vasculature. Importantly, the 
Wikswo group seeded the neurons and astrocytes within a collagen gel in the “brain” 
chamber to even better model brain structure, and also used human-derived cells within 
their system. Another noteworthy BBB device design is the Ingber group’s [80] use of a 
microfluidic system to create a cylindrical lumen inside a microchannel within which 
astrocytes, pericytes, and endothelial cells were seeded. This work is important because 
it incorporates the appropriate shape of the blood vessels (cylinder), unlike the 
rectangular channels used by other groups, and also removes the membrane barrier 
between cell types, allowing them to be in physical contact with each other, as they are 
in the body. 
2.5.2 Spheroids 
Another way to create physiologically relevant nervous system models is to place neurons 
and their support cells together and let them assemble or aggregate on their own. The 
creation of spheroid cultures relies on the cells’ natural proclivity to aggregate, rather than 
on the strict design of structural, chemical, and physical relationships used by microfluidic 
devices. A spheroid culture is both a way to create a more natural state for the cells under 
investigation, and a means to study the natural formation of cellular aggregates. Spheroid 
culturing technique is based on keeping cells in suspension so that they will join together, 
rather than settle on and form attachments to a particular cell-culturing surface. 
Aggregation can be encouraged through stirring, suspending cells in drops from a 
surface, and plating in non-adhesive microarray wells. Once aggregated, the spheroids 
tend to demonstrate behavior similar to that found in vivo, such as exhibiting the proper 
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intercellular relationships or secreting their own extracellular matrix (ECM) [81]. The 
creation of spheroids and spheroid networks can be useful in the study of intercellular 
interactions and cell-ECM interactions [81], toxicity studies [82], and even neural tissue 
transplantation [83]. 
As an example of spheroid neural cultures being used to study disease, the Lee lab [82] 
built an in vitro model of Alzheimer’s disease using a network of neurospheres to model 
the layered cellular architecture of the brain’s cortex for the study of beta amyloid 
exposure. Building on this model, Park et. al. [84] incorporated the constant fluid flow that 
is found in physiological systems. The potential implications for their model in the study 
of Alzheimer’s disease is important to note, particularly for understanding the response 
of the tissue to beta amyloid exposure as well as for toxicity studies for potential 
therapeutics. 
Another group, led by Kato-Negishi [83], created a network of neurospheres that could 
then be used as a stamp and placed directly onto cortical tissue. While it is unclear how 
this type of brain tissue would actually function once incorporated into a living system, the 
researchers did show integration between the stamped neurosphere network and the 
whole brain tissue; which is a promising step forward for future cognitive interface work. 
Recently, Pamies et al. [85] demonstrated the creation of a reproducible, size-controlled 
spheroid culture using induced pluripotent stem cells differentiated into a structure 
containing appropriately localized neurons, oligodendrocytes, and astrocytes as well as 
neural sub- populations, such as those expressing dopamine, glutamine, or GABA. Since 
they are derived from human cells and are uniformly made, these brain microphysiological 
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systems, as they are called, could be particularly useful for pharmaceutical or 
neurotoxicity studies. 
Spheroids can also be used within microfluidic devices. For example, the Kamm group 
[65] described an enhanced co-culture microfluidic device in which a 3D system was 
created that allows for the culture of both a neurosphere on one side of the device and a 
muscle strip on the other, with axonal outgrowth from the neurosphere connecting to the 
muscle strip (Figure 2.2a). 
2.5.3 Hydrogels, Fibers, and Other Soft Materials 
The incorporation of various soft materials into cell culture is another way that 
physiological relevance can be enhanced in an engineered system. Hydrogels are highly 
absorbent cross-linked polymers that can be used in a variety of ways. They are 
particularly useful in the creation of microphysiological systems because they are 
mechanically and structurally similar to tissue and extracellular matrix [86]. This similarity 
to natural tissue, along with a level of porosity that allows for cell migration and nutrient 
and waste exchange, combine to make hydrogels prime materials for creating 3D cell 
cultures [86,87]. 
Lozano et al. [87] designed a system in which a peptide-modified polymer, gellan gum- 
RGD, was mixed with cortical cells and printed using a 3D printing system into a layered 
structure similar to that of the cortex (Figure 2.2b). The authors found that the neurons 
and glia were functional, and that synapses formed between printed layers. Therefore, 
they succeeded in creating a 3D cortex-like structure with viable neurons encapsulated 
inside, demonstrating appropriate growth and neurite extension. Similarly, Kunze et al. 
[88] used microfluidic devices to create alginate-enriched agarose hydrogel layers that 
34 
 
model the structure of the cortex (Figure 2.2c). The layers can also be perfused with 
nutrients and/or stimulated with chemicals in a gradient and are oriented in the x-y plane 
for facile microscope imaging. While their system used only one type of cell, the 
importance of their device in correctly simulating the external environment for the neurons 
of the cortex cannot be dismissed. 
Huval et al. [89] created a 3D system in which a dorsal root ganglion explant was placed 
within a dual hydrogel encasement system that had been treated with both growth- 
permissive and growth-inhibiting molecules so that the axonal outgrowth followed a 
discrete nerve-like path. This “microscale organotypic model of peripheral nerve tissue,” 
as they described it, has a similar structure and electrophysiological function as nerve 
tissue, making it a potential model for use in pharmaceutical and clinical testing. It would 
also be an interesting model for injury, regeneration, and neurochemical studies. 
A multi-layered microfluidic device to fabricate hydrogel constructs that mimic the 
structure of a nerve bundle, with its complex cross-sectional morphology, was designed 
by Kitagawa et al. [90]. They used sodium alginate to create stiff microfibers that were 
encapsulated by a softer hydrogel, which included sodium alginate mixed with propylene 
glycol alginate. The PC12 neuron-like cells grew along the stiff microfibers, creating an 
analogous structure to an axon surrounded by Schwann cells. 
Hydrogels influence cellular responses based on the stiffness, charge, and other 
properties of the gel [91]. While the ability to tune a hydrogel creates unlimited 
opportunities for creating various environments within which cells can grow, the sensitivity 
of the cells to the hydrogel environment may not make them optimal for the study of in 
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vivo responses, unless a hydrogel that has the exact same parameters as the cell’s 
environment is used.  
Daud et al. [92] created nerve-like structures via electrospun polycaprolactone fiber 
scaffolds. These fibers, aligned in groups and created with uniform diameters of 1, 5, or 
8 µm, allowed for the alignment of neurons, axons, and Schwann cells as they grew in 
culture. They used primary cell cultures and dorsal root ganglion explants, observing that 
neuronal and Schwann cell co-localization occurred for the dorsal root ganglion cultures, 
but not as extensively for the neuronal and primary Schwann cell cultures. The authors 
also studied primary neuron cell culture versus neuron/Schwann cell co-culture and 
concluded that axons extended further in the presence of Schwann cells than without. 
Both results add evidence to the importance of using an in vitro system that is the most 
closely related to the in vivo system. 
A microscaffold system made from an array of microfabricated towers is the solution that 
Rowe et al. [93] designed to overcome the lack of appropriate circulation to 3D cell 
cultures. They used hollow microtowers that contained multiple fluid ports, which allowed 
for media and nutrient perfusion throughout the device. This group also included 
electrodes on the towers for ease of future electrophysiological stimulation or recording. 
As a final example, Zou et al. [94] used self-assembly of the peptide IKVAV to create a 
scaffold of nanofibers, which were useful for guiding the outgrowth of axons from a dorsal 





2.6 Applying MS to Microphysiological Systems for Chemical Analyses 
The microsystems highlighted in this review were initially developed to improve scientists’ 
ability to model in vivo physiology with many used to perform morphological, 
immunofluorescent, and even some biochemical analyses. Each of the microfluidic 
systems discussed are also well suited for chemical integration with mass spectrometric 
analysis and can be used to collect cellular releasates, or would only need small 
adjustments in the form of stimulation and sampling ports for coupling with off-chip 
analysis by MS. 
Microfluidic devices have a history of being coupled with mass spectrometric analysis 
[27,52,95-98], and we expect this will continue. Perfusion of media through input and 
output ports for stimulations and sample collection is the simplest approach, while others 
might opt for employing microdialysis-like methods or adding more intricate on-chip 
processing steps to the sample collection [96,98]. Although these adjustments could 
require changes to the design and fabrication of a microfluidic device, existing media 
perfusion ports can also be used for perturbations or sampling. For designs that do not 
have direct access, holes of varying diameters can be punched into the devices using 
biopsy punches or via less invasive sampling methods, such as a syringe and needle. 
Finally, researchers may opt to revise their designs and fabrication methods to create an 
optimized interface between their devices and the mass spectrometer. 
Neurospheres can be incorporated into MS in two ways. First, they can be cultured within 
a microfluidic framework, as described by Uzel et al. [65]. Within a microfluidic device, 
neurospheres would provide a physiologically relevant cell culture construct and sampling 
would occur through perfusion, similarly to how it is outlined above. Additionally, the 
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cellular and chemical composition of a neurosphere, as well as its ability to create its own 
extracellular matrix, would be interesting to study using MSI. The neurospheres can be 
sectioned and then subjected to MSI to examine their chemical make-up, as described 
by the Hummon group [53,54] in their study of spherical cultures (Figure 2.3) [54]. 
Impressively, they were able to identify proteins and their distributions within colon 
carcinoma spheroids. Additionally, the surroundings of the neurospheres could be directly 
imaged using SIMS or MALDI without sectioning, helping to better understand the 
development of the extracellular matrix and surrounding environment, similar to how our 
group images biofilms [99]. 
Systems created out of hydrogels, scaffolds, and fibers can be sectioned and imaged 
similarly to neurospheres, or can be perfused and have analytes collected via sampling 
from device output ports, similar to sampling from microfluidic devices. Additionally, 
procedures such as microdialysis may be successful for sampling from within a hydrogel 
or scaffolded “tissue”. Specifically for polymer-based systems, one issue that may occur 
is that even if sampling is successful, the polymer content may suppress or overwhelm 
the signal from the sample. However, the current success in coupling MS with microfluidic 
devices that employ polymer materials, as described above, the use of hydrogels for 
localized protein extraction prior to MS analysis [100], and the compatibility of MS with 
microsystems using poly(dimethylsiloxane) [101], polycarbonate [102], and poly(methyl 
methacrylate) [103], demonstrate that polymer contamination from devices may not be as 
large an issue as some have assumed. Should concerns arise when using specific 
polymer-based devices, these issues could be potentially resolved through data analysis 
techniques, such as subtraction of the peaks associated with the intervening polymers. 
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Further, the development of non-polymer-based materials, improved sample clean-up 
techniques., and increased instrumental resolution and sensitivity could be future 
solutions to potential polymer contamination issues. 
Additionally, single cell measurements for the detection of rare cells or the measurement 
of appropriate cell ratios/types within the system can be performed through direct 
sampling from the microphysiological device or by harvesting the cells through enzymatic 
digestion and dissociation and measuring their cell profiles using microarrays [42] or 
microscopy-guided MS analysis after dispersion [56]. 
We acknowledge that a limitation of using MS to chemically characterize 
microphysiological systems is the potentially low amount of analyte present in such small 
systems, particularly when performing non-targeted analyses. However, recent 
improvements to mass analyzers and sample introduction systems have led to large 
decreases in the sample amounts required, with work using zeptomole amounts of 
metabolites and proteins now being reported. However, when using MS for these small-
volume studies, researchers are cautioned that although the chemical information 
obtained by MS analysis does not require analyte preselection, the resulting data is often 
not comprehensive. 
Finally, when working with human tissue samples, there are often time delays, and issues 
with sampling variability and non-uniform storage conditions, all of which can greatly 
impact the chemical information obtained from the tissues. When robust 
microphysiological systems become available, they will be an excellent source of samples 
from which we could gain a multitude of chemical details about normal human growth, 
39 
 
development, and aging, as well as disease progression. It is important to develop the 
analytical techniques now for when that time comes.  
2.7 Conclusions 
For years, the study of neurochemistry has relied on both in vivo systems, which can be 
difficult to control, and a range of in vitro 2D cell cultures and organotypic slices, which 
offer improved control and access to the cells but are not ideal models for living systems. 
Now, thanks to both improved microtechnologies and a better understanding of the 
nervous system, we have the tools at hand to build in vitro systems that behave more 
closely to in vivo systems. 
A range of MS measurement approaches offer the most information-rich, non-targeted 
chemical characterization options available for characterizing metabolites, peptides, and 
proteins within a living system. Coupling microphysiological systems to mass 
spectrometers requires attention to the hyphenation details in order to obtain the greatest 
information on a dynamic cellular environment without introducing biases. While the 
analytical performance for mass spectrometers is impressive, there are numerous 
opportunities for improved interfaces between microphysiological systems and mass 
spectrometric measurement technologies, and we expect systems with enhanced spatial, 
chemical, and temporal resolution to be introduced in the coming years. Presently there 
are only a few examples of microphysiological systems having been used for analytical 
inquiries, and even fewer in neurochemistry; nonetheless, we look forward to the 
neurochemical insights to be gained from continued research in this area. We envision 
exciting progress in the integration of microphysiological systems with mass 
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spectrometric analysis and expect that the high information content of MS will enable new 






Figure 2.1: Microfluidic devices for the creation of microneurological systems. (a) Schematic illustration of 
the microfluidic compartmentalized CNS neuron co-culture platform. A 3D view of the circular device. 
Reproduced from Park J, Koito H, Li J, et al. Microfluidic Compartmentalized Co-Culture Platform for CNS 
Axon Myelination Research. Biomed Microdevices 2009;11:1145. Copyright (2009) with permission of 
Springer (59). (b) False-colored SEM image showing motor neurons (red) interacting with myotubules (blue) 
in the distal chamber of a microfluidic device. Scale bar: 5 µm. Reprinted from Southam KA, King AE, 
Blizzard CA, et al. Microfluidic Primary Culture Model of the Lower Motor Neuron–Neuromuscular Junction 
Circuit. J Neurosci Methods 2013;218:164-9. Copyright (2013) with permission from Elsevier (61). (c) Co-
culture of rat neonatal keratinocytes (stained for cytokeratin 5, red) with rat neonatal primary sensory 
neurons (stained for B3 tubulin, green) in a dual chamber device. Scale bar: 100 µm. Adapted from 
Tsantoulas C, Farmer C, Machado P, et al. Probing Functional Properties of Nociceptive Axons Using a 
Microfluidic Culture System. PLoS One 2013;8:e80722. Provided under Creative Commons license 3.0 
(71). (d) Schematic of a neurovascular unit created within a microfluidic device. Adapted from Brown JA, 
Pensabene V, Markov DA, et al. Recreating Blood-Brain Barrier Physiology and Structure on Chip: A Novel 
Neurovascular Microfluidic Bioreactor. Biomicrofluidics 2015;9:054124. Provided under Creative Commons 






Figure 2.2: The use of neurospheres and hydrogels in microphysiological model systems. (a) 
Schematic of the integration of neurosphere culture within a microfluidic device. Adapted from 
Uzel SGM, Platt RJ, Subramanian V, et al. Microfluidic Device for the Formation of Optically 
Excitable, Three-Dimensional, Compartmentalized Motor Units. Science Advances 2016;2. 
Provided under Creative Commons Attribution-NonCommercial 4.0 International license. 
http://advances.sciencemag.org/content/2/8/e1501429.full (65). (b) Hydrogel layered cortex 
models. Top: 3D printed hydrogel layers Bottom: fluorescent images showing the layers with  and 
without cells. The scale bar represents 100 µm. Reprinted from Lozano R, Stevens L, Thompson 
BC, et al. 3D Printing of Layered Brain-Like Structures Using Peptide Modified Gellan Gum 
Substrates. Biomaterials 2015;67:264-73, Copyright (2015) with permission from Elsevier (87). 
(c) Schematic of a microfluidic device used to create hydrogel layers imitating the cortex. 
Reprinted from Kunze A, Giugliano M, Valero A, et al. Micropatterning Neural Cell Cultures in 3D 
with a Multi-Layered Scaffold. Biomaterials 2011;32:2088-98. Copyright (2011) with permission 






Figure 2.3: MS imaging of spherical cultures. (a) A spherical liver cell culture. (b) Arrow is pointing 
to the spherical culture in a pipet tip. (c) Spherical culture size compared to a penny (the white 
spot next to Lincoln’s nose). (d) Spherical cultures imbedded in gelatin, sectioned, and placed on 
an indium tin oxide-coated microscope slide. The areas consisting of the cell culture slices are 
small and are located at the tips of the small black lines in the top image. (e) Representative mass 
spectra and corresponding ion intensity maps for MSI on the spherical culture. Adapted with 
permission from Li H, Hummon AB. Imaging Mass Spectrometry of Three- Dimensional Cell 





2.9 Work Cited 
1. Wikswo JP. The Relevance and Potential Roles of Microphysiological Systems in Biology 
and Medicine. Exp Biol Med (Maywood) 2014;239:1061-72. 
2. Baker BM, Chen CS. Deconstructing the Third Dimension – How 3D Culture 
Microenvironments Alter Cellular Cues. J Cell Sci 2012;125:3015-24. 
3. Huang S, Wikswo J. Dimensions of Systems Biology. Reviews of Physiology Biochemistry 
and Pharmacology. Berlin, Heidelberg: Springer; 2007. p. 81-104. 
4. Li X, Valadez AV, Zuo P, et al. Microfluidic 3D Cell Culture: Potential Application for 
Tissue- Based Bioassays. Bioanalysis 2012;4:1509-25. 
5. Baharvand H, Hashemi SM, Kazemi Ashtiani S, et al. Differentiation of Human Embryonic 
Stem Cells into Hepatocytes in 2D and 3D Culture Systems in Vitro. Int J Dev Biol 
2006;50:645- 52. 
6. Yue X, Lukowski JK, Weaver EM, et al. Quantitative Proteomic and Phosphoproteomic 
Comparison of 2D and 3D Colon Cancer Cell Culture Models. J Proteome Res 
2016;15:4265- 76. 
7. Kumar HR, Zhong X, Hoelz DJ, et al. Three-Dimensional Neuroblastoma Cell Culture: 
Proteomic Analysis between Monolayer and Multicellular Tumor Spheroids. Pediatr Surg 
Int 2008;24:1229-34. 
8. Desoize B, Jardillier J-C. Multicellular Resistance: A Paradigm for Clinical Resistance? 
Crit Rev Oncol/Hematol 2000;36:193-207. 
9. Edmondson R, Broglie JJ, Adcock AF, et al. Three-Dimensional Cell Culture Systems and 
Their Applications in Drug Discovery and Cell-Based Biosensors. Assay Drug Dev 
Technol 2014;12:207-18. 
10. Benya PD, Shaffer JD. Dedifferentiated Chondrocytes Reexpress the Differentiated 
Collagen Phenotype When Cultured in Agarose Gels. Cell 1982;30:215-24. 
11. Zietarska M, Maugard CM, Filali-Mouhim A, et al. Molecular Description of a 3D in Vitro 
Model for the Study of Epithelial Ovarian Cancer (Eoc). Mol Carcinog 2007;46:872-85. 
12. Frega M, Tedesco M, Massobrio P, et al. Network Dynamics of 3D Engineered Neuronal 
Cultures: A New Experimental Model for in-Vitro Electrophysiology. 2014;4:5489. 
13. Shield K, Ackland ML, Ahmed N, et al. Multicellular Spheroids in Ovarian Cancer 
Metastases: Biology and Pathology. Gynecol Oncol 2009;113:143-8. 




15. Strand FL, editor. Neuropeptides: Regulators of Physiological Processes. Cambridge, MA: 
The MIT Press; 1998. 
  
16. Xu X-J, Wiesenfleld-Hallin Z. Neuropeptides: Pain. In: Squire LR, editor. Encyclopedia of 
Neuroscience. Oxford: Academic Press; 2009. p. 931–4. 
17. Parenti C, Aricò G, Ronsisvalle G, et al. Supraspinal Injection of Substance P Attenuates 
Allodynia and Hyperalgesia in a Rat Model of Inflammatory Pain. Peptides 2012;34:412-
8. 
18. Hubbard RD, Quinn KP, Martinez JJ, et al. The Role of Graded Nerve Root Compression 
on Axonal Damage, Neuropeptide Changes, and Pain-Related Behaviors. Stapp Car 
Crash J 2008;52:33-58. 
19. Lee KE, Winkelstein BA. Joint Distraction Magnitude Is Associated with Different 
Behavioral Outcomes and Substance P Levels for Cervical Facet Joint Loading in the Rat. 
J Pain 2009;10:436-45. 
20. Zahavi EE, Ionescu A, Gluska S, et al. A Compartmentalized Microfluidic Neuromuscular 
Co-Culture System Reveals Spatial Aspects of GDNF Functions. J Cell Sci 
2015;128:1241-52. 
21. Roggenkamp D, Falkner S, Stäb F, et al. Atopic Keratinocytes Induce Increased Neurite 
Outgrowth in a Coculture Model of Porcine Dorsal Root Ganglia Neurons and Human Skin 
Cells. J Invest Dermatol 2012;132:1892-900. 
22. Millet LJ, Gillette MU. New Perspectives on Neuronal Development Via Microfluidic 
Environments. Trends Neurosci 2012;35:752-61. 
23. Tsamandouras N, Chen WLK, Edington CD, et al. Integrated Gut and Liver 
Microphysiological Systems for Quantitative in Vitro Pharmacokinetic Studies. AAPS J 
2017;19:1499-512. 
24. Blundell C, Tess ER, Schanzer ASR, et al. A Microphysiological Model of the Human 
Placental Barrier. Lab Chip 2016;16:3065-73. 
25. Kilic O, Pamies D, Lavell E, et al. Brain-on-a-Chip Model Enables Analysis of Human 
Neuronal Differentiation and Chemotaxis. Lab Chip 2016;16:4152-62. 
26. Johnson BN, Lancaster KZ, Hogue IB, et al. 3D Printed Nervous System on a Chip. Lab 
Chip 2016;16:1393-400. 
27. Croushore CA, Supharoek SA, Lee CY, et al. Microfluidic Device for the Selective 
Chemical Stimulation of Neurons and Characterization of Peptide Release with Mass 
Spectrometry. Anal Chem 2012. 
46 
 
28. Li L, Ren L, Liu W, et al. Spatiotemporally Controlled and Multifactor Involved Assay of 
Neuronal Compartment Regeneration after Chemical Injury in an Integrated Microfluidics. 
Anal Chem 2012;84:6444-53. 
29. Glish GL, Vachet RW. The Basics of Mass Spectrometry in the Twenty-First Century. Nat 
Rev Drug Discov 2003;2:140-50. 
30. Maher S, Jjunju FPM, Taylor S. Colloquium: 100 Years of Mass Spectrometry: 
Perspectives and Future Trends. Rev Mod Phys 2015;87:113-35.  
31. Rubakhin SS, Sweedler JV. A Mass Spectrometry Primer for Mass Spectrometry Imaging. 
In: Rubakhin SS, Sweedler JV, editors. Mass Spectrometry Imaging: Principles and 
Protocols. Totowa, NJ: Humana Press; 2010. p. 21-49. 
32. Romanova EV, Aerts JT, Croushore CA, et al. Small-Volume Analysis of Cell–Cell 
Signaling Molecules in the Brain. Neuropsychopharmacology 2014;39:50-64. 
33. Hillenkamp F, Karas M. The MALDI Process and Method. MALDI MS. Wiley-VCH Verlag 
GmbH & Co. KGaA; 2007. p. 1-28. 
34. Dreisewerd K. Recent Methodological Advances in MALDI Mass Spectrometry. Anal 
Bioanal Chem 2014;406:2261-78. 
35. Wilm M. Principles of Electrospray Ionization. Mol Cell Proteomics 2011;10:M111.009407. 
36. Qi M, Philip MC, Yang N, et al. Single Cell Neurometabolomics. ACS Chem Neurosci 
2017;9:40-50. 
37. Watson JT, Sparkman OD. Introduction to Mass Spectrometry: Instrumentation, 
Applications, and Strategies for Data Interpretation. Wiley; 2013. 
38. Comi TJ, Do TD, Rubakhin SS, et al. Categorizing Cells on the Basis of Their Chemical 
Profiles: Progress in Single-Cell Mass Spectrometry. J Am Chem Soc 2017;139:3920-9. 
39. Signor L, Boeri Erba E. Matrix-Assisted Laser Desorption/Ionization Time of Flight 
(MALDI- TOF) Mass Spectrometric Analysis of Intact Proteins Larger Than 100 Kda. J 
Visualized Exp 2013:50635. 
40. Jansson ET, Comi TJ, Rubakhin SS, et al. Single Cell Peptide Heterogeneity of Rat Islets 
of Langerhans. ACS Chem Biol 2016;11:2588-95. 
41. Romanova EV, Rubakhin SS, Monroe EB, et al. Single Cell Mass Spectrometry. Single 
Cell Analysis. Wiley-VCH Verlag GmbH & Co. KGaA; 2009. p. 109-33. 
42. Urban PL, Jefimovs K, Amantonico A, et al. High-Density Micro-Arrays for Mass 
Spectrometry. Lab Chip 2010;10:3206-9. 
43. Cockrill SL, Foster KL, Wildsmith J, et al. Efficient Micro-Recovery and Guanidination of 
Peptides Directly from MALDI Target Spots. BioTechniques 2005;38:301-4. 
47 
 
44. Ong T-H, Tillmaand EG, Makurath M, et al. Mass Spectrometry-Based Characterization 
of Endogenous Peptides and Metabolites in Small Volume Samples. Biochim Biophys 
Acta 2015;1854:732-40. 
 
45. Hatcher NG, Richmond TA, Rubakhin SS, et al. Monitoring Activity-Dependent Peptide 
Release from the CNS Using Single-Bead Solid-Phase Extraction and MALDI TOF MS 
Detection. Anal Chem 2005;77:1580-7. 
46. Fenn JB, Mann M, Meng CK, et al. Electrospray Ionization–Principles and Practice. Mass 
Spectrom Rev 1990;9:37-70.  
47. Klepárník K. Recent Advances in the Combination of Capillary Electrophoresis with Mass 
Spectrometry: From Element to Single-Cell Analysis. Electrophoresis 2013;34:70-85. 
48. Niessen WMA. Progress in Liquid Chromatography–Mass Spectrometry Instrumentation 
and Its Impact on High-Throughput Screening. J Chromatogr 2003;1000:413-36. 
49. Wu C, Dill AL, Eberlin LS, et al. Mass Spectrometry Imaging under Ambient Conditions. 
Mass Spectrom Rev 2013;32:218-43. 
50. Shariatgorji M, Svenningsson P, Andrén PE. Mass Spectrometry Imaging, an Emerging 
Technology in Neuropsychopharmacology. Neuropsychopharmacology 2014;39:34-49. 
51. Jo K, Heien ML, Thompson LB, et al. Mass Spectrometric Imaging of Peptide Release 
from Neuronal Cells within Microfluidic Devices. Lab Chip 2007;7:1454-60. 
52. Zhong M, Lee CY, Croushore CA, et al. Label-Free Quantitation of Peptide Release from 
Neurons in a Microfluidic Device with Mass Spectrometry Imaging. Lab Chip 
2012;12:2037-45. 
53. Ahlf Wheatcraft DR, Liu X, Hummon AB. Sample Preparation Strategies for Mass 
Spectrometry Imaging of 3D Cell Culture Models. J Visualized Exp 2014:52313. 
54. Li H, Hummon AB. Imaging Mass Spectrometry of Three-Dimensional Cell Culture 
Systems. Anal Chem 2011;83:8794-801. 
55. Comi TJ, Makurath MA, Philip MC, et al. MALDI MS Guided Liquid Microjunction 
Extraction for Capillary Electrophoresis–Electrospray Ionization MS Analysis of Single 
Pancreatic Islet Cells. Anal Chem 2017;89:7765-72. 
56. Comi TJ, Neumann EK, Do TD, et al. microMS: A Python Platform for Image-Guided Mass 
Spectrometry Profiling. J Am Soc Mass Spectrom 2017;28:1919-28. 




58. Majumdar D, Gao Y, Li D, et al. Co-Culture of Neurons and Glia in a Novel Microfluidic 
Platform. J Neurosci Methods 2011;196:38-44. 
59. Park J, Koito H, Li J, et al. Microfluidic Compartmentalized Co-Culture Platform for CNS 
Axon Myelination Research. Biomed Microdevices 2009;11:1145. 
 
60. Kim Y-t, Karthikeyan K, Chirvi S, et al. Neuro-Optical Microfluidic Platform to Study Injury 
and Regeneration of Single Axons. Lab Chip 2009;9:2576-81. 
61. Southam KA, King AE, Blizzard CA, et al. Microfluidic Primary Culture Model of the Lower 
Motor Neuron–Neuromuscular Junction Circuit. J Neurosci Methods 2013;218:164-9. 
62. Ionescu A, Zahavi EE, Gradus T, et al. Compartmental Microfluidic System for Studying 
Muscle–Neuron Communication and Neuromuscular Junction Maintenance. Eur J Cell 
Biol 2016;95:69-88. 
63. Achyuta AKH, Conway AJ, Crouse RB, et al. A Modular Approach to Create a 
Neurovascular Unit-on-a-Chip. Lab Chip 2013;13:542-53. 
64. Croushore CA, Sweedler JV. Microfluidic Systems for Studying Neurotransmitters and 
Neurotransmission. Lab Chip 2013;13:1666-76. 
65. Uzel SGM, Platt RJ, Subramanian V, et al. Microfluidic Device for the Formation of 
Optically Excitable, Three-Dimensional, Compartmentalized Motor Units. Sci Adv 
2016;2:e1501429. 
66. Chang Young L, Romanova EV, Sweedler JV. Laminar Stream of Detergents for 
Subcellular Neurite Damage in a Microfluidic Device: A Simple Tool for the Study of 
Neuroregeneration. J Neural Eng 2013;10:036020. 
67. Bear MF, Connors BW, Paradiso MA. Neuroscience: Exploring the Brain. 2nd ed. 
Philadelphia: Lippincott Williams & Wilkins; 2001. 
68. Devor M. Unexplained Peculiarities of the Dorsal Root Ganglion. Pain 1999;Suppl 6:S27-
35. 
69. Hogan Q. Labat Lecture: The Primary Sensory Neuron: Where It Is, What It Does, and 
Why It Matters. Reg Anesth Pain Med 2010;35:306-11. 
70. Taylor AM, Blurton-Jones M, Rhee SW, et al. A Microfluidic Culture Platform for CNS 
Axonal Injury, Regeneration and Transport. Nat Methods 2005;2:599-605. 
71. Tsantoulas C, Farmer C, Machado P, et al. Probing Functional Properties of Nociceptive 
Axons Using a Microfluidic Culture System. PLoS One 2013;8:e80722. 
72. Tsutsumi M, Nakatani M, Kumamoto J, et al. In Vitro Formation of Organized Structure 
between Keratinocytes and Dorsal-Root-Ganglion Cells. Exp Dermatol 2012;21:886-8. 
49 
 
73. Klusch A, Ponce L, Gorzelanny C, et al. Coculture Model of Sensory Neurites and 
Keratinocytes to Investigate Functional Interaction: Chemical Stimulation and Atomic 
Force Microscope–Transmitted Mechanical Stimulation Combined with Live-Cell Imaging. 
J Invest Dermatol 2013;133:1387-90. 
74. Bird MM. Establishment of Synaptic Connections between Explants of Embryonic Neural 
Tissue in Culture: Experimental Ultrastructural Studies. Exp Brain Res 1985;57:337-47. 
75. Vikman KS, Backström E, Kristensson K, et al. A Two-Compartment in Vitro Model for 
Studies of Modulation of Nociceptive Transmission. J Neurosci Methods 2001;105:175-
84. 
76. Ohshiro H, Ogawa S, Shinjo K. Visualizing Sensory Transmission between Dorsal Root 
Ganglion and Dorsal Horn Neurons in Co-Culture with Calcium Imaging. J Neurosci 
Methods 2007;165:49-54. 
77. Shipshina MS, Fedulova SA, Veselovskii NS. Induction of Long-Term Depression of 
Synaptic Transmission in a Co-Culture of DRG and Spinal Dorsal Horn Neurons of Rats. 
Neurophysiology 2011;43:261-70. 
78. Phan DT, Bender RHF, Andrejecsk JW, et al. Blood–Brain Barrier-on-a-Chip: 
Microphysiological Systems That Capture the Complexity of the Blood–Central Nervous 
System Interface. Exp Biol Med;0:1535370217694100. 
79. Brown JA, Pensabene V, Markov DA, et al. Recreating Blood-Brain Barrier Physiology 
and Structure on Chip: A Novel Neurovascular Microfluidic Bioreactor. Biomicrofluidics 
2015;9:054124. 
80. Herland A, van der Meer AD, FitzGerald EA, et al. Distinct Contributions of Astrocytes and 
Pericytes to Neuroinflammation Identified in a 3D Human Blood-Brain Barrier on a Chip. 
PLoS One 2016;11:e0150360. 
81. Fennema E, Rivron N, Rouwkema J, et al. Spheroid Culture as a Tool for Creating 3D 
Complex Tissues. Trends Biotechnol 2013;31:108-15. 
82. Choi YJ, Park J, Lee S-H. Size-Controllable Networked Neurospheres as a 3D Neuronal 
Tissue Model for Alzheimer's Disease Studies. Biomaterials 2013;34:2938-46. 
83. Kato-Negishi M, Tsuda Y, Onoe H, et al. A Neurospheroid Network-Stamping Method for 
Neural Transplantation to the Brain. Biomaterials 2010;31:8939-45. 
84. Park J, Lee BK, Jeong GS, et al. Three-Dimensional Brain-on-a-Chip with an Interstitial 




85. Pamies D, Barreras P, Block K, et al. A Human Brain Microphysiological System Derived 
from Induced Pluripotent Stem Cells to Study Neurological Diseases and Toxicity. ALTEX 
2017;34:362-76. 
86. Turunen S, Haaparanta A-M, Äänismaa R, et al. Chemical and Topographical Patterning 
of Hydrogels for Neural Cell Guidance in Vitro. J Tissue Eng Regen Med 2013;7:253-70. 
87. Lozano R, Stevens L, Thompson BC, et al. 3D Printing of Layered Brain-Like Structures 
Using Peptide Modified Gellan Gum Substrates. Biomaterials 2015;67:264-73. 
88. Kunze A, Giugliano M, Valero A, et al. Micropatterning Neural Cell Cultures in 3D with a 
Multi-Layered Scaffold. Biomaterials 2011;32:2088-98. 
89. Huval RM, Miller OH, Curley JL, et al. Microengineered Peripheral Nerve-on-a-Chip for 
Preclinical Physiological Testing. Lab Chip 2015;15:2221-32. 
90. Yoichi K, Yoji N, Yuya Y, et al. Patterned Hydrogel Microfibers Prepared Using 
Multilayered Microfluidic Devices for Guiding Network Formation of Neural Cells. 
Biofabrication 2014;6:035011. 
91. Wang TY, Forsythe JS, Parish CL, et al. Biofunctionalisation of Polymeric Scaffolds for 
Neural Tissue Engineering. J Biomater Appl 2012;27:369-90. 
92. Daud MFB, Pawar KC, Claeyssens F, et al. An Aligned 3D Neuronal-Glial Co-Culture 
Model for Peripheral Nerve Studies. Biomaterials 2012;33:5901-13. 
93. Rowe L, Almasri M, Lee K, et al. Active 3-D Microscaffold System with Fluid Perfusion for 
Culturing in Vitro Neuronal Networks. Lab Chip 2007;7:475-82.  
94. Zou Z, Zheng Q, Wu Y, et al. Growth of Rat Dorsal Root Ganglion Neurons on a Novel 
Self- Assembling Scaffold Containing IKVAV Sequence. Mater Sci Eng 2009;29:2099-
103. 
95. Wei H, Li H, Gao D, et al. Multi-Channel Microfluidic Devices Combined with Electrospray 
Ionization Quadrupole Time-of-Flight Mass Spectrometry Applied to the Monitoring of 
Glutamate Release from Neuronal Cells. Analyst 2010;135:2043-50. 
96. Mao S, Zhang J, Li H, et al. Strategy for Signaling Molecule Detection by Using an 
Integrated Microfluidic Device Coupled with Mass Spectrometry to Study Cell-to-Cell 
Communication. Anal Chem 2013;85:868-76. 
97. Dugan CE, Kennedy RT. Measurement of Lipolysis Products Secreted by 3T3-L1 
Adipocytes Using Microfluidics. Methods Enzymol 2014;538:195-209. 
98. Li X, Hu H, Zhao S, et al. Microfluidic Platform with in-Chip Electrophoresis Coupled to 




99. Baig NF, Dunham SJB, Morales-Soto N, et al. Multimodal Chemical Imaging of Molecular 
Messengers in Emerging Pseudomonas Aeruginosa Bacterial Communities. Analyst 
2015;140:6544-52. 
100. Rizzo DG, Prentice BM, Moore JL, et al. Enhanced Spatially Resolved Proteomics Using 
on-Tissue Hydrogel-Mediated Protein Digestion. Anal Chem 2017;89:2948-55. 
101. Chan JH, Timperman AT, Qin D, et al. Microfabricated Polymer Devices for Automated 
Sample Delivery of Peptides for Analysis by Electrospray Ionization Tandem Mass 
Spectrometry. Anal Chem 1999;71:4437-44. 
102. Xu N, Lin Y, Hofstadler SA, et al. A Microfabricated Dialysis Device for Sample Cleanup 
in Electrospray Ionization Mass Spectrometry. Anal Chem 1998;70:3553-6. 
103. Meng Z, Qi S, Soper SA, et al. Interfacing a Polymer-Based Micromachined Device to a 
Nanoelectrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass 





Measuring Cellular Microenvironments and Release via MS 
3.1 Notes  
This chapter is an excerpt from a review written by Dr. Ta-Hsuan Ong, Dr. Emily 
Tillmaand, Monika Makurath, Dr. Stanislav Rubakhin, and Dr. Jonathan Sweedler. 
(Biochim Biophys Acta. 2015 Jul;1854(7):732-40. doi: 10.1016/j.bbapap.2015.01.008) 
and is reproduced with permission. The excerpt that follows is the section of the review 
that I wrote, reviewing improved methods for measuring chemical components of 
extracellular environments using mass spectrometry (MS). 
3.2 Introduction  
The investigation of stimulated cellular release provides an opportunity to determine a 
subset of cellular metabolites and peptides that are likely to be involved in cell-to-cell 
signaling. Secretomics, the study of the compounds released from a cell, uses a wide 
range of methodologies, including MS, microfluidics, Western blotting, enzyme-linked 
immunosorbent assays, gel electrophoresis, radioimmunoassay / labeling with 
radioactive isotopes, and amperometric detection [1-9]. Released compounds vary from 
small diatomic gases to large proteoglycans and peptides; thus, it is not surprising that a 
range of characterization approaches are required to assay this large variety of analyte 
types.  
MS is an important tool for studying cellular release as it provides multiplexed information 
about the protein, peptide, and metabolite content of the releasate without the need for 
analyte pre-selection. The focus of cellular release studies range from biomarker 
detection and identification to the determination of protein concentrations [1]. We have 
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chosen to highlight work that has involved the detection and identification of cell-to-cell 
signaling molecules in the nervous system. Uncovering the peptide composition of cellular 
releasate helps to elucidate the functional roles of observed peptides by relating their 
release parameters to specific stimulation paradigms. For peptides with known activities 
and targets, it may help to define the physiological role of the studied cell. MALDI-time-
of-flight (TOF) MS is often used to study peptide secretion due to its salt tolerance, low 
detection limits, and ability to be hyphenated with a variety of sample conditioning 
approaches [10]. As with all single cell studies, secretomics is complicated by the 
chemical complexity of extracellular environments, low analyte amounts, and the need to 
remove unwanted chemical components from the sample prior to MS analysis. 
Microfluidic technologies enable efficient single cell culture, direct cell stimulation, and 
more specific temporal and spatial capture of released analytes. 
3.3 Using Microfluidics for Sampling 
Many microfluidic systems have been designed for the capture, treatment, and analysis 
of single cells, some of which have been applied to investigate analyte release from 
individual cells or small cellular structures [8, 11-13]. Wei et al. [14] developed a series of 
microfluidic chips that incorporate cell culture and on-chip pretreatment coupled with 
electrospray (ESI)-quadrupole-TOF MS for analysis. In order to detect glutamate secreted 
from stimulated PC12 cells, the cells were cultured and stimulated in microchannels on 
one chip and then the extracellular fluid was moved through tubing to a miniature 
extraction chip in which the sample was flowed over polymer solid phase extraction (SPE) 
beads for pretreatment. After pretreatment, the sample was once again moved through 
tubing to the ion source. This series of chips could easily be used for the analysis of 
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peptides released upon stimulation. Microfluidic devices designed for the detection of 
peptides are used in biomarker detection assays. Yang et al. [15] presented a device in 
which specific peptides are affinity captured in microchannels lined with antibodies. This 
particular system allows detection of as few as 300 peptide molecules and can be when 
applied in targeted analysis of released peptides.   
Quantitative analyses of released analytes can also be performed using a microfluidic 
platform hyphenated to MS. Zhong et al. [19] developed a device for the quantification of 
peptides released from A. californica bag cell neurons. The device consisted of one 
serpentine channel treated with octadecyltrichlorosilane (OTS), used to collect the 
peptides at specific locations. A continuous flow of extracellular fluid brought the released 
peptides into contact with the OTS. This OTS layer with captured molecules was then 
interrogated using MALDI MSI. The distance that the peptide was detected along the 
length of the channel correlated with the amount of the peptide in the sample. 
3.4 Using SPE During Sample Collection 
Collection of the extracellular media and its direct analysis via MALDI-TOF MS is a 
powerful approach for the analysis of normal and pathological peptide secretion [16]. 
However, even though MALDI-TOF MS has a high inorganic salt tolerance, the high levels 
of salts present in the physiological extracellular media hinders effective molecular 
characterization with MS. Therefore, SPE is often used for sample conditioning as it 
improves detection, minimizes sample loss, and decreases the salt content before the 
MS measurement. An analytical system developed by Croushore et al. [17] allowed for 
the selective stimulation of cultured A. californica bag cell neurons through a device in 
which fluid flow was controlled via applied external pressures and pneumatically 
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controlled microvalves. Once the cells were stimulated, microliter volumes of the cellular 
microenvironment were collected, purified using SPE, and analyzed by MALDI-TOF MS 
analysis. This approach allowed low temporal resolution studies of analyte release from 
low-density cultures and single cells.  
Mao et al. [18] studied intercellular communication through the integration of stimulation, 
release, and pretreatment steps all on one chip. A microfluidic device capable of culturing 
two distinct cell populations was used for stimulation of one population and a surface 
tension plug control was used to control the chemical signaling between the populations. 
Once the desired stimulation occurred, samples of the extracellular media were moved 
through the chip and into micro-SPE columns for analyte capture and sample 
conditioning. After pretreatment, the analysis was performed using ESI-Q-TOF-MS (Fig. 
3A). 
Commercially available, as well as home built SPE devices, are widely used to desalt and 
concentrate samples prior to analysis via MS. C18 reversed phase media-packed pipet 
tips have been used for the conditioning of releasates collected from clusters of bag cell 
neurons of A. californica [16], as well as from low-density bag cell neuron cultures [17]. 
Due to the large volume of C18 material used, this approach can be utilized when release 
from multiple cells is investigated. However, reducing the volume of SPE material, 
therefore, leading to higher analyte preconcentration, aids in the detection of the small 
amounts of analytes released from a single cell. In one example, a small number of SPE 
particles were mounted onto the surface of Parafilm M. The ~30 µL volume of collected 
extracellular media containing cell releasate was deposited onto the particles through a 
fused silica capillary (Fig. 3B) [16].  
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Further improvement in the spatial detection of peptide release was achieved by the use 
of SPE beads placed directly on the processes of cultured A. californica bag cell neurons 
(Fig. 3C) [20]. Alternatively, SPE packed pipette tips or cartridges, as demonstrated by 
Hatcher et al., can be used to collect peptide release [21]. Finally, to improve both spatial 
detection and sampling efficiency, lauryl methacrylate-ethylene glycol dimethacrylate 
porous polymer monolithic columns have been used to investigate both A. californica and 
mammalian systems, attaining sub-picomolar limits of detection with sample volumes of 
~ 4 µL [3]. 
Additional improvements in analyte retention can be realized by acidification, alkylation, 
or addition of ion-pairing reagents to the sample. However, in most cases these 
modifications are not easily applied to the extracellular environment without interfering 
with the physiological activity of the studied cells. Therefore, to increase SPE analyte 
extraction efficiency in released peptide analysis, Fan et al. [22] customized particle-
embedded monolithic capillaries with pyrrolidone or ethylenediamine in poly(stearyl 
methacrylate-co-ethylene glycol dimethacrylate) and used them to collect A. californica 
bag cell neuron releasates. The complete system consisted of two capillaries connected 
to individual syringe pumps, one for application of the secretagogue to the individual 
neurons at a rate of 0.25 µL/min and the other for collection and pretreatment of the 
releasate at the same flow rate for 30 minutes, allowing for low femtomole limits of analyte 
detection and specific analyte targeting (Figure 3D). This SPE approach was improved in 
a follow up study [23] with the use of a concentric dual capillary system consisting of an 
outer capillary that surrounds the stimulation and sampling area, and an inner octadecyl-
modified silica nanoparticle-filled capillary to collect and pretreat the ~10 µL sample. The 
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outer capillary, which delivers the secretagogue, either surrounds the neuron or is 
positioned above the targeted area of the tissue and remains in that position while the 
inner sampling capillary can be removed and replaced if multiple collections of releasates 
are necessary (Fig. 3E). This set-up allows relatively high temporal and spatial resolution 
of cellular release investigation as well as reduced sample dilution. 
3.5 Conclusion 
This chapter discusses improved methods for studying the chemical content of 
extracellular environments and cell-to-cell interactions. These methods are particularly 
useful when studying chemically complex systems with low analyte amounts. Continual 
improvement of both sampling and detection techniques prove important to the 
advancement of fields that rely on such information, including the study of neurochemical 





Figure 3.1 A variety of SPE-based analyte collection approaches have been developed and 
applied to small volume sample analysis. (A) An integrated microfluidic device allowing cell 
stimulation, cell-cell communication, and sample pretreatment. (Reprinted with permission from 
reference [18]. Copyright 2012 American Chemical Society). (B) Schematic of sample collection 
from A. californica bag cell neurons and its SPE pre-treatment prior to MALDI MS analysis. 
(Adapted with permission from reference [16]. Copyright 2001 WILEY-VCH Verlag.) (C) 
Placement of SPE beads (arrows) directly on neurites of cultured neurons. (Reprinted with 
permission from reference [20]. Copyright 2005 National Academy of Sciences of the United 
States of America.) (D) A two-capillary system allowing secretagogue application, released 
compound collection, and sample processing. (Reprinted with permission from reference [22]. 
Copyright 2011 American Chemical Society.) (E) A concentric dual capillary system used for 
temporal and spatial investigation of release. Reduced analyte dilution and flexible sample 
conditioning using octadecyl-modified silica nanoparticles are important properties. (Reproduced 
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The dorsal root ganglion (DRG) and its anatomically and functionally associated spinal 
nerve and ventral and dorsal roots are important components of the peripheral sensory-
motor system in mammals. The cells within these structures use a number of peptides as 
intercellular signaling molecules. We performed a variety of mass spectrometry (MS)-
based characterizations of peptides contained within and secreted from these structures, 
and from isolated and cultured DRG cells. Liquid chromatography-Fourier transform MS 
was utilized in DRG and nerve peptidome analysis. In total, 2724 peptides from 296 
proteins were identified in tissue extracts. Neuropeptides are among those detected, 
including calcitonin gene-related peptide I, little SAAS, and known hemoglobin-derived 
peptides. Solid phase extraction combined with direct matrix-assisted laser desorption / 
ionization time-of-flight MS was employed to investigate the secretome of these 
structures. A number of peptides were detected in the releasate from semi-intact 
preparations of DRGs and associated nerves, including neurofilament- and myelin basic 
protein-related peptides. A smaller set of analytes was observed in releasates from 
cultured DRG neurons. The peptide signals observed in the releasates have been mass-
matched to those characterized and identified in homogenates of entire DRGs and 
associated nerves. This data aids our understanding of the chemical composition of the 
mammalian peripheral sensory-motor system, which is involved in key physiological 
functions such as nociception, thermoreception, itch sensation, and proprioception. 
4.3 Introduction 
A large amount of sensory information within the mammalian nervous system is conveyed 
from the organism’s periphery to the spinal cord and brain stem via sensory neurons 
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residing in the dorsal root ganglion (DRG), which consists of the neuron cell bodies and 
support cells [1, 2]. A sensory neuron has a single axon extending from the cell body that 
bifurcates, sending one process to the dorsal region of the spinal cord, while the other 
process innervates a variety of targets [1, 3, 4]. DRG neurons innervate a number of 
target organs, including skin, muscles, and joints [5, 6], and are involved in 
mechanoreception, limb proprioception, thermoreception, and nociception. A number of 
neuropeptides and other cell-to-cell signaling peptides have been identified within DRGs, 
including substance P and calcitonin gene-related peptide I (CGRP-1) [7]. Many common 
pain medications (e.g., opioids) target this neuronal network. DRGs are structurally 
associated the spinal nerve (SN) and its dorsal root (DR) and ventral root (VR). The DR 
and SN contain neurites from the sensory neurons. The VR possesses mostly terminals 
of spinal motoneurons and presents an opportunity for a comparative analysis of motor 
and sensory components of the nervous system. 
Both normal and pathological functions of the peripheral sensory-motor system depend 
on the overall chemical composition of corresponding cells and their extracellular 
environments. Important studies have been performed to better understand the 
metabolite, lipid, and protein content of DRGs and their surrounding structures [8-14]. 
However, the cell-to-cell signaling molecules in these areas and their release have not 
been completely characterized. Measurements of activity-dependent release are 
challenging for several reasons. First, cells release a broad range of physiologically active 
compounds over a wide concentration range. Second, only small amounts of the 
compounds within the tissue are released, making measurement detection limits 
important. Moreover, peptide signaling can be terminated by internalization of the signal 
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or efficient enzymatic extracellular degradation. Therefore, effective capture and 
accumulation of released peptides is important for successful measurements. Lastly, the 
collection of the sample should minimally perturb the system and allow for a controlled 
stimulation of release and efficient analyte collection.  
Methods that combine analytical techniques, such as liquid chromatography (LC)-MS, 
have become mainstream approaches used in proteomic investigations of tissues, 
organs, and cell cultures [15-23]. In contrast to LC-MS, direct assay of tissues or cells 
using matrix-assisted laser desorption / ionization (MALDI) time-of-flight (TOF) MS is also 
effective, either via mass spectrometry imaging [24-26] or by characterization of the 
isolated cells, nerves and ganglia deposited on a conductive sample plate [27, 28]. Both 
LC-electrospray ionization (ESI)-MS and direct MALDI MS can be used to investigate 
peptide release. Direct MS is well suited for the smallest volume samples and can 
accommodate larger numbers of samples as a separation is not required. However, most 
released analytes are present at low concentrations and require preconcentration before 
the MS analysis. Also, the extracellular media contains high inorganic salt levels that are 
not compatible with direct MS measurements. Therefore, effective methods for collecting 
released material and conditioning / concentrating the peptides are required. For 
example, solid phase extraction (SPE) using collection capillaries or probes placed at 
appropriate locations in close proximity to tissue regions, cell populations in culture, or 
individual cells enables the measurement of compounds released upon electrical or 
chemical stimulation [29-31]. 
Microfluidics-based cell culturing systems can also be used to provide a wealth of 
information pertaining to tissue and cell biochemistry, growth, and morphology [32, 33]. 
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We previously reported a microfluidic device that permits the culture and maintenance of 
neurons, temporal application of selective chemical stimuli, and collection of peptide 
release, with the releasate analyzed using MALDI-TOF MS [34]. The advantages of 
interfacing microfluidics to MALDI include its small sample-volume requirements, wide 
dynamic range for peptide characterization [35, 36], and ease of making a large number 
of measurements, although tandem MS (MS/MS)-based identification of released 
compounds using direct MALDI MS tends not to be as effective as LC-ESI-MS. Therefore, 
the separation and preconcentration of peptides on an LC system aids in the identification 
of endogenous peptides and proteins. Well-known benefits of having LC on the front end 
of MS include minimized suppression effects from co-eluting ion species and increased 
dynamic range for better detection of low abundance peptides. The combination of direct 
tissue measurements with LC-Fourier transform (FT)-ESI-MS and cell release 
measurements using MALDI-TOF MS is particularly effective in examining peptide 
release, thereby enabling the assignment of signals detected in release by mass 
matching to peptides characterized in the larger samples [30, 37]. 
One of our long-term goals is to recreate different functional networks of well-defined 
DRG cells within engineered microfluidic devices [38-40] so that we can characterize the 
biochemical responses, including cellular release, of these networks to different stimuli 
and changing microenvironments. However, in order to establish and validate our working 
model and perform the required measurements, it is important to have an inventory of the 
compounds present within and released from DRGs and their associated structures. Here 
we present a series of LC-ESI-FTMS/MS investigations of the peptide content of the rat 
peripheral sensory-motor system, including the DR, VR, SN, and DRG, as well as isolated 
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DRG cells. In parallel, SPE-assisted MALDI MS and LC-ESI-FTMS were used to 
characterize the release from semi-intact preparations of DRGs with attached nerves, a 
robust DRG cell culture was established in miniaturized wells, and a number of peptides 
identified as being released from the DRG cells and nerves. The data obtained on the 
peripheral sensory-motor system peptidome and secretome will be used to enable follow-
up studies on the function of this complex neuronal system, and on the growth and 
formation of defined DRG networks in engineered microfluidic devices. 
4.4 Experimental 
4.4.1 Animals and Tissue Dissection 
All procedures related to animal handling and euthanasia were performed in accordance 
with local, state, and federal regulations, and approved by the Illinois Institutional Animal 
Care and Use Committee. DRGs, spinal cords, SNs, VRs, and DRs were surgically 
dissected from 2.5–3 month-old Sprague-Dawley outbred male rats (Harlan Laboratories, 
Inc., Indianapolis, IN, USA), 21–28 day postnatal Sprague-Dawley outbred male rats 
(Charles River, St. Constant, QC, Canada), or 6–12 week-old Long-Evans/BluGill male 
and female rats (University of Illinois at Urbana−Champaign, USA), euthanized by 
decapitation. To reduce the detrimental metabolic effects of a stopped blood flow, 40–
120 mL of ice-cold modified Gey’s balanced salt solution (mGBSS) were injected under 
the skin above the location of the DRGs of interest (the lumbar area) immediately after 
decapitation. The spinal canal was surgically opened, the spinal cord removed, and DRGs 
with adjacent nerves were individually isolated and placed into ice cold mGBSS 
containing (in mM): 1.5 CaCl2, 4.9 KCl, 0.2 KH2PO4, 11 MgCl2, 0.3 MgSO4, 138 NaCl, 
27.7 NaHCO3, and 0.8 Na2HPO4, and 25 HEPES, pH 7.2. In some experiments other 
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media types were used as described below. Most of the presented work used 2.5–3 
month-old Sprague-Dawley outbred male rats (Harlan Laboratories, Inc.). Animals of 
other strains, sexes, and ages investigated in the DRG peptidomics experiments 
produced similar results to data obtained from the Sprague-Dawley rats. 
4.4.2 DRG Cell Isolation  
Immediately after dissection, DRGs were sustained in a volume of ice cold Hibernate A 
media (BrainBits, Springfield, IL, USA) for up to 48 h. For dissociation, approximately 10 
DRGs dissected from 2.5–3 month old Sprague-Dawley outbred rats were digested in a 
solution of 0.25% collagenase (Worthington Biochemical Corp, Lakewood, NJ, USA) in 
DRG cell culture media containing Neurobasal A without phenol red (Life Technologies, 
Carlsbad, CA, USA), 100 U/mL penicillin/streptomycin (Life Technologies), 0.5 mM 
GlutaMAX (Life Technologies), 50 ng/mL nerve growth factor (Life Technologies), 50 
ng/mL brain-derived neurotrophic factor (BDNF) (Prospec Bio, Rehovot, Israel), and 500 
μL B27 Growth Supplement (Life Technologies) for 1.5 h at 37 ⁰C. After digestion, the 
samples were subjected to centrifugation for 3 min at 200 ×g. The supernatant was 
removed, and the pellet washed with Hank’s Balanced Salt Solution (HBSS) (Life 
Technologies). The sample was centrifuged, the supernatant removed, and the pellet 
digested using 0.25% trypsin with ethylenediaminetetraacetic acid (Life Technologies) for 
15 min at 37 ⁰C. After incubation, the sample was centrifuged, supernatant removed, and 
0.5–1 mL DRG cell culture media + 1% fetal bovine serum (Life Technologies) added to 
inactivate the trypsin. The pellet was mechanically dissociated by trituration with fire-
polished pipettes. Following trituration, some of the pellet was allowed to re-settle. Once 
a small pellet formed in the bottom of the microcentrifuge tube, the supernatant was 
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removed and spun for 3 min at 200 ×g. After centrifugation, the supernatant was removed 
and the pellet washed with HBSS. After a final centrifugation, the cell pellet was 
resuspended in 1 mL of DRG cell culture media per 10 original DRG.  
4.4.3 DRG Cell Culture 
Polydimethylsiloxane (PDMS) blocks, punched with 1.5 or 2 mm diameter biopsy punches 
(Acuderm, Inc. Ft. Lauderdale, FL, USA) to create small restricted-space culture wells, 
were attached to either glass coverslips or PDMS substrates. Prior to cell plating, glass 
coverslips were treated with concentrated H2SO4 for 24 h to remove any contaminants 
and then washed with distilled water. The PDMS was sterilized in an O2 plasma cleaner 
for 30 s at 100 W. After treatment, the substrates were washed with 70% ethanol and air 
dried in a sterile cell culture hood for 30 min. To functionalize the substrates for neuronal 
culture, 0.05 mg/mL poly-D-lysine (PDL) (BD Biosciences, Franklin Lakes, NJ, USA) and 
0.1 mg/mL laminin (Sigma Aldrich, St. Louis, MO, USA) were placed on the substrates 
and incubated for at least 1 h at 37 ⁰C. Prior to seeding, the PDL/laminin solution was 
removed and substrates were washed with HBSS. A 5–10 µL DRG cell suspension in 
DRG cell culture media obtained from 2.5–3-month old Sprague-Dawley rat ganglia was 
seeded into the restricted space wells. To regulate evaporation, about 200 mL of HBSS 
was added to the dish outside of the wells. The seeded cells were cultured at 37 ⁰C and 
with 5% CO2 for 7–10 days before stimulations. DRG cell culture media was added every 
2–3 days, or more frequently if levels appeared low due to evaporation.  
4.4.4 Release Stimulation and Analysis 
Regional whole DRG release sampling. Left and right L4 DRGs, with the roots and spinal 
nerve attached, were collected from 2.5–3-month old Sprague-Dawley outbred rats after 
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euthanasia by decapitation. Immediately after decapitation, cold mGBSS (120 ml, 4 ⁰C) 
was injected into the subepidermal areas neighboring the SNs and their corresponding 
DRG. Rat trunks were maintained on ice during the surgical dissection procedure. The 
collected semi-intact preparations of DRGs with attached nerves were sequentially 
incubated in ice cold Na+-free artificial cerebrospinal fluid (aCSF-1) composed of (in mM): 
KCl 2.5, NaH2PO4 1.25, CaCl2 0.5, MgCl2 3.5, NaHCO3 26, glucose 10 and sucrose 233, 
and HEPES 15 for approximately 3 h, followed by ice cold aCSF-1 supplemented with 63 
mM NaCl for 20 min. This series of incubations reduced analyte release induced by 
surgical isolation. Next, the DRGs and nerves were moved into standard oxygenated 
artificial cerebrospinal fluid (aCSF-2) (in mM): NaCl 115, KCl 2.5, NaH2PO4 1.25, CaCl2 
0.5, MgCl2 3.5, NaHCO3 26, HEPES 15, and incubated at 36 ⁰C for 20–30 min. The 
structures were placed into an incubation chamber with multiple SPE probes [C18 ZipTip 
pipette tips (Millipore, Billerica, MA, USA)] mounted near specific areas of the peripheral 
sensory-motor system. Outward flow of the aCSF-2 through the pipette tips was 
maintained during the process. Release from the semi-intact preparation was stimulated 
by replacing aCSF-2 with a high K+ aCSF-3 (100 mM KCl, with a corresponding reduction 
in Na+). Solution flow inside the pipette tips was reversed to inflow, and incubation and 
analyte collection continued for 20 min at 36 °C. Four experiments were performed using 
four animals and eight L4 ganglia. Analytes retained on the pipette tips were eluted onto 
a metal MALDI sample plate and mixed with 2.5 μL of 2,5-dihydroxybenzoic acid (DHB) 
MALDI matrix solution (10 mg/mL DHB in acetonitrile (ACN)/water (50:50)). 
Sampling of release from DRG cell cultures. To chemically stimulate DRG cell release, a 
high K+ DRG cell culture media bath (60 mM K+) was used on the restricted-space 
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cultures 7–10 days after seeding. Details on the fluid exchanges used to stimulate release 
were as follows: first, a control sample consisting of DRG cell culture media in which the 
cells had been incubating was collected. At this point, fresh media was placed on the cells 
and they were incubated for 30 min. That media was then removed, creating a pre-
stimulation sample. Next, the high K+ DRG cell culture media was added to the cells and 
removed after 30 min, creating a stimulation sample. A final bath of DRG cell culture 
media was added to the cells, and collected as the post-stimulation sample after 30 min.  
Depending on the experiment and numbers of wells with viable cultures, samples from 
1–10 culture wells per dish were combined by sample type before further processing for 
MALDI MS and/or LC-ESI-FTMS measurements. An initial exploratory release 
experiment used cells cultured from a single rat; samples obtained from individual cell 
culture wells were subjected to MALDI analysis. Another experiment, also with a single 
animal, pooled samples from multiple wells for both MALDI and FTMS analysis. Next, we 
performed six separate cell culture experiments (using six different animals, with samples 
collected on six separate days). We collected control, pre-stimulation, stimulation, and 
post-stimulation samples from each viable well (for a total of 143 wells containing viable 
cultures), and then combined the samples from individual wells together by dish (18 
dishes total). For the combined samples, the analytes were desalted and concentrated 
using SPE probes [C18 ZipTip pipette tips (Millipore)]. The bound sample was washed 
with 5% methanol/0.1% TFA in deionized water and eluted, first with 50% ACN/0.1% TFA 
and then with 75% ACN/0.1% TFA solutions. The eluted samples were mixed 1:1 with 
the DHB MALDI matrix (10 mg/mL DHB in ACN/water (50:50)) on a metal sample plate. 
Mass spectrometric profiling was performed using an UltrafleXtreme MALDI-TOF MS 
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workstation (Bruker Daltonics, Billerica, MA, USA) in the reflectron mode operating at 
positive polarity. Individual mass spectra were analyzed with flexAnalysis (version 3.3, 
Bruker Daltonics). External mass calibration was performed using peptide calibration 
standard II (Bruker Daltonics). Differential comparisons between multiple experiments 
were done using the ClinProTools (Bruker Daltonics) software. In addition to the MALDI 
MS measurements, release samples were analyzed with LC-ESI-FTMS; for this 
experiment, the analytes collected from 34 culture wells from several of the experiments 
were pre-concentrated and desalted using SPE, pooled, and then subjected to LC-ESI-
FTMS (as described below). 
4.4.5 Peptide Identification in Biological Samples  
Six groups of DRGs and associated nerve tissues were subjected to peptide extraction 
and analyzed with LC-ESI-FTMS. To extract the peptides, DRGs were immersed in ice-
cold acidified acetone (acetone/water/HCl, v/v/v, 40/6/1) immediately after isolation from 
the animals until all dissections were finished. For groups 1 and 2, the collected DRGs 
were transferred into 12 mM of ice cold HCl, homogenized, and placed in an ice bath for 
1 h. Supernatant was collected and combined with the acidified acetone mentioned above 
after centrifugation at 20,000 ×g for 15 min. For groups 3–6, the DRGs were placed into 
an 80 ⁰C water bath for 10 min to stop enzymatic protein degradation. The heat-denatured 
DRGs were homogenized, placed in an ice bath for 1 h, and centrifuged as described 
above. The supernatant was saved and tissue pellets were resuspended in 600 µL of 
0.25% acetic acid solution and placed on ice for a 1 h peptide extraction. After 
centrifugation, the saved supernatant was combined with the acidified acetone. The 
combined peptide extracts from all experiments were cleaned using C18 spin columns 
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(Thermo Fisher Scientific, Waltham, MA, USA), dried down with a Speedvac 
concentrator, and reconstituted in H2O/ACN (95:5). 
Each extracted peptide sample was separated on a nanocapillary column (10 cm × 75 
μm inner diameter) containing ProteoPepTM II media (C18, 300 Å, 5 μm, New Objective, 
Inc., Woburn, MA, USA) using an Eksigent nanoLC 1D Plus system (SCIEX, 
Framingham, MA, USA) and analyzed with an 11 Tesla FT mass spectrometer (LTQ-FT 
Ultra, Thermo Fisher Scientific). Separation conditions were as follows: 1) buffer A,  95% 
water, 4.8% ACN, and 0.2% formic acid; 2) buffer B, 95% ACN, 4.8% water, and 0.2% 
formic acid; 3) gradient conditions were: 0–80 min, 0–30% B; 80–105 min, 30–45% B; 
105–120 min, 45–60% B; 120–125min, 60–85%; 125–130 min, 85–85%; 130–145 min, 
85–0%; 4) the operating flow rate was 300 nL/min. 
Data acquisition on the LTQ-FT mass spectrometer consisted of a full scan event (m/z 
300–2000 at 50K resolving power) and data-dependent collision-induced dissociation 
FTMS/MS scans of the five most abundant peaks from the previous full scans. MS/MS 
settings were as follows: isolation width = m/z 10; minimum signal threshold = 5000 
counts; normalized collision energy = 35%; activation Q = 0.25; activation time = 50 ms. 
The RAW files were searched against a lab-built rat proteome database using PEAKS 
software (version 7.0, Bioinformatics Solutions Inc., ON, Canada) and ProSightPC 
(Thermo Fisher Scientific). For database search with PEAKS, 15 ppm and 0.1 Da mass 
tolerances were used for MS and MS/MS modes, respectively. Identified peptides with 
score (-logP > 15) were kept. For ProSightPC, 81.1 Da and 10 ppm mass tolerance were 
used for MS and MS/MS modes. Identified peptides with p value < 10-4 were kept. A large 
mass tolerance was used here because of the ProsightPC biomarker search mode, which 
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involves matching an observed mass to the theoretical masses of possible subsequences 
in the protein database, and then comparing calculated fragments of those subsequences 
to observed fragments. A large mass tolerance window allows peptides with post-
translational modifications (PTMs) to be matched to the subsequences. The value of 81.1 
Da was used here because it can cover the mass shifts related to most common PTMs, 
including amidation, oxidation, and phosphorylation. Peptide identifications with p value 
< 10-4 were kept.  
4.4.6 Calculation of Peptide Signal Intensity Fold Changes across Cell Culture 
Stimulations   
Comparisons of the peptide profiles were performed on the MALDI MS data from the six 
cell culture experiments in their original format using averaged peak statistics functions 
(Kruskal-Wallis test for not normally distributed peak signal intensities as determined by 
the Anderson-Darling normality test) in ClinProTools (version 3.0, Bruker Daltonics). 
Representative spectra acquired from each culture dish from each of the six experiments 
were combined into control, pre-stimulation, stimulation, and post-stimulation sample 
data sets and imported into ClinProTools as separate classes. Each set consisted of 18 
spectra. The spectra preparation settings were: a resolution of 800; top hat baseline 
subtraction of 10% minimal baseline width; 2 cycles of Savitzky-Golay smoothing with a 
width of 2.0 m/z; and a data reduction factor of 3. Peak picking was done on the class 
average spectrum with a signal-to-noise threshold of 3.00. The Benjamini-Hochberg 
procedure was automatically applied to correct for the multiple testing hypothesis issue 
commonly associated with MS data. Peak statistics were calculated by ClinProTools after 
manual removal of signals originating from the physiological media, and addition of 
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signals that were not automatically picked. Peak statistic tables were generated and 
manually analyzed for trends in the change of average peak intensity over the four class 
types.  
4.5 Results and Discussion 
4.5.1 Peptidomics of the DRG Tissues 
Our first goal was to characterize the endogenous peptides present within the DRG and 
nerves, and to determine those that were secreted. Accordingly, our initial studies 
involved characterization of the peptides present within the DRG. Unlike standard bottom 
up proteomics experiments, we did not digest the proteins and characterize the resulting 
peptides, but instead, worked with the peptides naturally present within the samples. 
Here, six groups of DRG tissues were extracted and analyzed with LC-ESI-FTMS, with 
2290 peptides from 296 proteins identified after de novo sequencing and database search 
using the PEAKS software. The database search was performed again using a different 
search tool, ProsightPC (Thermo Fisher Scientific). The ProsightPC search identified 
1650 peptides, 434 of which were unique peptide identifications to the total readout. In 
summary, 1216 peptides were identified by both PEAKS and ProsightPC; 1074 peptides 
were exclusively identified by PEAKS and 434 by ProsightPC. Two and four groups of 
DRG tissues were processed with the two different peptide extraction methods described 
above. As a result, 145 proteins were observed with both extraction procedures, and 84 
and 67 proteins were unique for just one of the extraction procedures, respectively. Our 
results suggest that peptide and protein coverage is increased by using different sample 
processing approaches. Identified peptides were categorized into functional classes, as 
shown in Figure 4.1. The neuronal category represents 40% of all of the peptides detected 
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and consists of peptides related specifically to neuron structure or processes involved in 
neuron formation, function, and maintenance. Among them, several peptides originating 
from proteins involved in neurotransmission and implicated in neurodegenerative 
diseases were identified, such as complexin-1 [41] and gamma-synuclein [42], as well as 
those involved in axon growth and myelination, including vimentin [43] and periaxin [44].  
Endogenous cell-cell signaling peptides act as neurotransmitters and neuromodulators. 
Among the results from six experiments, 18 neuropeptides derived from five prohormones 
were detected. Figure 3.2 shows examples of MS/MS spectra of neuropeptides of various 
lengths, including LVV-hemophin-7, (mass 1323.10 Da), calcitonin gene-related peptide 
I 19-37 (CGRP-1 19-37, mass 1921.95 Da), and secretogranin-2 derived peptide (mass 
3679.80 Da). Another prohormone described most commonly in the DRG is 
protachykinin-1. Short forms of neuropeptide K cleaved at dibasic sites and a C-flanking 
peptide were also detected.  
The presence of CGRP-1 and its mRNA in rat DRGs has been previously reported in 
immunohistochemistry and in situ hybridization studies [45, 46]; CGRP-1 has been shown 
to be essential for pain signaling and increases innervation in DRGs during inflammation 
[46]. Here, full length CGRP-1 (1-37) was detected and confirmed with MS/MS. In 
addition, three truncated forms of CGRP-1 (1-37) were identified from the DRG tissues, 
including CGRP-1 1-17, 18-37, and 19-37. The cleavage site had one arginine, a 
monobasic site that is often involved in neuropeptide enzymatic processing. Saghatelian 
and coworkers [47] discovered that the CGRP-1 1-17, 18-37, and 19-37 are produced 
enzymatically by peptidases. Therefore, those short forms identified in this work are likely 
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endogenous signaling molecules and not products of degradation of CGRP-1 during 
sample preparation. 
The majority of bioactive peptides are generated from larger precursor proteins. However, 
in recent years it has been shown that bioactive peptides can also be generated from the 
cleavage of cytosolic proteins [48]. As a notable example, hemoglobin can be processed 
to yield multiple bioactive peptides, including the hemorphins [49]. Hemoglobin-derived 
(Hb) peptides have been found in a number of cells types within the body, from lens and 
alveolar cells to macrophages, and have also been found within neurons and 
oligodendrocytes, as well as in the sciatic nerve [49]. We observed several hemoglobin-
derived peptides within the tissue samples, including N-terminus extended LVV-
hemorphin-3, and lengthened forms of neokyotorphin and LVV-hemorphin-7. Hemorphins 
are a group of endogenous opioid peptides derived from the β-chain of hemoglobin. They 
work as signaling molecules by binding to opioid receptors and play roles in pain and 
inflammation [50, 51]. LVV-H7 produces attenuate hyperalgesia effects at the spinal level. 
Perhaps the hemorphins detected in these systems participate in the regulation of 
hyperalgesia given the projection of DRGs toward the spinal cord.  
4.5.2 Peptide Profiling of Release   
Our next goal was to determine what molecules are released from the DRG and 
associated nerves, as well as from the cells within the DRG. We used two distinct means 
to probe release: a semi-intact preparation that consisted of the DRG and nerves, and a 
separate set of experiments using a miniaturized microfabricated chamber to allow us to 
culture isolated DRG cells, exchange the culturing fluid to stimulate release, and then 
efficiently collect releasate for characterization. 
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4.5.2.1 Regional Release from DRG and Associated Nerves 
SPE analyte collection was performed simultaneously at four anatomically defined 
regions of the mammalian sensory-motor system: the DR, VR, DRG, and SN. After 
stimulating release with elevated K+ media and characterizing the releasates using 
MALDI MS, more than 100 compounds were observed in the releasates, in both 
metabolite and peptide mass ranges. Although MALDI MS profiling of release from 
biological structures provides the opportunity for multiplexed, semiquantitative, spatially, 
and temporally resolved assessment of the chemical composition of release, identifying 
the compounds using MALDI MS alone can be challenging. In this work we molecular 
mass-matched the signals observed in releasates with the identities of the compounds 
characterized using LC-FTMS from similar tissues.  
A number of peptides known to be released from nervous tissue were observed. 
Thymosin beta-4 was detected, which is consistent with the results of prior release 
experiments from a larger variety of tissues [30, 52, 53]. In fact, the ubiquitous nature of 
thymosin beta 4 in release experiments suggests it can be used as a marker for effective 
release stimulation and efficient sample collection. The metabolite and peptide profiles of 
the releasates we observed from different regions of the mammalian sensory-motor 
system were similar. Further, since all regions had neuronal termini and only the DRG 
had the neuronal cell bodies, these results suggest that nerve terminal- and glia-related 
compounds dominate the profiles. Our previous MS imaging study demonstrated 
considerable chemical heterogeneity in the chemical content between the DRGs, VRs, 
DRs, and SNs [54], so it is intriguing that we observed similar compounds released from 
these regions, as we expect that the content and release profiles would be correlated. In 
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agreement with the observations of similar release profiles for all regions, principal 
component analysis of the corresponding data sets did not allow us to separate the 
analyte profiles of release from these regions. Our inability to distinguish the release 
profiles from these distinct regions may be explained by the dominant release of peptides 
originating from neurofilament L and M proteins, myelin-related proteins, and vimentin. 
Such highly abundant peptides may be obscuring differences in release of much lower 
concentration peptides.  
4.5.2.2 Release from Entire DRG and Cell Culture 
The experiments described above used semi-intact preparations, and releasates were 
collected by placing collection pipettes at specific, spatially defined locations. In the next 
set of experiments, we investigated release from isolated DRGs and groups of cultured 
DRG cells within restricted-volume culture wells. The collection system used a flow-
through design, and either culture media or stimulation media (with elevated K+ added to 
cause secretion) was flowed through the chamber for the designated time period. First, 
we optimized the collection procedure by measuring release from the entire DRG within 
the device and ensuring that the ganglion released enough material for characterization. 
Comparisons between release from a ganglion and cultured cells may yield information 
about the peptide differences observed from in vitro versus in vivo measurements. DRGs 
contain more intact connections between cells and thus, should more closely mimic the 
semi-intact preparation used above and the in vivo environment (Figure 4.3).  
Next, pre- and post-stimulation studies from isolated DRGs were performed with DRG 
cell culture media additions. Elevated K+ (60 mM) solution was added for two exposure 
periods: 15 min and 30 min.  Signals not observed in the pre-stimulation appeared 
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following stimulation, and the intensities of a number of signals increased in the mass 
spectra of the stimulation samples versus mass spectra of the pre-control samples. As 
one example, a signal corresponding with neurofilament light polypeptide became 
detectable in the stimulation sample. Finally, intensities of several signals were found to 
change in the post-control samples, including those that correspond to peptides 
originating from neurofilament medium polypeptide. 
Following isolated ganglion stimulation, a low-density DRG cell culture containing ~20 
neurons within a 1.5 mm PDMS well was stimulated with elevated K+ solution for 30 min. 
Peptides were characterized with MALDI-TOF MS. A series of mass spectra in the 
peptide region are shown in Figure 4.4a. Similar to ganglion stimulation data, a number 
of peaks increased in intensity following the application of elevated K+, suggesting a 
potentiation of release in response to stimulation. The peptides from the cultured DRG 
cell release experiments were also analyzed with LC-ESI-FTMS. The identification results 
show the presence of 28 peptides from 11 proteins. Peptides having known functions 
related to cell to cell signaling, including LVV-hemorphin-7, VV-hemorphin-7, and their C-
terminus extended forms, were detected.  
Interestingly, when compared together (Figure 4.4b), few signals overlap between the 
ganglion and dispersed cell culture stimulation data. An explanation for this is that the 
ganglion data contains signals that were released or secreted in abundance within the 
tissue, obscuring lower-abundance peptides. By having isolated a much smaller subset 
of cells from the cluster and culturing them, we are able to observe release from fewer 
cells so that cell-to-cell chemical heterogeneity may have become more obvious.  
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These results led us to move forward with multiple high-K+ stimulations using DRG cell 
cultures. In total, extracellular media was sampled from cultures involving DRGs from six 
rats on six different days, resulting in the preparation of control, pre-stimulation, 
stimulation, and post-stimulation samples from cells cultured in multiple wells within 18 
different cell culture dishes. Analysis of these samples using MALDI-TOF MS revealed 
41 signals of interest. When compared against the LC-ESI-FTMS data of the inventory of 
characterized compounds from the DRGs, the molecular masses matched 26 peptides 
from 19 different proteins. These proteins include those involved in axonogenesis and 
neurite extension such as neurofilament heavy, medium, and light polypeptides [55], and 
vimentin [56], and those expressed in peripheral neurons and Schwann cells, such as 
high mobility group protein B1 [57], gamma synuclein [42, 58], and peptidyl-prolyl cis-
trans isomerase FKBP1A [59]. In addition, proteins integral to the function of nervous 
tissue, such as periaxin and myelin protein P0 [60, 61], were detected within the samples. 
Interestingly, one potential hemorphin peptide, L.LVVYPWTQRYFDSF.G, was detected 
in the MALDI-TOF MS analysis of samples from the cell stimulation experiment. 
The average intensity of the peptides in each condition class was used to determine 
changes across classes (control, pre-stimulation, stimulation, post-stimulation, and a 
DRG cell culture media blank). Eight signals showed an upward trend in their relative 
intensity between pre-stimulation and stimulation or post-stimulation samples (Table 4.1). 
Of the signals showing an intensity increase, three were identified by mass matching to 
the LC-ESI-FTMS data. Mast cell protease 1-derived peptide signal increased 1.4 and 
1.6 fold from pre-stimulation to stimulation, and pre-stimulation to post-stimulation, 
respectively, while myelin protein P0-derived peptide increased 1.8 fold for both 
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conditions. The signal of a peptide derived from histone H2B had a 1.4 fold increase from 
pre-stimulation to post-stimulation. In addition, 12 signals showed intensity increases 
between the control and pre-stimulation samples. These include the previously mentioned 
histone H2B, myelin protein P0, and mast cell protease 1-derived peptides, as well as 
nine unassigned signals. We do not believe these increases between the pre-stimulation 
and control are related to K+-stimulated release, but rather, they may be related to the 
action of removing the culture media and/or the addition of fresh media, both of which 
could have induced mechanical and/or chemical stimulation.  
4.5.2.3 Peptidomic Analysis of Peptides Released from DRG Cell Culture 
In order to aid in identifying the compounds released from these cells, we also performed 
an LC-ESI-FTMS study of the released peptides. Releasate solutions collected after the 
stimulation experiments were concentrated and subjected to LC-FTMS analysis as 
described above. Obtaining enough analyte for an LC-ESI-FTMS-based peptidomic study 
of released materials was challenging. We expected that high femtomoles to low 
picomoles of material would be needed for efficient MS/MS peptide sequencing. 
However, by increasing cell density, performing sample collection in small wells, and 
combining samples, a number of peptides were identified in the release samples. 
As before, we detected several hemorphins, now confidently assigned. Both LVV-
hemorphin-7 and VV-hemorphin 7, as well as longer fragments of both peptides, were 
observed. These observed Hb-derived peptides act on opioid receptors and most have 
functions relating to antinociception. Thus, from a functional perspective, their presence 
in release makes sense, although the mechanisms of their synthesis and processing 
within these cells it not understood. LVV-hemorphin-7 has also been shown to regulate 
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blood pressure and play a role in learning and memory, as well as cholinergic 
transmission [49]. Further study into the biosynthetic pathways and release of Hb-derived 
peptides within DRG tissue and cells is important. Besides Hb-derived peptides, several 
other classes of peptides were also identified, including thymosin-beta 4, neurofibromin, 
and myelin basic protein. Neuferricin was also detected and is involved in neuronal 
apoptosis and plays an important role in neurotrophin signaling during neuronal 
development [62]. 
4.6 Conclusions 
The DRG and adjacent nerves play an essential role in transmitting sensory information 
from the periphery to the central nervous system, and are major targets in investigations 
of mechanisms of pain, mechanical injury, and regeneration.  We studied this structurally 
well-defined system across levels, from isolated cells to whole tissue, and releasates, to 
investigate the peripheral sensory-motor system’s peptidome and secretome. This broad 
range of sample types, and the cellular and chemical heterogeneity of the samples 
created measurement challenges that we partially addressed using a range of analytical 
protocols and platforms.   
We used a variety of sample preparation and conditioning steps, and multiple ionization 
and mass analyzers during this work. The individual workflows and instrumentation have 
different figures of merit and were selected according to the requirements of the 
experimental objective. To identify peptides in a complex cellular sample, we used LC-
ESI-FTMS, whereas to characterize many samples containing low levels of peptides from 
volume-limited and concentration-limited release samples, we used direct MALDI-TOF 
MS. The advantages of LC-ESI-FTMS for obtaining comprehensive peptide profiles are 
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well established, and direct MALDI MS provides an opportunity to profile large numbers 
of individual samples without purification in a short period of time. This combined work 
flow has been shown to be effective in a number of peptidomics experiments [16, 27, 63, 
64], and was particularly effective in these experiments. As a result, we generated more 
complete peptidome and secretome datasets for the peripheral sensory-motor system, 
providing a better understanding of its chemical composition.  
The inventory of peptides and proteins we report here enables a range of follow-up 
studies using small numbers of cells that form defined networks within engineered 
structures. This investigation of the peptidomes and secretomes of the peripheral 
sensory-motor system has revealed new candidates for peptide neuromodulators, 
hormones, and trophic factors that may have important roles in local and distal 
intercellular communication. Characterizing the spatiotemporal and chemical parameters 
of cellular release provides unique functional insights in fundamental and specific 
mechanisms of peripheral sensory-motor system function. 
4.7 Addendum 
The studies outlined in this paper are led to the identification of a large number of 
molecules. One question that remained was: “Where are the neuropeptides in the 
release?” As was mentioned, even neuropeptides that had been detected previously by 
our lab through mass spectrometry imaging of tissue slices from the DRG, spinal cord 
and spinal nerves and are known to be present in these structures were not detected in 
the release samples. One plausible reason for this lack of expected neuropeptides is not 
that the peptides are not released in our model, but rather that their detection is limited 
by both the types of mass spectrometric analysis performed and the sampling approach 
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due to the relatively low abundance of our target molecules compared to other peptide 
molecules in the sample. In fact, in later experiments we were able to detect released 
neuropeptides using the more sensitive and specific enzyme-linked immunosorbent 
assay coupled with an improved sampling protocol. Since we still believe in the 
importance of our long-term goals to recreate different functional networks of well-defined 
DRG cells within engineered microfluidic devices [38-40] so that we can characterize the 
biochemical responses, including cellular release, of these networks to different stimuli 
and changing microenvironments, the other aspects of my project addresses ways that 










Figure 4.1. Using LC-FTMS, the peptides within DRG tissue extracts have been characterized, 
identified, and grouped by function, with the largest number of peptides corresponding to neuronal 






Figure 4.2. Representative MS/MS sequencing of peptides obtained from DRG tissue and 
release experiments. (a) MS/MS fragmentation of LVV-hemorphin (m/z 662.86, 2+); (b) MS/MS 
fragmentation of CGRP-1 19-37 (m/z 961.98, 2+); (c) MS/MS fragmentation of secretogranin-2 
















Figure 4.3. Mass spectra comparing peaks from stimulation collections from cluster (maroon) and 
culture (blue). Although a number of signals in the peptide range were observed for both samples, 














Figure 4.4. Representative mass spectra acquired with MALDI-TOF MS showing relative 
changes in peak profiles detected within the peptide mass region upon stimulating release from 
DRG clusters and cultured cells. (a) Series of mass spectra showing signals within the peptide 
molecular mass region following control and stimulation of an entire DRG. Peaks which increased 
in intensity or newly appeared are highlighted with an asterisk. (b) Series of mass spectra of 
release collected from ~20 DRG neurons within a 1.5 mm PDMS well. Pre- and post- controls 
were performed with DRG extracellular media; 60 mM elevated extracellular K+ was added to 








Table 4.1. Relative changes in average signal intensities detected in pre-stimulation (pre), 
stimulation (stim), post-stimulation (post), and control samples. Signals were observed in samples 
collected in six different experiments performed on six different animals. Refer to Table S5 for 
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< 0.000001 2.26 8.13 11.01 13.25 3.94 0.75 5.58 6.01 9.11 1.77 
1268.75 Unassigned 
Peak 
< 0.000001 1.62 3.73 4.66 5.37 2.35 0.57 1.98 1.92 2.69 0.84 
Table 4.2. Peak statistics data from ClinProTools including the averages, standard deviations, and covariance for selected 












0.0000059 8.5 7.16 5.47 4.54 2.15 7.48 7.38 3.38 1.55 0.71 







isozyme L1  




























subunit 6A1  
mitochondri
al 
< 0.000001 4.74 2.54 1.26 1.22 0.69 3.26 1.02 0.58 0.53 0.15 
































< 0.000001 6.16 3.39 1.57 0.9 0.51 6.48 4.43 2.34 0.61 0.15 
























< 0.000001 2.43 1.92 1.04 0.95 0.73 1.13 1.01 0.38 0.38 0.23 



















protein 1  
















< 0.000001 3.93 1.94 0.75 0.61 0.35 3.1 1.52 0.46 0.36 0.09 
 
   
  




Theoretical Mass m/z (MALDI) Protein ID Peptide Sequence Identification Stim/ Pre Post/ Pre Pre/ Control 
600.17 601.17 Unassigned   0.47 0.31 0.54 
615.27 616.27 Unassigned   0.47 0.31 0.54 
649.86 650.86 Unassigned   0.50 0.48 0.54 
738.43 739.43 Unassigned   0.66 0.72 0.90 
767.71 768.71 sp|P02091|HBB1_
RAT A.LAHKYH Hemoglobin subunit beta-1 0.44 0.38 0.68 
769.68 770.68 Unassigned   0.79 0.66 0.65 
915.69 916.69 sp|P06907|MYP0_
RAT Y.AMLDHSRS.T Myelin protein P0 0.45 0.32 0.67 
1179.79 1180.79 tr|G3V8B3|G3V8B
3_RAT E.RIAGEASRLAH.Y Histone H2B 0.46 0.32 0.57 
1203.85 1204.85 sp|Q62658|FKB1A
_RAT L.VFDVELLKLE 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A 0.50 0.48 0.54 
1212.86 1213.86 tr|F1LQ96|F1LQ96
_RAT M(+42.01)DVFKKGFSI.A Gamma-synuclein 0.56 0.39 0.62 
1212.86 1213.86 tr|G3V8B3|G3V8B
3_RAT G.TKAVTKYTSSK Histone H2B 0.66 0.72 0.90 
1252.72 1253.72 sp|P09650|MCPT1
_RAT Y.NFYSNLHDIM.L Mast cell protease 1 0.56 0.39 0.62 
1267.75 1268.75 Unassigned   0.50 0.48 0.54 




RAT K.SKGLGESRKDKK Myelin protein P0 0.56 0.39 0.62 
1331.81 1332.81 sp|P19527|NFL_R
AT Y.SAPVSSSLSVRRS.Y Neurofilament light polypeptide 0.79 1.43 1.43 
1331.81 1332.81 tr|G3V7S2|G3V7S
2_RAT E.IIEETKVEDEK.S Neurofilament medium polypeptide 0.62 0.61 0.75 
1353.68 1354.68 sp|P31000|VIME_
RAT L.NDRFANYIDKV.R Vimentin 1.35 1.63 3.60 
1572.59 1573.59 sp|P51886|LUM_R
AT M.SKLPAGLPTSLLTLY.L Lumican 0.65 0.63 0.68 
1572.59 1573.59 sp|Q00981|UCHL1
_RAT MQLKPMEINPEML.N 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 1.75 1.78 4.07 
1574.87 1575.87 sp|P09650|MCPT1
_RAT R.AAGWGQTGVTKPTSNT.L Mast cell protease 1 0.76 0.63 0.84 
1574.87 1575.87 sp|P31000|VIME_
RAT T.VETRDGQVINETSQ.H Vimentin 0.51 0.41 0.63 
1819.61 1820.61 sp|P02091|HBB1_




K.A Actin  cytoplasmic 2 0.76 0.63 0.84 
1856.81 1857.81 Unassigned   0.46 0.36 0.63 
1871.86 1872.86 Unassigned   0.74 0.73 0.97 
1897.02 1898.02 sp|P10818|CX6A1_
RAT L.FHNPHMNPLPTGYEDE 
Cytochrome c oxidase subunit 6A1  
mitochondrial 0.48 0.35 0.55 
1897.02 1898.02 tr|D3ZWM5|D3ZW
M5_RAT  Histone H2B 0.45 0.32 0.67 









Nucleoside diphosphate kinase alpha 
isoform 0.77 0.67 0.75 
2009.07 2010.07 sp|P63159|HMGB1
_RAT M.SAKEKGKFEDMAKADKAR.Y High mobility group protein B1 0.65 0.63 0.68 
2009.07 2010.07 tr|D3ZCR3|D3ZCR
3_RAT  Protein Hmg1l1 1.63 1.64 1.71 
2059.9 2060.9 tr|D4A817|D4A817
_RAT  Histone H2B 0.90 0.87 1.88 
2059.9 2060.9 tr|G3V8B3|G3V8B
3_RAT F.VNDIFERIAGEASRLAHY.N Histone H2B 0.99 0.94 1.83 
2059.9 2060.9 tr|D3ZWM5|D3ZW
M5_RAT  Histone H2B 1.44 1.43 1.64 
2098.2 2099.2 tr|D3ZWM5|D3ZW
M5_RAT L.LPGELAKHAVSEGTKAVTKY.T Histone H2B 0.74 0.67 1.30 
2210.15 2211.15 Unassigned   1.25 1.44 2.30 
2245.86 2246.86 Unassigned   0.54 0.46 0.52 
2271.3 2272.3 sp|Q63425|PRAX_
RAT V.KLPKIPDMAVPDVRLPELQL.P Periaxin 0.57 0.39 0.65 
2358.82 2359.82 Unassigned   0.44 0.38 0.44 
2439.19 2440.19 Unassigned   0.46 0.27 0.55 
2481.21 2482.21 Unassigned   0.61 0.43 0.53 
Table 4.3 (cont) 
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2497.08 2498.08 Unassigned   0.52 0.43 0.60 
2558.41 2559.41 Unassigned   0.66 0.63 0.65 




LHGGGSLHY.A Neurofilament heavy polypeptide 0.40 0.21 0.59 
2628.5 2629.5 Unassigned   0.54 0.49 0.79 




A.F Heat shock 27kDa protein 1 0.52 0.37 0.53 
2806.86 2807.86 Unassigned   0.62 0.68 2.49 
3501.77 3502.77 Unassigned   1.65 1.94 1.08 
3515.78 3516.78 Unassigned   1.77 2.26 10.38 
3806.51 3807.51 Unassigned   0.39 0.31 0.49 
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Peptide Characterization of Mouse Itch Models and Itch-related 
Neurons 
5.1 Notes 
The project outlined in this chapter was born out of a collaboration with Dr. Qin Liu, 
Associate Professor of Anesthesiology at the Center for the Study of Itch at Washington 
University School of Medicine in St. Louis. Dr. Liu’s insights and understanding of the 
sensory nervous system have been very useful for this project. Jeff Guo from the Liu lab 
was instrumental in generating the itch models and helping with dissections. Sheena 
Chatrath and Nathaniel Grabinski, also in the Liu lab, helped with behavioral analysis. In 
the Sweedler lab, Krishna Anapindi and Eduardo De La Toba were integral in performing 
mass spectrometric analysis and data analysis. Ed also helped with behavioral analysis 
in the second set of experiments. Ashley Lenhart helped with the first set of data analysis. 
5.2 Introduction 
Disorders of the peripheral sensory system such as chronic pain and itch remain an 
important health problem for which the full extent of molecular players is not yet 
understood. These sensory modalities are detected through the primary sensory neurons, 
with their nerve endings located in the skin and their cell bodies in the dorsal root ganglion 
(DRG). Primary sensory neurons have a single axon which bifurcates and projects from 
the peripheral nerve endings to the dorsal horn (DH) of the spinal cord, transmitting 
important sensory information to the central nervous system via signaling molecules such 
as neurotransmitters and neuropeptides [1, 2]. While classical neurotransmitters are well 
studied and have relatively defined roles in information signaling, neuropeptides are more 
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diverse and wide-acting [3], making it difficult to study the wide range of influences these 
molecules have on sensory processes.  
Through targeted methods such as immunoassays or through studies of RNA expression, 
we have been able to gain much information about the neuropeptides involved in the 
system. However, these methods do not provide dynamic information about the wide 
range of molecules involved in such systems as increased expression does not always 
translate to increased peptide content and/or release due to the multiple post-translational 
processing steps performed to make neuropeptides [4, 5] and the limited scope of 
targeted studies. Therefore, to gain a better understanding of the endogenous peptide 
content of the DRG, we previously performed peptidomics on healthy DRG tissue from 
rat [6]. Now, we are extending our study of the peptidomics of the DRG to that of tissue 
modeling a diseased state, through mouse models of itch. 
Chronic itch (pruritis) occurs in over 20% of the population and is associated with various 
medical conditions [7, 8]. Unfortunately, the molecular mechanisms of itch sensation are 
not well understood and there are many itch symptoms that are not responsive to common 
anti-itch treatments [9]. Recent work has begun to delineate pain and itch sensory 
responses and has shown that Mas-related G-protein coupled receptors (Mrgprs) [10], 
specifically MrgprA3, MrgprC11, and MrgprD, are important players in the itch sensing 
pathway [11, 12]. Cells containing these receptors specifically respond to chemical 
agonists known to cause itch, such as chloroquine and histamine, which are MrgprA3 
agonists, bovine adrenal medulla peptide 8-22 (BAM8-22) and SLIGRL-NH2, which are 
MrgprC11 agonists, and β-alanine, which is an MrgprD agonist [9, 13]. Morphological, 
immunohistochemical, and functional characterizations of these Mrgpr-expressing 
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subpopulations of sensory neurons provide useful information. However, the in-depth 
peptidomic characterization of the cell signaling molecules found within and released from 
these cells could greatly improve our understanding of the system.  
Due to their prevalence in the nervous system and their involvement in multiple 
physiological processes [3], including sensory responses in the DRG, neuropeptides are 
important molecules to characterize. The involvement of neuropeptides in pain response 
is extensive and we expect to find similar complexity in the neuropeptides involved in itch 
sensation. Already, substance P (SP) [14], endothelin-1 [15, 16], neuromedin B (NMB) 
[17], calcitonin-gene related peptide (CGRP) [18], natriuretic peptide B and the kappa-
opioid dynorphin [19] are implicated in the itch response. A recent study in the Liu lab has 
shown that NMB is expressed in both MrgprA3+ and MrgprD+ neurons and that NMB 
deficiency causes impaired itch responses to multiple pruritogens in mice. This impaired, 
but not completely eliminated response indicates that there may other signaling 
molecules involved in the transmission of itch sensation. Transcriptomic studies have 
demonstrated that other neuropeptides, such as natriuretic polypeptide b, agouti-related 
peptide, neurotensin, and adenylate cyclase activating polypeptide 1 are upregulated in 
itch sensing neurons [20]. Therefore, a characterization and comparison of the full peptide 
content of peripheral nervous system tissues within itch models is apt. 
There are a few ways to generate itch within a rodent model. The AEW model, utilizing a 
15 s application of acetone and diethylether to pre-shaved skin followed with a 30 s 
application of water, is an established model [21] for pruritis which has also been used to 
demonstrate changes in DRG cell responsiveness [22] as well as immunohistochemical 
changes in the dorsal horn of the spinal cord [23] upon development of itch-related 
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behavior. This model has also been used to investigate the changes in peptidergic fiber 
accumulation within various itch-producing paradigms and has indeed shown that the 
number of peptidergic fibers in the skin increases in dry skin models [24].  
For a more disease-specific model, the vitamin D analogue, MC903, is applied to the skin 
to model the disease atopic dermatitis [25, 26]. Atopic dermatitis is a widely prevalent 
chronic disease of the skin that includes inflammation, skin barrier dysfunction, and a 
wide IgE immune response [27]. This model triggers a Th1/Th2 immune response within 
the skin as well as causes increased levels of IgE in the blood and other markers of atopic 
dermatitis, making it a systemic model rather than the localized dry skin model [28]. 
This project utilizes both itch models in a hypothesis-forming study. The goal of this work 
is to find changes in the amount of individual peptides within the DRG and dorsal horn 
(DH) of the spinal cord on treated versus non-treated sides of the animal.  
5.3 Experimental 
5.3.1 Itch Model Generation 
5.3.1.1 AEW (dry skin) Model 
3 B6J WT mice were used to create a dry skin model using acetone, diethylether, and 
water. The model is created by shaving the skin on the upper flank and treating one side 
with a 1:1 acetone/diethylether mixture for 15 s followed by an application of water for 30 
s. This treatment was continued twice daily for 7 d. The other side of the animal is shaved 
and treated as a control, providing us with 3 treatment and 3 control samples for each 





5.3.1.2 MC903 (atopic dermatitis) Model 
6 B6J WT mice were used to create an atopic dermatitis model. The model is created by 
shaving the skin on the upper flank of the animal and treating one side with the vitamin D 
analogue MC903 once daily for 6 d. The other side is shaved and treated as a control, 
providing 6 treatment and 6 control samples from each tissue dissected. Scratch bouts 
were recorded on day 5 and sampling was performed as described below. 
5.3.1.3 Behavioral Assessment 
Animals were video recorded from above in their cages for at least one hour at baseline 
and after 7 days of treatment for the AEW mice and 5 days of treatment for the MC903 
mice.  Upon review of the video, the number of scratch bouts per side for each animal 
were counted and recorded (Table 5.1).  
5.3.2 Itch Model Tissue Sampling 
DH, DRG, and skin samples corresponding to the correct spinal levels and treatment 
versus control side were dissected from each animal. Immediately upon dissection, the 
tissues were stabilized using the Denator Stabilizor system. The tissues were then frozen 
at -80 °C prior to peptide extraction and analysis. 
5.3.3 Itch Model Peptide Extraction and Clean-Up 
The frozen tissues were homogenized using a pellet pestle cordless motor after the 
addition of 200 µL of ice-cold LC-MS grade water. For the first stage of peptide extraction, 
the homogenized tissue suspensions were placed on ice for 30 min. Following this 
extraction, the samples were centrifuged at 14000 ×g for 10 min and the supernatants 
were saved. 200 µL of ice-cold acidified methanol (methanol: formic acid: water 90:9:1) 
were added to the remaining tissue pellets and vortexed for 30 s followed by a 30 min 
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incubation on ice for the second stage peptide extraction. This procedure was repeated 
for the third stage peptide extraction using 200 µL of ice-cold acetic acid water solution 
(0.25%) as the extraction buffer. The supernatants from all extraction steps and were 
combined and dried using a SpeedVac system (LabConco, MO).  
The dried samples were reconstituted in 200 µL of water and loaded onto equilibrated 
C18 spin columns for desalting (Thermo Fisher Scientific, MA). After clean-up, peptides 
were eluted four times: twice with 50 µl each of 50%/50% H2O/ACN solution with 0.1 % 
formic acid (FA) and 0.01 % trifluoroacetic acid (TFA) and twice with 50 µl each 30%/70% 
H2O/ACN solution with 0.1 % formic acid (FA) and 0.01 % trifluoroacetic acid (TFA). For 
different regions, either 5 or 10% of the eluted peptide extract were taken out from each 
of the, pooled and saved in a clean microcentrifuge tube. All samples were evaporated to 
dryness using a SpeedVac system. 
5.3.4 Nanoflow UHPLC for Peptide Identification and Quantitation of Itch Model 
Samples 
For each itch model region, the pooled sample was reconstituted in 10 µl of 99%/1% 
H2O/ACN solution with 0.1% FA. 10 µl of sample was loaded at 15ul/min onto an Acclaim 
PepMap100 C18 peptide trap cartridge (Thermo, MA) for pre-concentration. After 3 min, 
the trap was put in-line with the analytical column and the samples were separated on a 
C18 column (Acclaim Pepmap, 2Å, 75 µm x 150 mm, Thermo, MA) using a Thermo 
Ultimate 3000 RSLC system operated at uniform flow rate of 300nL/min. H2O with 0.1% 
FA and ACN with 0.1% FA were used as solvent A and B, respectively. The peptides 
were eluted using the following gradients:  0-3 min, 1-1% B; 3-6 min, 1-10% B; 6-90 min, 
10-70% B; 90-100 min, 70-99% B; 100-110 min, 99-1% B; 110-120 min, 1-1% B. For 
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quantitation, the dried samples were reconstituted in 10 µl of 99%/1% H2O/ACN solution 
with 0.1% FA and centrifuged at 14,000 xg for 10 min. 8 µl of the supernatant was 
collected, transferred to an auto sampler vial and 7 µl of it was used for analysis with a 
Thermo Ultimate 3000 RSLC (Thermo Fisher Scientific, MA) coupled to high-resolution 
Impact HD Q-TOF mass spectrometer (Bruker Daltonics, MA). The same LC-conditions 
were used both for MS/MS and MS analysis.   
5.3.5 Mass Spectrometric Instrument Parameters 
5.3.5.1 Orbitrap 
Top speed data-dependent precursor ion selection was used for all the three modes on 
Thermo Quadrupole-Iontrap-Orbitrap with a cycle time of 3 s.  The parent ions were 
scanned with an Orbitrap resolution of 120K with an AGC target of 200000. Dynamic 
exclusion was turned on with the following settings: exclusion time = 60 s; mass tolerance 
= +/- 10 ppm; repeat count = 2. For the Orbitrap (OT) detection, the parent ions were 
scanned in the range of 200-1200 m/z, the fragment ions were scanned with an Orbitrap 
resolution of 30K, maximum injection time of 60 ms and AGC target of 50000. Precursor 
ions with a charge ranging from +1 to +7 were considered. A normalized collision energy 
(NCE) value of 35% was used for the CID fragmentation.  
5.3.5.2 QTOF 
The samples were subjected to LC-MS analysis using Bruker IMPACT HD QqTOF 
outfitted with CaptiveSpray nanosource. The data was acquired in MS1 mode over a 
range of 290-3000 m/z with a cycle time of 3 s. A fixed MS1 scan rate of 1 Hz was used. 




5.3.6 Bioinformatic Search Criteria for Peptide Library Construction 
The acquired .RAW files from Thermo Orbitrap Fusion were imported into PEAKS 7.5 or 
8 software (Bioinformatics Solutions Inc., Canada) and searched against a mouse 
proteome database with 81,515 proteins downloaded from UniProt for identification. The 
following database searching parameters were used: precursor mass tolerance, 20 ppm; 
fragment mass tolerance, 0.1 Da; no enzymatic cleavage; variable PTMs including 
acetylation, amidation, phosphorylation, half-disulfide bond, pyroglutamination and Met 
oxidation; maximum number of variable PTM, 3.  A false discovery rate (FDR) threshold 
of 1% was used to filter the identified peptide sequences. The list was also manually 
validated to remove possible artifacts such as incorrect post-translational modifications 
(PTMs), due to statistical sequence assignment by the search engine.  
5.3.7 Peptide Quantitation 
The peptide quantitation was performed using SKYLINE software developed by the 
MacCoss lab [29, 30]. A SKYLINE project was built for each region of interest. First, the 
SKYLINE-compatible .mzxml file was exported from PEAKS using its inbuilt algorithm 
loaded into its corresponding project to build a peptide library. The following settings were 
used for importing the PEAKS search data onto SKYLINE: min.length of peptide = 3, 
max.length of peptide = 60, pick peptides matching: library, rank peptides: intensity, 
modifications: all the modifications used in bioinformatic search with a maximum of 4 
variable modifications per peptide. Regression Fit, Normalization Method and Regression 
Weighting were all set to none. Only y ions with charge state +1 to +4 were used for 
peptide library construction. The library contained information including identified 
peptides and their m/z. After peptide library construction, LC-MS data files from different 
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regions were imported into their corresponding projects. Savitzky-Golay smoothing was 
applied to all the MS1 chromatograms after import. SKYLINE extracted the ion 
chromatograms (XIC) for peptides contained in the library from every single imported LC-
MS file and the integrated peak areas were used for quantitation. To ensure the correct 
peaks were picked for quantitation, three criteria were set: the mass error between the 
detected m/z in the LC-MS results and the theoretical peptide m/z was less than 20 ppm; 
the retention time difference between LC-MS and LC-MS/MS experiments was less than 
5 min; and the Isotope Dot Product score (idotp), which represents similarity between 
expected and observed precursor isotope distribution, was over 0.95. Peptides fulfilling 
all three criteria were kept and quantified by adding the peak areas corresponding to the 
first three isotopic peak patterns. For peptides with multiple charge states detected, the 
peak areas for different charge states were summed. The summed peak areas were 
baseline subtracted, log2 transformed and exported to Microsoft Excel for further 
statistical analysis.   
5.3.8 Statistical Analysis 
5.3.8.1 LOESS Normalization to Account for Run-to-run Variability 
A locally weighted regression analysis (LOESS) was used normalize the peptide peak 
areas in different runs using the online tool Normalyzer [31]. Normalization was performed 
to account for run-to-run variability introduced due to various factors such as sampling 
artifacts, instrumental variability and pipetting errors. The normalization was performed 
with the assumption that the sum of all the quantifiable peptide areas matched to the 
peptide library should be equal/similar across all the biological replicates of a given 
treatment. The data is transformed into the standard M (log ratio) and A (mean average) 
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scales within a specific treatment group. The MA plot is constructed using replicates from 
the same treatment group and fitted with a polynomial using a local regression based 
weighted least squared (WLS) method. Based on the size of residuals between the 
individual M values and the WLS curve, a new set of fitted M’ values are computed. The 
weighted regression assigns smaller weights to larger residuals and higher weights to 
smaller residuals to ensure the data is locally normalized. This process of fitting WLS 
curve is iterated until there is convergence. The final set of transformed M’ values are 
used to assign the new normalized peak areas for each of the considered peptides. 
Therefore, LOESS normalization corrects systematic bias present in the sample without 
removing the biological variability.  
5.3.8.2 Student’s t-test to Identify the Significantly Changed Peptides and Proteins 
To identify the peptides which had a significant change between the treatment and control 
samples, paired, 2-tailed Student’s t-test with equal variance was used. The peptides that 
show up to be significantly different in both the independent cohorts were compared. The 
ones that fall below the set value (p ≤ 0.05) in both the sets were considered significant 
differences.   
5.3.9 Protein Analysis using PANTHER 
A PANTHER (Protein ANalysis THrough Evolutionary Relationships) analysis was 
performed using the protein accession numbers for the detected peptides [32, 33]. 
Comparisons were made between various groups, including all detected proteins and 






5.4.1 Peptide Quantitation of Itch Models 
After the analysis with SKYLINE and the statistical analysis, 53 peptides from 38 
precursor proteins were identified to be statistically different in amount between the 
treated and control samples at a confidence interval of 95%, without a false discovery 
rate (FDR) correction (Table 5.2). More specifically, in the DH, 9 peptides in the AEW 
model and 7 in the MC903 model were found to have different expression levels between 
the treated and control samples. Likewise, in the DRG samples, 19 peptides in the AEW 
model and 18 peptides in the MC903 models were found to be different in expression 
levels between the treated and control samples. Some of the peptides determined to be 
significant by the paired t test did not actually have peak area values for all three samples. 
Therefore, these peptides were removed from the list leaving 7 significantly different 
peptides in the DH MC903 model, 8 in the DH AEW model and 14 in both the DRG AEW 
and MC903 samples, making a total of 43 peptides detected to be significantly different 
among all models (Figures 5.1- 5.4).  
11 of the peptides detected with statistical significance are derived from known 
prohormones, with 6 being known neuropeptides (somatostatin-28, dynorphin B29, C-
terminal flanking peptide TAC1, substance P, nocistatin, PEN), and one, fibrinopeptide A, 
while not derived from a verified prohormone, has been implicated in neurochemical 
responses (Table 5.3 and Figure 5.5). It is notable to point out, however, that PEN was 
only detected in 2 out of the 3 samples. 
However, it must be noted that because this study is a hypothesis-driving study, this data 
has not been corrected for the FDR. Hundreds of peptides were detected by the mass 
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spectrometer for each group (294 for MC903 DH, 317 for DRG AEW, 181 for DH AEW, 
and 349 for MC903 DRG), but only a small number of peptides are considered to have 
changed significantly in each group (7, 14, 8, and 14 respectively). Therefore, an FDR 
correction would not give any significant changes. Due to the importance of not missing 
a truly significant result and the expectedly low number of peptides that would be 
expected to change compared to the number of peptides that can be detected in a 
sample, we chose to make this particular study a hypothesis-forming study.  
PANTHER analysis showed potentially interesting differences between the protein make-
up of the significantly changed peptides compared to all detected peptides. Specifically, 
the changes in the molecular function and protein class classifications proved interesting 
(Figure 5.6). Within the molecular function group, the ratio of the proteins related to 
transporter activity increased in the significantly changed groups compared with total. 
Additionally, proteins with translation regulator activity and structural molecule activity did 
not show up in the changed groups. Perhaps more interesting is the protein class 
comparison, in which the protein make-up of the significantly increased group looks very 
different than the protein make-up of the significantly decreased and not changed groups. 
Within these groups, there is an increase in the ratio of enzyme modulators and signaling 
molecules in the significantly increased group while there is an increased ratio of nucleic 
acid binding proteins and oxidoreductase observed in the significantly decreased group.  
 5.5 Discussion 
The goal of this project was to determine changes in the neuropeptide content of DRG 
within the context of an itch model. Encouragingly, changes in a few key neuropeptides 
were observed between the treatment and control model, namely substance P, 
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somatostatin-28, dynorphin B-29 and PEN. Additionally, there were quite a few 
statistically significant changes in levels of other peptides that may be of note, even if they 
are not specifically neuropeptides.  
Substance P (RPKPQQFFGLM(-.98)) is an undecapeptide cleaved from the prohormone 
protachykinin-1 and is found in and released from both peripheral and central sensory 
neuron terminals in response to noxious stimuli [34]. Substance P acts on target neurons 
by inducing slow, long-lasting depolarizations which cause hypersensitization and can 
also act on blood vessels and immune cells to increase the inflammatory response [3, 34, 
35]. Specific to itch-related functions, substance P has been shown to elicit scratching 
upon injection into the rostral back of mice [14], has been specifically implicated in the 
transmission of non-histaminergic itch signals in the spinal cord [36], and has been shown 
to be increased in the plasma of patients with atopic dermatitis [37].  
A shortened form of the neuropeptide Somatostatin-28 (89-100) was also significantly 
decreased in the atopic dermatitis model. However, this peptide was detected in the DRG 
rather than the DH. Somatostatin has long been implicated in the pain response, but has 
recently also been specifically investigated for its role in itch transmission, particularly due 
to its expression in a subpopulation of sensory neurons known to respond to itch [38-40]. 
It was found that somatostatin plays an important role in the transmission of itch by 
inhibiting the peptide dynorphin, which has been shown to inhibit itch response [19, 40]. 
It is unclear from these publications which length of somatostatin is involved in these 
systems. Perhaps our use of mass spectrometry and exact peptide sequencing can shed 
some clarity on this situation. Interestingly, a shortened form of Dynorphin B-29 was 
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significantly increased in the dorsal horn of AEW models, perhaps indicating an itch-
inhibitory counter-reaction. 
The relationship of the neuroendocrine peptide, PEN, to itch is less straightforward. PEN 
is significantly increased in AEW-treated DRG. A role for this peptide in sensory response, 
however, has not been determined as it is usually associated with feeding or appetite-
related behaviors.  
Peptides derived from prohormones also implicated in sensory responses and/or 
signaling such as proenkephalin A, secretogranins 1 and 3, and pronociceptin were also 
increased in the AEW model DRG samples. A peptide from thymosin beta-10 was 
decreased in the MC903 DRG samples. 
While some of the peptide changes detected in this project seem to fit into the narrative 
we would expect, others seem to be paradoxically changing. MS measures the amount 
of peptide in the tissue; if a peptide undergoes activity dependent release, its amount 
within the tissue will first decrease. However, a longer-term use of a peptide can result in 
more synthesis and accumulation. Thus, an increase in the use of a specific peptide 
during our itch model will change the amount detected, but the direction of change 
depends on peptide release/synthesis dynamics and is difficult to predict. Neuropeptide 
signaling is a dynamic system in which location, timing, and sampling methods all 
influence which peptides are more or less present as well as if we can detect that change. 
The purpose of this preliminary study is for us to get a feel for which peptides we should 
be looking at more closely within itch model systems and why. Once those peptides are 
determined, we can look further into understanding timing, location, and release patterns. 
Toward this end, the results of the PANTHER study provide insight into which functions 
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the changing peptides may be involved in, helping us to determine if the changes we are 
seeing make biological sense. 
Additionally, it is also important to look at the nerve endings to fully understand the 
neuropeptide response. Detection of peptide content and release at the nerve endings is 
challenging, due to the low amount of peptide material in such samples and the high 
amount of other material, such as skin peptide content. So far, we have not been 
successful in analyzing the skin samples for neuropeptides from these animals for these 
reasons. However, the incorporation of such data is very important to the understanding 
of this system. 
5.6 Future Directions 
The project described in this chapter is a hypothesis-driving study. Therefore, the 
experiments are being repeated to test their validity and reproducibility before more labor-
intensive validation studies are undertaken. For the second study, we increased the 
number of animals to 20. This number allows for 5 replicates for each treatment group 
(MC903 and AEW) with 2 animals per replicate. The treatment, sample collection, and 
behavioral analysis (Table 5.4) has been performed for these samples. As a result of the 
behavioral data, we did remove two animals per set, leaving 4 replicates of 2 animals 
each. The samples are currently being analyzed. If the hypothesis is correct, we will 







Figure 5.1: All statistically significantly changed peptides in the dorsal horn MC903 model 




Figure 5.2: All statistically significantly changed peptides in the dorsal horn AEW model 





Figure 5.3: All statistically significantly changed peptides in the DRG MC903 model (normalized 





Figure 5.4: All statistically significantly changed peptides in the DRG AEW model (normalized 





Figure 5.5: Changes in peptides that are classified as known neuropeptides between control and 
treatment models.  Substance P is from DH MC903 model, dynorphin B-29 and nocistatin from 
DH AEW model, C-terminal flanking peptide, fibrinopeptide A, and PEN from DRG AEW model 





Figure 5.6:  PANTHER Analysis of the proteins that all detected peptides are derived from (left 
column) , the proteins that all significantly changed  peptides are derived from (2nd column), the 
proteins that all significantly increased peptides are derived from (3rd column), and the proteins 





Mouse ID Genotype Sex Treatment Bouts of Scratching (30 min) 
 





    
L Flank R Flank L Flank R Flank 
WT424 B6/J F AEW (L Flank) X X 107 62 
WT442 B6/J F AEW (L Flank) X X 109 38 
WT443 B6/J F AEW (L Flank) X X 37 10 
WT421 B6/J F MC903 (R Flank) 0 55 X X 
WT422 B6/J F MC903 (R Flank) 2 90 X X 
WT423 B6/J F MC903 (R Flank) 18 7 X X 
WT450 B6/J F MC903 (R Flank) 0 1 X X 
WT451 B6/J F MC903 (R Flank) 0 0 X X 
WT452 B6/J F MC903 (R Flank) 0 3 X X 
 







Table 5.2  Peptide Changes in Mouse Itch Models 
     
Tissue Model Peptide Sequence Average 
Normalized Areas 






   
 
AEW 
      
  
SFARAPQLDL 24.7 24.9 0.007 Secretogranin-1 --- 
  
SQENPNTYSEDLDV 23.4 23.7 0.012 Preprodynorphin:Pro
enkephalin-B 
shortened form of 
dynorphin B-29 
  
V(+42.01)NPTVFF 21.5 22.1 0.012 peptidyl-prolyl cis-
trans isomerase A  
--- 
  
RSPQLEDEAKELQ 19.4 19.7 0.031 Proenkephalin-A part of the propeptide 
  
LSDDDRVTWAEQQYE 20.0 20.5 0.032 Neuroendocrine 
convertase 1 
part of the propeptide 
  
M(+42.01)EMDKRIYLEL 24.0 24.7 0.033 Acidic leucine-rich 
nuclear 
phosphoprotein 32 










ELSAERPLNEQIAEAEAD 20.6 21.2 0.041 Secretogranin-3 --- 









      
  





LGALFNPYFDPLQWKNSDFE 23.4 23.8 0.010 Secretogranin-1 --- 
  
A(+42.01)EDIKTKIKNY 21.5 20.7 0.020 Cytochrome C 
Oxidase subunit 6B1 
--- 
  






18.9 18.5 0.034 Thymosin beta-10 --- 
  





20.9 21.1 0.044 Somatostatin antrin plus propeptide 
        
DRG 
      
 
AEW 
      
  
SLKQTPLSR 18.4 18.0 0.002 Clathrin Light Chain --- 














19.5 17.1 0.005 Beta-globin --- 
  
S(+42.01)GGKYVDSEGHLY 23.7 23.3 0.007 Caveolin-1 --- 
  








ALNSVAYERSAMQNYE 22.2 20.1 0.015 Tachykinin 1 C- terminal flanking 
peptide 
  




25.4 23.8 0.022 Nefl protein --- 
  
QELRPTLNELGISTPEELGLDKV 19.3 20.5 0.028 Cytochrome c 




GEGILPDGGEYKPPSDS 20.3 19.0 0.035 Epsilon-Sarcoglycan 
splicing variant 3B 
--- 
  
LPLVDTH 20.5 21.2 0.036 Vimentin --- 








RPTLNEL 18.9 19.5 0.039 Cytochrome c 




TSHVQEEQTEVEETIEATK 25.1 24.0 0.042 Nefl protein --- 
  
A(+42.01)ASTDIAGLEESFRKF 22.2 20.4 0.043 Tubulin 
polymerization-
promoting protein 
family member 3 
--- 
  








      
  




PSQMEHAMET 18.3 15.5 0.001 S100 calcium 
binding protein A10 
--- 
  
SANSNPAMAPRE 21.5 20.7 0.001 Somatostatin shortened form of 
Somatostatin-28 
  
ITAFNDGLNHLDSL 21.2 19.7 0.002 Beta-globin --- 








FQKVVAGVAA 21.1 20.9 0.007 Beta-globin --- 
  
TLGAHDVSKTESTQQK 20.0 18.8 0.007 Mast cell protease 4 --- 
  













FGGSGTSSRP 18.7 19.2 0.022 Vimentin --- 
  




LSDLHAHKL 18.9 16.9 0.027 Alpha globin 1 --- 
  






SNLHDIM 22.0 18.6 0.040 Mast cell protease 4 --- 
  
SPGGAYVTR 20.5 20.1 0.044 Vimentin --- 































Table 5.3: List of peptides from known prohormones and/or known signaling molecules that were found to be significantly different in 







Peptide Name Region Itch 
Model 
Peptide Sequence P-Values 
Somatostatin-28 
(1-12)* 
DRG MC903 SANSNPAMAPRE 0.001 
Secretogranin-1 
(588-597) 
DH AEW SFARAPQLDL 0.007 
Secretogranin-1 
(516-535) 
DH MC903 LGALFNPYFDPLQWKNSDFE 0.010 
Dynorphin B-29 
(15-28)* 
DH AEW SQENPNTYSEDLDV 0.012 
C-Terminal 
Flanking 
Peptide TAC 1* 
DRG AEW ALNSVAYERSAMQNYE 0.014 
Proenkephalin A 
(196-208) 
DH AEW RSPQLEDEAKELQ 0.031 
Secretogranin-3 
(38-55) 
DH AEW ELSAERPLNEQIAEAEAD 0.041 
Substance P* DH MC903 RPKPQQFFGLM(-.98) 0.043 
Somatostatin 
(25-76) 





DH AEW VRSLVQV 0.047 
Fibrinopeptide 
A* 
DRG AEW TDTEDKGEFLSEGGGVR 0.047 






Animal Treatment Baseline Bouts of Scratching Day 7 Bouts of Scratching  
1-1 AEW (Right Side) L: 2 R: 4 L: 2 R: 0 
1-2 AEW (Right Side) L: 4 R: 0 L: 15 R: 27 
1-3 AEW (Right Side) L: 0 R: 6 L: 8 R: 58 
1-4 AEW (Right Side) L: 0 R: 6 L: 37 R: 64 
1-5 AEW (Right Side) L: 2 R: 3 L: 5 R: 14 
2-1 AEW (Left Side) L : 0 R: 0 L: 50 R: 8 
2-2 AEW (Left Side) L: 1 R: 0 L: 82 R: 19 
2-3 AEW (Left Side) L: 0 R: 1 L: 1 R: 4 
2-4 AEW (Left Side) L : 0 R: 0 L: 5 R: 2 
2-5 AEW (Left Side) L: 1 R: 0 L: 117 R: 10 
3-1 MC903 (Right Side) L: 3 R: 0 L: 0 R: 33 
3-2 MC903 (Right Side) L: 0 R: 4 L: 2 R: 27 
3-3 MC903 (Right Side) L: 1 R: 2 L: 0 R: 26 
3-4 MC903 (Right Side) L: 1 R: 4 L: 0 R: 3 
3-5 MC903 (Right Side) L: 0 R: 2 L: 3 R: 17 
4-1 MC903 (Left Side) L : 6 R: 5 L: 61 R: 25 
4-2 MC903 (Left Side) L: 0 R: 0 L: 22 R: 13 
4-3 MC903 (Left Side) L: 2 R: 4 L: 98 R: 21 
4-4 MC903 (Left Side) L : 0 R: 3 L: 32 R: 2 
4-5 MC903 (Left Side) L: 10 R: 2 L: 64 R: 8 
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Characterization of Neuropeptide Release from Dorsal Root Ganglion 
Neurons upon Chemical Stimulation 
 
6.1 Notes  
Throughout the project described in this chapter, Ashley Lenhart worked diligently to 
improve our sample preparation methods for neuropeptide detection and helped with the 
stimulations and sample preparation. Krishna Anapindi helped with LC-MS/MS analysis 
and provided great insights on peptide detection, Jeff Guo at the Liu Lab at Washington 
University in St. Louis helped with calcium imaging of experiments, Dr. Stanislav 
Rubakhin helped with DRG dissections, Yujin Lee helped with cell culture, and Dr. Thanh 
Do provided encouragement and revived my search for substance P by helping with the 
tissue homogenate samples.  
6.2 Introduction 
The initial goal of this project was to detect and characterize a wide range of 
neuropeptides released from sensory neurons in a spatially and temporally relevant 
manner. Matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass 
spectrometry (MS) was chosen due to its ability to provide quick and accurate information 
about chemicals detected in the peptide mass range without a need for large sample 
sizes or targeted analysis [1-3]. Unfortunately, we have been unable to detect known 
neuropeptides released from cultured sensory neurons in this manner [4]. What follows 
is our attempt to rectify this issue. 
To address the difficulty of detecting the pico-femtomolar concentration of neuropeptide 
within the release samples, one of the most well-known neuropeptides in the sensory 
137 
 
nervous system, substance P, was used as a goal for detection. Substance P is a peptide 
that is released both peripherally and centrally in response to changes in pH, temperature, 
cytokine activity, and other inflammatory responses which sensitizes the neurons upon 
which it acts [5-7]. Substance P has been detected via immune-based assays in 
releasates from sensory neurons upon high potassium activation [8-10] and, therefore, 
should be detected upon high potassium stimulation of our DRG cell cultures. This 
chapter outlines a series of changes implemented to our procedures and protocols to 
troubleshoot the detection of substance P in released samples.  Multiple methods were 
employed, with one aim to ensure correct stimulation and sampling protocols and the 
other aim to improve detection of substance P using standards. Toward the first aim, 
calcium imaging was implemented to verify stimulation of the cells, cell culture amounts 
were increased, immunostaining was used to verify the presence of substance P, and 
release and homogenized samples were analyzed using MALDI, liquid chromatography 
(LC)-MS/MS and enzyme-linked immunosorbent assay (ELISA). Toward the second aim, 
a series of dilutions of substance P standard in water and cell culture media were 
performed, solid phase extraction parameters were tested, and new matrix application 
techniques were employed.  
6.3 Experimental  
6.3.1 DRG Cell Dissociation and Seeding  
Dorsal Root Ganglia (DRG) were isolated from adult or neonatal rats and sustained in a 
bath of ice cold Hibernate A (BrainBits Springfiled, IL) for up to 24 h before dissociation. 
For postnatal day 2-5 rats, DRG were digested in a solution of 0.2% type II collagenase 
and 0.6% protease in DRG serum-free media containing Neurobasal A without phenol 
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red (Life Technologies Carlsbad, CA), 100 U/mL penicillin/streptomycin (Life 
Technologies), 0.5 mM GlutaMAX (Life Technologies), 50 ng/mL NGF (Life 
Technologies), 50 ng/mL BDNF (Prospec Bio Rehovot, Israel), and 500 µL B27 Growth 
Supplement (Life Technologies) for 30 min at 37 ºC. After digestion, the samples were 
subjected to centrifugation for 2-3 min at 200 xg. The supernatant was removed, and the 
pellet washed with Hank’s Balanced Salt Solution (HBSS) (Life Technologies). Upon 
centrifugation using the same parameters, the supernatant was removed and the pellet 
triturated using fire-polished pipets. Following trituration, the supernatant was removed 
and centrifuged after the debris was allowed to settle at the bottom of the tube. After 
centrifugation, the supernatant was removed and the pellet washed with HBSS. A final 
centrifugation was performed after which the pellet was resuspended in 200 µL of media 
and 20 µL of cell suspension was added to the cell seeding well of a device treated with 
poly-D-lysine (BD Biosciences Franklin Lakes, NJ) and Laminin and incubated for 30 min 
at 37 ºC. If appropriate, the device is tilted to enhance movement of cells toward the 
microchannels. After 30 min, all wells were filled with 150 µL of media. The cells were 
incubated at 37 ºC, with a media change at 24 h and then every 3 d until needed for 
experiments. 
For adult rats, DRGs were digested in a solution of 0.25% collagenase (Worthington 
Biochemical Corp, Lakewood, NJ, USA) in DRG cell culture media for 1.5 h at 37 ⁰C. After 
digestion, the samples were treated the same as the neonatal rat samples, with the final 





6.3.2 Chemical Stimulation for Release  
To stimulate nonspecific peptide release from DRG cells, cell culture media with 60mM 
K+ was used, rather than the normal 5mM K+ that is present in the cell culture media. 
First, a control sample consisting of the media in which the cells were incubated was 
collected. Next, fresh media was added through the inlet port and the cells were incubated 
at 37 °C for 5 min. After incubation, that media was removed through the outlet port, 
creating a wash sample. Next, media containing 60 mM KCl was added to the cells. After 
5 min, the high potassium media was removed and labeled the stimulation sample. A final 
wash of media was added to the cells and collected as the post-stimulation sample 5 min 
after addition to the cells (Figure 6.1).  
To stimulate nonspecific peptide release from DRG cells cultured in standard dishes, the 
same media stimulation steps were used, except the media was carefully added and 
removed as bath stimulations rather than flown through the inlet and outlet ports. 
Additionally, a few experiments were performed in which one set of cells were not 
stimulated at all. These samples were used as a non-stimulation sample. 
6.3.3 Calcium Imaging of Stimulated Cells 
DRG cells were cultured for 24 h and then washed with calcium imaging buffer (in mM: 
130 NaCl, 3 KCl, 0.6 MgCl2, 10 HEPES, 10 Glucose, 1.2 NaHCO3, 2.5 CaCl2, ~290 
mOsm, pH 7.4) twice before incubation with Fura2-AM for 30 min. After incubation, the 
cells were washed twice and then stimulated with 60 mM KCl in both calcium imaging 





6.3.4 Immunofluorescent Imaging of Cultured Cells 
DRG media was replaced with a 4% paraformaldehyde (Ted Pella, CA) fixation bath at 
room temperature for 15-20 min. The cells were then washed with PBS (Life Technologies 
Carlsbad, CA) five times, with the last wash lasting five min with shaking. 0.25% Triton X 
(Sigma-Aldrich St. Louis, MO) was added to the cells for 10 min to permeabilize the 
membranes. A wash was performed and a blocking solution of 5% normal goat serum 
(NGS) (Life Technologies) in PBS was added for 30 min for dish cultures and 1 h for 
devices with shaking. Another wash step was performed and the primary antibody in a 
2% NGS solution was added and incubated overnight at 4 ºC. After incubation, a wash 
was performed, and the second primary antibody was added and incubated overnight. 
After that incubation, another wash was performed and the secondary antibody in a 2% 
NGS solution was added to the culture for 1-2 h. If 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) was used, the culture was rinsed and DAPI added to the culture 
and incubated for 20 min. Finally, the cells were subjected to a final wash step, rinsed 
with DI water for 30 s, and mounted with ProLong Gold Antifade (Life Technologies) onto 
a glass slide. If not visualized immediately, the slides were kept in the dark at 4 ºC until 
imaging with a Zeiss Axio Imager M2 (Carl Zeiss AG, Oberkochen, Germany). Primary 
Antibodies: Substance P polyclonal antibody (Enzo Life Sciences), β3 tubulin monoclonal 
antibody (Santa Cruz Biotechnology), and DAPI nuclear stain (Thermo Fisher Scientific). 
Secondary antibodies: Alexa Fluor (Life Technologies) goat antibodies with excitation 





6.3.5 Released Sample Preparation for MALDI MS 
Samples were processed via a series of desalting and concentrating steps using Zip Tip 
C18 pipet tips (Millipore, Billerica, MA) and eluted onto a ground steel MALDI target 
(Bruker Daltonics Inc., Billerica, MA) with 75% ACN/0.1% TFA solution, as outlined in a 
previous publication [4]. Initially, final eluted samples were combined on the MALDI target 
in a 1:1 ratio of DHB using a dry droplet method. To improve analyte detection, dilutions 
of a peptide standard were subjected to various matrix application methods, including 
sample:DHB ratios of 5:1 and 10:1, changing the matrix to ɑ-Cyano-4-hydroxycinnamic 
acid (CHCA), and implementing a triple layer MALDI matrix application which consists of 
first applying CHCA in a thin layer, allowing it to crystalize, applying it in a dried droplet 
form, adding the sample, and washing the sample with cold, acidified water once it has 
dried.  
6.3.6 Released Sample Preparation for LC-MS and ELISA 
200 µL of sample were removed per dish per sample set and immediately acidified using 
10% volume of 5% TFA in water. The samples were kept on ice until all samples were 
collected, after which they were spun down to remove any solid debris and then dried 
using a SpeedVac concentrator. After drying, the samples were re-suspended in a 98:2 
water:ACN with 0.1% FA and 0.01% TFA solution, vortexed vigorously, and spun again 
to remove any remaining solid debris. The supernatant was taken and desalted with 95:5 
water:ACN with 0.1% FA and 0.01% TFA solution using a pre-equilibrated C18 spin 
column. The sample was then eluted twice with 50:50 water:ACN with 0.1% FA and 
0.01% TFA and three times with 30:70 water:ACN with 0.1% FA and 0.01% TFA. After 
elution, the samples were once again dried in a SpeedVac concentrator. For LC- 
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triplequadrupole(QQQ)-MS analysis, the samples were re-suspended in 20 µL 50:50 
ACN:water solution with 1% FA. For ELISA analysis, the samples were re-suspended in 
50 µL assay buffer and the ELISA methods were carried out according to the 
manufacturer’s instructions. 
6.3.7 Homogenized Sample Preparation for MALDI-TOF, LC-MS and ELISA 
Homogenized sample preparation followed a previously published protocol [11]. Briefly, 
200 µL of ice-cold acidified methanol (90% methanol, 9% water, 1% HCL) were added to 
each cell culture dish. The cells were scraped and rinsed twice using additional ice-cold 
acidified methanol, then added to a conical tube and kept on ice until all dishes in the 
sample set were harvested. The samples were then subjected to homogenization, 
separated into 200 µL aliquots and dried via a SpeedVac concentrator. After drying, the 
samples were re-suspended in 98:2 water:ACN with 0.1% FA and 0.01% TFA and 
prepared for LC-MS and ELISA analysis as indicated above. For MALDI analysis, the 
dried sample was mixed with 50 mg/mL 2,5-dihydrobenzoic acid (DHB) in 50:50 
ethanol:water with 1% TFA and spotted onto a ground steel MALDI plate for analysis. 
6.3.8 MALDI-TOF Analysis 
A select group of samples were analyzed using an ultrafleXtreme TOF mass 
spectrometer (Bruker Daltonics). Mass calibration is performed using peptide calibration 
standard II (Bruker Daltonics). Individual mass spectra were analyzed with flexAnalysis 
(version 3.3, Bruker Daltonics). 
6.3.9 LC-MS Analysis  
Samples were analyzed with a UHPLC system coupled with an EVOQ QQQ-MS (Bruker 
Daltonics, Billerica, MA, USA). For separation, Solvents A and B were water/0.1% FA and 
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ACN/0.1% FA respectively. The gradient for elution was 5% B for 0-1 min, increased to 
85% B for 1-8 min, 85% B for 8-9 min, decreased to 5% B for 9-10 min, and 5% for 10-
12 min at a 500 μL flow rate.  
6.3.10 ELISA Analysis 
A Substance P competitive ELISA kit (Enzo Life Sciences, Farmingdale, NY) was used 
according to the manufacturer’s instructions. The 405 wavelength was read using an 
Epoch plate reader (BioTek, Winooski, VT, USA) without correction, and the standard 
curve was fitted with the appropriate nonlinear or polynomial regression using Gen5 
software (BioTek, Winooski, VT, USA). Sample concentrations were calculated based on 
the best fit curve, usually a non-linear 5PL, 4PL regression or second order polynomial.  
6.4 Results  
6.4.1 DRG Cell Culture 
Neonatal rat DRGs were successfully dissociated, seeded, and cultured within various 
microfluidic devices (Figure 6.2). Neonatal and adult rat DRGs were successfully 
dissociated, seeded, and cultured within cell culture dishes.  
6.4.2 High Potassium Stimulation of Cells in Dishes and Microfluidic Devices 
High potassium stimulation of cells dissociated from adult and neonatal rat DRG resulted 
in calcium influx into the cells as shown by calcium imaging, both in normal bath culture 
stimulations as well as when stimulation media was flown across both axons and cell 
bodies within microfluidic devices (Figure 6.3). Additionally, stimulation with capsaicin 
resulted in calcium influx into the correct subset of small-diameter sensory neurons, 
validating that the cell culture contains nociceptive TRPV1 neurons, which would release 
substance P upon activation (Figure 6.3) [7].  
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6.4.3 Detection of Substance P in Homogenized DRG Tissue, Cultured DRG Cells, 
and Release Samples 
Substance P was detected in cultured DRG cells via immunofluorescent imaging (Figure 
6.4), LC-QQQ-MS analysis, and ELISA. Substance P was also detected in homogenized 
DRG tissue via LC-QQQ-MS analysis, ELISA, and MALDI-TOF analysis (Figure 6.5).  
Two sets of stimulation experiments were performed using microfluidic devices and 
analyzed via ELISA and MALDI MS. The first experiment pooled 9 sets of samples while 
the second pooled 16. In both experiments, the MALDI analysis showed no identifiable 
substance P peak, whereas the ELISA did provide results (Table 6.1, Figure 6.6). The 
stimulation sample had the highest concentration of substance P with 4.9 pg/mL and 4.5 
pg/mL, respectively. Both controls contained no substance P, washes contained 2.3 
pg/mL and 2.9 pg/mL, respectively, and post sample contained 0 and 1.3 pg/mL, 
respectively. Due to the low concentrations of these release samples, further experiments 
were performed with larger cell amounts and with glass bottomed dishes, which allow for 
more complete sample collection. One set of these results shows control and stimulation 
samples containing similar amounts of SP (448 and 375 pg/mL, respectively), while the 
other shows control, stimulation, and post samples as exceeding the amount detectable 
by the assay (>10,499 pg/mL). Encouragingly, the wash, blank, and no stimulation 
samples (Figures 6.6 and 6.7) show low concentrations of substance P, except for in one 
instance in which the wash may have stimulated the cells, while the cell homogenate 




LC-QQQ-MS analysis shows similar signal intensity of substance P for all stimulation 
samples (in the hundreds of counts per second), with a ten-fold increase in intensity for 
the substance P detected in the cellular homogenate (Figure 6.8).  
6.4.4 Detection of Substance P Standard Dilutions using MALDI MS 
Substance P standard solutions were best detected using a triple-layer CHCA matrix 
application method with a cold, acidified water wash of the sample (Figure 6.9). They 
were not detected in media samples, even when detected in water samples diluted at the 
same time (Figure 6.10A and B). SPE did improve detection of substance P standards 
diluted with cell culture media, but not with water (Figure 6.10C and D). 
6.5 Discussion and Future Directions 
While it is unfortunate that we are yet unable to detect substance P in DRG release 
samples using MALDI MS, the data show that our cells do contain substance P, are being 
stimulated by our stimulation paradigms, and do release substance P in a detectable 
amount upon 60 mM K+ stimulation. We have targeted detection of substance P using 
QQQ-MS but have not been able to detect appropriate levels allowing for quantitation.  
While an obvious solution to this issue would be to increase sample amount, the eventual 
goal is to be able to detect release within small, specialized cell culturing systems. 
Therefore, sampling from ever-increasing amounts of cells does not seem like the best 
way forward. 
We have used multiple improvements to our sample preparation techniques for MALDI 
MS with the goal of detecting substance P (and, hopefully, other neuropeptides) at a 
physiologically relevant concentration. Through performing serial dilutions of a standard, 
we began simply, with diluted standard in water using our standard detection methods 
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with DHB in a 1:1 ratio. We quickly learned that this was not the best method for detection 
of substance P in our samples and tried a variety of matrix applications before settling on 
the triple layer CHCA application method. 
Since the actual cell release samples are not diluted in water but are instead collected 
within cell culture media, the next step was to test the detection of the standard dilutions 
in cell culture media. As expected, the salt content of the media masked the substance P 
in the samples, which was only detected after application of a solid phase extraction 
method, Zip Tipping the samples. However, the Zip Tipping of the samples only resulted 
in the detection of the standard at the highest concentration, leading us to believe that 
too much sample was being lost during the Zip Tip procedure itself. To curb sample loss 
during Zip Tipping, we decided to use a nonspecific blocking agent, bovine serum 
albumin, to block any surface that the sample came into contact with to decrease 
nonspecific or irreversible binding of the analyte to the various surfaces within the 
experiment. Unfortunately, this blocking step did not help with the analyte detection. 
While our current technology does not allow us to effectively use mass spectrometry for 
untargeted detection of neuropeptides released from sensory neurons in a spatially 
relevant manner, we are encouraged by the robustness of our current cell culture model 
to behave as expected. Once we gain the ability to detect expected neuropeptides at 
physiologically relevant levels, it should be straightforward to apply the sample 
preparation and detection methods to the sampling protocols to look for spatial 
differences in peptide release from the devices, differences in peptide release in cells co-
cultured with skin and/or spinal cord cells, and differences in peptide release based on 



















Figure 6.2: DRG cells were successfully cultured in microfluidic devices. A: DRG cells in the cell 
culture well of an SND150, DIV 7. B: SND150 with axons crossing through the microchannels to 
the axon side (black arrow). C: axons (black arrows) can be seen crossing through the 









   
Figure 6.3: Calcium imaging of adult and P3 DRG cells cultured after 24 hours. A: appropriate 
sensory neuron stimulation via 1nM capsaicin versus 60 mM KCl, red denotes calcium influx into 
the cell. B: plot of 340/380 ratio over time for specific neuronal cell bodies. C and D: stimulation 
of axonal side of microfluidic device, led to activation of two sensory neuron cell bodies. 





Figure 6.4: Immunofluorescent staining of DRG cells in culture. Red: substance P; Green: β3 





Figure 6.5:  Substance P (m/z 1347, circled) was detected using MALDI-TOF MS analysis in 





Figure 6.6: Concentrations of substance P measured by ELISA in cell culture releasates at 






Figure 6.7: Comparison of stimulation versus no stimulation concentrations of substance P 




Figure 6.8: Representative spectra of substance P was detected in stimulation release samples 
and cultured cell homogenate samples using LC-QQQ-MS. Peaks with similar intensities were 
detected for control, wash, stimulation, and post samples while the cultured cell homogenate 





Figure 6.9: Substance P (m/z = 1348.5) peak detected in 7 out of 9 dilutions using the CHCA 



















Figure 6.10: Substance P dilutions in water (A and C) and media (B and D). Substance P (m/z 
1347.8) can be detected in 100nM, 10 nM, 1nM, 10 fM, and 1fM dilutions in water (A), but cannot 
be detected in any dilutions in media (B). After using solid phase extraction, Substance P could 
be slightly detected in 100 nM and 10 nM dilutions in water (C), and well detected in 100 nM 























    
 
Microdevices 30 DRGs in dishes 12 DRGs in GB dish 
 
9 pooled 16 pooled Normal Glass-bottomed 
Blank  --- --- 223 1.42 --- 
Control 0 0 448 >10500 69 
Wash 2.3 2.9 211 96 109 
Stimulation 4.9 4.5 375 >10500 86 
Post 0 1.3 182 >10500 >10500 
No Stimulation --- --- --- 19.5 0 
Homogenized Cells --- --- 2532 --- --- 
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 Advancements Toward a Biologically Relevant DRG Culture System 
7.1 Notes 
Much of the cell culture and imaging described in this chapter was performed by 
undergraduate assistants Yujin Lee, Ashley Lenhart, and Zachary Daniels. Yujin also 
created the CAD designs for our microfluidic device prototypes. Additionally, this project 
relies on the microfabrication expertise of Dr. Mikayla Yoder and Hanxiao Su, 3D printing 
expertise of Dr. Sean Lehman, the patience of photomask maker Jeff Grau, and the 
guidance and advice of Drs. Adina Badea, Joselle McCracken, Ralph Nuzzo, and 
Stanislav Rubakhin. 
7.2 Introduction 
As discussed in Chapter 2, there are many reasons why creating a physiologically 
relevant system is important for the study of neurochemistry, particularly when the goal is 
to characterize molecules that are released from cells at low concentrations under specific 
conditions. For this reason, and because of marked differences between the morphology 
of DRG cells in culture versus in vivo [1-3], we decided it is important to move away from 
bath stimulations of DRG cells in culture and move toward systems that are more 
physiologically and structurally relevant. We have worked toward accomplishing this goal 
by focusing on a few areas of cell culture improvement: growing aligned axons, spatial 
separation of nerve endings and cell bodies, and co-culture with relevant cell types. 
When DRG cells are dissociated and seeded onto a flat surface, they extend more than 
one axon and these axons grow in many directions (Figure 7.1). This increased axonal 
output and lack of directionality does not provide a structurally relevant model for chemical 
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release. Within the body, the axons of primary sensory neurons travel together in parallel 
within the nerve either toward the nerve endings of the skin and viscera or toward the 
secondary sensory neuron within the spinal cord [1, 2]. This set-up allows the nerve 
endings of the primary sensory neurons to detect stimuli and communicate that 
information from the periphery to the spinal cord [2].  Neuropeptide release occurs both 
at locations within the skin and within the spinal cord, facilitating this communication [4]. 
Therefore, to accomplish the goal of understanding neuropeptide release from sensory 
neurons upon specific stimulation, it is important to replicate the structural relationship 
found in vivo. To do so, it is helpful to create a culture system which promotes growth of 
straight and aligned axons as well as separates the cell bodies spatially from the nerve 
endings.  
Microfluidic devices are devices that utilize the physics of small volume fluidics for a 
specific outcome. In biological applications, microfluidic devices can be used for small 
volume cell culture applications using micrometer size features, such as channels and 
patterns. These features are useful for providing growth guidance as well as spatial 
separation of DRG neuron cell bodies and axonal endings [5-8]. Microfluidic devices used 
for the culture of neurons usually consist of separate compartments for cell seeding and 
axonal growth connected by a series of microchannels. The microchannels are small 
enough to allow only the axons and cell bodies of small glial cells through them, providing 
structural separation. Additionally, fluidic isolation can be achieved between the different 
cell culture chambers by keeping the fluid levels within the cell culture chambers equal.  
Another application of microfluidic devices is that they are useful for guiding, 
compartmentalizing, and controlling interactions between different types of cells cultured 
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within the same device [5, 9-11]. This functionality is one that we considered in our design 
of the new device, since the DRG neurons interact with multiple cells, especially 
keratinocytes and secondary sensory neurons. Creating a device in which these cells can 
be cultured within separate compartments in an appropriate structural paradigm is 
paramount to the relevance of in-device cellular stimulation and release studies. 
Keratinocytes, a type of skin cell, are a target for sensory neuron innervation, particularly 
by C-fibers [12]. Various studies have demonstrated successful co-culture of 
keratinocytes and dorsal root ganglion cells as well as functional interactions between the 
two cell types [12-15]. Particularly useful to our project is the demonstration that sensory 
nerve endings can influence the growth of keratinocytes through specific release of the 
neuropeptide CGRP [15] and that the presence of keratinocytes in cultures with sensory 
neurons changes the neuropeptide content of the innervating fibers [12].  
At the other end of the system, secondary sensory neuron cell bodies are located in the 
dorsal horn of the spinal cord and are what the primary sensory neurons synapse onto to 
communicate information from the periphery to the higher order brain structures [4]. Co-
cultures of both DRG cells and explants with dorsal horn neurons from the spinal cord 
have also been successful at demonstrating functional connections between the cell 
types in vivo [16-19] and researchers have even gone so far as to use these co-cultures 
for potential therapeutic studies [20].  
With DRG, it is also possible to culture the entire structure as an explant [16, 21, 22]. 
While the explant method is helpful for maintaining the correct cell ratios and structure of 
the ganglia, both sustaining the viability of the tissue and supporting robust axonal 
outgrowth can be challenging. However, improved methods of three-dimensional 
162 
 
culturing, such as those discussed in Chapter 2, may improve upon those challenges and 
make DRG explant culture a viable option for future work performed in these devices. 
7.3 Experimental  
7.3.1 DRG Cell Isolation and Culture 
DRG were isolated from postnatal day 2-5 rats and sustained in a bath of ice cold 
Hibernate A (BrainBits Springfiled, IL) for up to 24 h before dissociation. DRG were 
digested in a solution of 0.2% type II collagenase and 0.6% protease in DRG serum-free 
media containing Neurobasal A without phenol red (Life Technologies Carlsbad, CA), 100 
U/mL penicillin/streptomycin (Life Technologies), 0.5 mM GlutaMAX (Life Technologies), 
50 ng/mL NGF (Life Technologies), 50 ng/mL BDNF (Prospec Bio Rehovot, Israel), and 
500 µL B27 Growth Supplement (Life Technologies) for 30 min at 37 ºC. After digestion, 
the samples were subjected to centrifugation for 2-3 min at 200 xg. The supernatant was 
removed, and the pellet washed with Hank’s Balanced Salt Solution (HBSS) (Life 
Technologies). Upon centrifugation using the same parameters, the supernatant was 
once again removed and the pellet triturated using fire-polished pipets. Following 
trituration, some of the pellet was allowed to re-settle. Once a small pellet was formed in 
the bottom of the microcentrifuge tube, the supernatant was removed and centrifuged. 
After centrifugation, the supernatant was removed and the pellet washed with HBSS. A 
final centrifugation was performed after which the pellet was resuspended in 200 µL of 
media and 20 µL of cell suspension was added to the cell seeding well of a device treated 
with poly-D-lysine (BD Biosciences Franklin Lakes, NJ) and laminin and incubated for 30 
min at 37 ºC. If appropriate, the device was tilted to enhance movement of cells toward 
the microchannels. After 30 min, all wells were filled with 150 µL of media. The cells were 
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incubated at 37 ºC, with a media change at 24 h and then every 3 d until the cells were 
used for experiments. 
7.3.2 Keratinocyte Isolation and Culture 
Keratinocyte dissociation followed the protocols outlined in two recent papers [5, 23]. 
Briefly, the skin was removed from 2-d old rats and stretched dermis side down onto an 
untreated polystyrene cell culture dish and kept cold for approximately 1 h. Next, the skin 
was transferred dermis side down onto a 0.25% solution of trypsin without EDTA in HBSS 
and incubated floating on the solution overnight at 4 ºC. After incubation, the skin was 
stretched epidermis side down onto an untreated polystyrene cell culture dish in a sterile 
cell culture hood and the dermis was carefully removed using forceps. The dermis was 
moved into 10 mL of cold DMEM and cut with sterilized scissors until the skin pieces were 
small enough to be triturated by a 10 mL pipet. After trituration, the triturated solution was 
transferred into a 15 mL conical tube while leaving behind as many sheets of tissue as 
possible. The solution was centrifuged at 200 xg for 5 min, the supernatant was aspirated 
and pellet was re-suspended in DMEM and passed through a 70 µm cell filter. The filtrate 
was centrifuged again, supernatant aspirated, and the pellet was resuspended in 200 µL 
of a media consisting of 2:1 solution of DMEM:F12 supplemented with 5% FBS and 10% 
Pen/Strep. Cells were counted and the sample was adjusted to 50,000 cells per 10 µL 
solution and 10 µL solution was seeded into the prepared well of the microfluidic device. 
After 30 min of seeding, 100 µL of the DMEM/F12 media was added to each keratinocyte 





7.3.3 Secondary Sensory Neuron Isolation and Culture 
Secondary sensory neuron isolation was carried out following a process outlined by 
Vikman et. al. [17]. First, the spinal cord was dissected out of the rat. Then, the dorsal 
third of each side of the spinal cord was removed and incubated in 0.25% Trypsin for 20 
min at 37 ºC. After incubation, the spinal cords were rinsed with HBSS and triturated in 
cell culture media containing 1% FBS. After a final centrifugation, the cells were re-
suspended in cell culture media and seeded at 20,000 cells per well. Media changes 
occurred every 3 d. 
7.3.4 Explant Cultures 
DRG explants were placed on a PDL and laminin coated glass surface, PDMS slab, or 
PDMS slab with microchannels, and media was carefully exchanged every 1-3 d. So as 
not to disturb the explant, the media exchange was performed as slowly and as far away 
from the explant as possible. 
7.3.5 Stamping 
A PDMS mold with various sized microgroves was used as the stamp. The stamp was 
incubated in a 100 µg/mL PDL and laminin solution for 1.5 h, dried, and placed onto an 
ethanol-cleaned glass coverslip. Initial tries used fluorescent PDL and lines were detected 
on the coverslip after stamping. Cells were seeded onto glass slides at various densities. 
7.3.6 Microfluidic Device Design and Preparation 
The commercially available microfluidic devices used in this project were purchased from 
Xona Microfluidics. The devices included the Standard Neuron Device (SND) 150 and 
450 and the Tri-Chamber Device (TCD) 500. Device preparation for cell culture followed 
the protocol outlined in the product manual. Briefly, the microscope slides upon which the 
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devices were placed were cleaned with 70% ethanol or isopropanol in a sterile cell culture 
hood for 30 min and then air dried for 30 min in the sterile cell culture hood. They were 
then incubated with 0.5 mg/mL PDL in sterile water at 37 °C for at least 4 h.  After 
incubation with PDL, the surfaces of the slides were washed 3 times with sterile water 
and the slides were incubated in sterile water for at least 3 h and dried in the sterile cell 
culture hood, usually overnight, but for at least 2 h. 
The in-house designed microfluidic devices used in this project were designed using CAD 
software. The design includes cell culture chambers divided by microchannels and an 
elongated axonal growth area which will house 3D printed poly-2-hydroxyethyl 
methacrylate (HEMA) laponite constructs for axonal guidance and improved nerve-like 
growth (Figure 7.2). The first iteration consists of a central DRG cell culturing channel 
with a “central” (left) and “peripheral” (right) cell culture chamber, each separated by an 
axonal growth chamber, all separated by microchannels (10 µm wide, 3 µm high, 200 µm 
long for the outside microchannels, 100 µm long for the inside microchannels). The 
second iteration consists of three cell culture chambers separated by microchannels (10 
µm wide, 3 µm tall, 200 µm long for the outside microchannels, 100 µm for the inside 
microchannels) and one large 5 mm axon growth chamber, in which the poly-HEMA 
laponite constructs are placed to encourage axonal growth. The cell culture and growth 
chambers are 50-100 µm high, 5-6 mm long and 0.5-5 mm wide. The device requires a 
two-layer photolithography mask process, which means that two photomasks were 
created, one with the microchannels, which are 3 µm high, and the other consisting of the 
rest of the features, with the SU-8 spun to 100 µm. Once the SU-8 mask was created, the 
devices were molded using sylgard-187 poly-dimethylsiloxane (PDMS) and allowed to 
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cure for at least 24 h at 65 °C. Once fabricated, the devices were treated in the same 
manner as the commercial devices. 
On cell culture day, the microfluidic devices were removed from their packaging and extra 
dust was removed using scotch tape. Then, the devices were incubated in 70% ethanol 
for 30 minutes and air dried in the sterile cell culture hood for 1 h. Once the devices were 
dry, they were placed onto the PDL-coated, dried microscope slides and pressure was 
applied to form a seal. 0.2 mg/mL laminin was flown through the device in a sequential 
manner to allow full coverage of the cell culture surfaces with laminin. Full incubation time 
for laminin is 1 h at 37 °C. After laminin incubation, the laminin was washed out with either 
sterile water or media, and cell culture media was added to the wells and incubated for at 
least 1 h, or until the cells were ready for seeding. If the device was also used for 
keratinocytes, the side of the device that held keratinocytes was additionally coated with 
30 µg/mL collagen and 10 µg/mL fibronectin for 30 min.  
For DRG cell seeding, the cell pellet was re-suspended in 200 µL of media and 20 µL of 
cell suspension was added to the cell seeding well of the device and incubated for 30 min 
at 37 ºC. If appropriate, the device was tilted to enhance movement of cells toward the 
microchannels. After 30 min, all wells are filled with 150 µL of media. The media was 
exchanged 24 h after cell seeding and then once every 3 d after that.  
For keratinocyte seeding, the cell pellet was re-suspended so that there are 50,000 cells 
per 10 µL of solution and 10 µL were added to the keratinocyte side of the device. After 
the 30 min incubation period, 100 µL of media was added to the wells leading to the 
keratinocyte channel, to ensure flow from the neuronal channels to the keratinocyte 




DRG media was replaced with a 4% paraformaldehyde (Ted Pella, CA) fixation bath at 
room temperature for 15-20 min. The cells were then washed with PBS (Life Technologies 
Carlsbad, CA) five times, with the last wash lasting 5 min with shaking. 0.25% Triton X 
(Sigma-Aldrich St. Louis, MO) was added to the cells for 10 min to permeabilize the 
membranes. A wash was performed and a blocking solution of 5% normal goat serum 
(NGS) (Life Technologies) in PBS was added for 30 min for dish cultures and 1 h for 
devices with shaking. Another wash step was performed and the primary antibody in a 
2% NGS solution was added and incubated overnight at 4 ºC. After incubation, a wash 
was performed, and the second primary antibody was added and incubated overnight. 
After that incubation, another wash was performed and the secondary antibody in a 2% 
NGS solution was added to the culture for 1-2 h. If 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) was used, the culture was rinsed and DAPI added to the culture 
and incubated for 20 min. Finally, the cells were subjected to a final wash step, rinsed 
with deionized water for 30 s, and mounted with ProLong Gold Antifade (Life 
Technologies) onto a glass slide. If not visualized immediately, the slides were kept in the 
dark at 4 °C until imaging with a Zeiss Axio Imager M2 (Carl Zeiss AG, Oberkochen, 
Germany). Primary Antibodies: Rabbit monoclonal glutamine synthetase antibody 
(Thermo Fisher Scientific), mouse monocolonal anti-beta-III tubulin (Santa Cruz 
Biotechnology, Santa Cruz, CA); rabbit anti-cytokeratin 5 (ab53121) (Abcam, Cambridge, 
MA) and DAPI nuclear stain (Thermo Fisher Scientific). Secondary antibodies: Alexa 




7.4 Results and Discussion 
7.4.1 Stamping 
The stamping of PDL onto glass slides was successful. After the addition of cells, a trend 
can be seen in which the cells align and grow along the PDL in straight lines. However, 
there is too much cross over between axons that grow on one line and then move toward 
another as well as too many cell bodies located throughout the culture (Figure 7.3) for 
stamping to remain a viable method for growing sensory neuron axons in a straight line.  
7.4.2 Microfluidic Devices 
Successful growth of axons through the microfluidic device microchannels was difficult to 
obtain. For over a year, we worked to improve axonal migration through the channels by 
optimizing many parameters including cell seeding concentration, device position, growth 
factor gradients, use of bovine serum albumin during the dissociation procedure, and 
more. We finally obtained success by switching to neonatal animals. Once the switch was 
made, no adjustments were needed to the cell culture protocol to encourage axon growth 
through the microchannels. At that point, we worked to determine which type of device 
and microchannel length was best for our purposes (Fig 7.4). The cell growth occurs quite 
quickly through the SND 150 and the exchange of fluids may be difficult to control during 
the stimulation protocol. The SND 450 and TCD 500 both provide good separation while 
maintaining successful cultures. The TCD 500 allows for even greater control as there 
are 3 cell culture channels.  
7.4.3 Co-cultures 
Keratinocyte co-culture was attempted once with success (Figure 7.5). The main issue is 
that only a small portion of the cells on the keratinocyte side of the device stained with 
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anti-cytokeratin 5, an appropriate marker for keratinocyte cells. Therefore, we need to 
identify the other cells in the culture are and if it is appropriate to have them in the co-
culture system or if we need to find ways to remove them. 
Spinal cord co-culture has been attempted, but not been met with success. However, the 
culture was attempted using whole spinal cord tissue. The prospect of only dissecting and 
dissociating the dorsal horn of the spinal cord is not only biologically sound, but also 
seems promising due to published results of both embryonic and neonatal dorsal horn 
tissue being used for successful studies [17-20]. 
7.4.4 Explant Cultures 
Successful culture of DRG explants is well documented in the literature [21, 22, 24]. Initial 
forays into explant cultures were unsuccessful due to limited axonal outgrowth. However, 
recent attempts to culture explants along a series of microgroves within a PDMS block 
has been met with modest success (Figure 7.6). While there are no signs of direct axonal 
outgrowth from the explants, there are areas of cell growth along the microgrooves that 
may have been where the explants were connected to the device at one point. In addition, 
there is evidence of cellular outgrowth from some, although not all, of the explants. 
7.4.5 Primary Sensory Microphysiological System Iteration 1 
The first iteration of our primary sensory microphysiological system was designed to 
address the limited length of axonal outgrowth allowed for in the commercial devices. 
Therefore, our system consisted of five chambers fluidically isolated by microchannels 
(Figure 7.7). More specifically, the chambers included a central chamber for primary 
sensory neuron culture, two middle chambers for axonal growth and two outer chambers 
for target cells such as skin and spinal cord cells. The central and outer chambers were 
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connected to inlet and outlet ports for cell and media addition and sample collection. We 
were able to successfully fabricate the devices as well as culture and sustain cells within 
the device for up to 1.5 weeks. One challenge raised by this design was that it was difficult 
to get the axons to travel through the middle chambers to the outer microchannels. 
Therefore, it was ultimately decided that the device could benefit from axonal guidance 
through the middle chambers, so a second iteration was designed. 
7.4.6 Primary Sensory Microphysiological System Iteration 2 
The goal of the second device design was to provide axonal guidance through the 
elongated axonal culture area. This ability is necessary for the re-creation of the in vivo 
structural relationships of primary sensory neurons. To do this, we introduced poly(2-
hydroxyethyl) methacrylate (pHEMA) laponite XLG (LAP) (LAP; Na+0.7 [(Si8 Mg5.5 Li0.3) 
O20(OH)4]-0.7) scaffolds to our device. pHEMA is a neutral hydrophilic polymer hydrogel 
material amenable to 3D printing by direct ink-writing, which makes it useful for printing a 
scaffold design onto a slide which will house the microdevice [25]. LAP is a silicate 
nanoclay inorganic composite that, when incorporated into HEMA-based inks, increases 
the buildability of the ink, providing more options for scaffold shape design. On-going work 
in the Nuzzo group shows that pHEMA-LAP ink is a promising guidance structure for 
nerve-like growth of DRG cells in culture [26].  
We also lengthened the axonal chamber within which the scaffold would be placed and 
re-imagined the device to have four chambers: one for primary sensory neuron cell 
culture, one for axonal outgrowth, and two for target cell culture (Figure 7.8). The left-
most chamber is separated from the middle chamber by 100 µm length microchannels, 
which represent the relatively short distance that the axons travel into the spinal cord. The 
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middle chamber with inlet and outlet ports is for primary sensory neuron cell culture, while 
the 5 mm long middle chamber without inlet and outlet ports is the axonal growth 
chamber, where the scaffolds are placed. The right-most chamber is separated from the 
axon chamber by 50 µm length microchannels and is meant for the culture of skin target 
cells.   
The assembly of this device requires printing the scaffold onto a glass slide, 
functionalizing it, and then placing the microfluidic device over the scaffold so that the 
scaffold fits inside the axonal elongation chamber (Figure 7.8). Preliminary cell culture of 
primary sensory neurons within this device was also successful, although moving fluid 
into the large axonal chamber is challenging. We now include the punching of media inlet 
holes into the PDMS as part of our procedure to add cell culture media directly to the 
axonal chamber.  
7.5 Conclusion 
This chapter has outlined our movement toward building a more physiologically relevant 
system for growth, stimulation, and release of neurochemicals from DRG cells. First with 
the transition to using microfluidic devices and then through each new device design, we 
moved closer to the desired functionality. The success of culturing neonatal DRG cells in 
the newly designed microfluidic devices allows us to move forward with further 
characterizing axonal growth along the incorporated scaffolds. Of course, our ultimate 
goal is to use the device to build a complete microphysiological system, including DRG, 
DH, and skin cells, allowing us to study cellular stimulation and release utilizing relevant 
structural and functional relationships between the cultured cells. Our initial success with 
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both the first and second iterations of our new device is encouraging, and we are excited 

















Figure 7.2: The first (left) and second (right) iterations of the microfluidic portion of the primary 
sensory system microphysiological device. The first iteration consists of a central DRG cell 
culturing channel with a “central” (left) and “peripheral” (right) cell culture chamber, each 
separated by an axonal growth chamber, all separated by microchannels (10 µm wide, 3 µm high, 
200 µm long for the outside microchannels, 100 µm long for the inside microchannels). The 
second iteration consists of three cell culture chambers separated by microchannels (10 µm wide, 
3 µm tall, 200 µm long for the outside microchannels, 100 µm for the inside microchannels) and 
one large 5 mm axon growth chamber, in which the poly-HEMA laponite constructs will be placed 





Figure 7.3: DRG cells plated at high concentration (A and B) and low concentration (C and D) on 











Figure 7.4: Panel A: DRG cells cultured in TCD 500. Top to Bottom: Far axonal well, middle well, 
cell seeding well. Left are brightfield images at DIV 6, right side are representative fluorescent 
images from similar areas of the device, at the same magnification. Green: Beta 3 tubulin, 
neuronal marker; red: glutamine synthetase, glial marker; blue: DAPI, nuclear marker. Panel B: 
DRG cells cultured in SND 450 DIV 6; top: cell seeding well; bottom: axonal well. Panel C: DRG 













Figure 7.5: DRG cell-Keratinocyte co-culture in SND450. Green: beta-III tubulin neuronal marker; 
red: cytokeratin 5 keratinocyte marker; blue: DAPI nuclear stain. Top (L-R): Control DRG cell 
culture brighfield image with cells on left and axons on right; overlay of brightfield and 
immunofluorescent images; axonal side of microfluidic device. Bottom (L-R): DRG cell-
keratinocyte co-culture with DRG cells seeded on left side and keratinocytes seeded on right; 
immunofluorescent image of both sides of co-culture with keratinocytes are only on right side of 
device; immunofluorescent image of axonal/keratinocyte side of microfluidic device.    
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Figure 7.6: Axonal outgrowth from DRG explants. A: cellular growth along microchannels from 
cells deposited by an explant which is no longer attached to the PDMS substrate. B: Cells left on 
the PDMS by an explant which is no longer attached to the substrate. No outgrowth is observed 
from the cells. C: Direct cell outgrowth from a small explant. D: No cell outgrowth noticed from a 










Figure 7.7: The first iteration of the primary sensory microphysiological system. Top: design of 
the microfluidic system. Left: microchannel layer (length 200 µm for outer channels, 100 µm for 
inner channels, height 3 µm for all); middle: cell culture chambers (height 100 µm), and input and 
output wells; right: zoomed in image of one device design. Bottom: DRG cells cultured and 








Figure 7.8: Top: Complete microphysiological system iteration 2. Bottom: DRG cells cultured 
within the microphysiological system iteration 2 and interacting with the scaffold (top right corner 
of left image, across center of right image).  
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Conclusions and Future Outlook 
8.1 Conclusion  
Within this dissertation, I have explored the neurochemical contents of the dorsal root 
ganglia, their cells, and their interfacing tissues, as well as the ability to measure 
neuropeptide release from such systems. Along the way, I became interested in the 
creation of a structurally relevant cell culture system for the primary sensory neurons as 
well as validated our cell culture and stimulation/release paradigms.  While much work 
remains to be done in these categories, I have created a solid platform from which future 
projects can move. 
8.2 Future Outlook 
8.2.1 Itch Peptide Studies 
The validation set of itch peptidomics experiments is underway. If we find specific 
peptides that are reliably changing in the itch model treatment versus control, we should 
both follow up with validating the itch-related function of these peptides as well as look 
into the dynamics of those peptide within the system. For example, it is not enough to just 
know that a particular peptide changes in amount, instead it would be better to track that 
peptide over time to understand dynamically when that peptide is involved in the cellular 
response to the treatment. These types of experiments are much more involved, but could 
be extremely useful in understanding the pathogenesis of such diseases. 
Additionally, it would be useful to develop an improved method for neuropeptide 
extraction from skin. So far, we have not been able to successfully extract neuropeptide 
signal from skin samples, as the peptides derived from skin proteins are so much more 
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prevalent they saturate the system. The nerve endings in the skin are important sensory 
and release sites for perturbations, so it would be particularly useful to understand what 
neuropeptides are responding at the site of damage and which neuropeptides might be 
implicated in continuing the sensitization and disease response cycle.  
Finally, I could see the integration of different aspects of my project by using the 
microphysiological system described in Chapter 7 to better study the release mechanisms 
of the peptides that are identified as important to the pathogenesis of itch. 
8.2.2 Cellular Release Measurements 
The ability to detect neuropeptides released from cells in an untargeted way is an area of 
possible growth for this project. My results have shown that it is possible to culture small 
amounts of cells within restricted spaces and detect release of a neuropeptide, Substance 
P, from those cells using enzyme-linked immunosorbent assay (ELISA). However, we 
have been unable to detect similar levels of peptide release using current mass 
spectrometric techniques that are amenable to untargeted studies. Of course, there are 
many options for targeted studies of such release. However, when studying a system as 
complex as the neuropeptide system, it is important to detect the multiple peptide players 
that might be involved in a single response to a perturbation rather than just target one or 
two. Therefore, I could see the integration of the cell culture and ELISA techniques 
outlined in Chapter 6 to guide improvements in sample preparation and analyte detection 
methods for untargeted mass spectrometry of cellular release.  
8.2.3 Microphysiological System 
The microphysiological system project has a variety of directions for potential growth. 
First, the integration of the hydrogel scaffold within the microfluidic device is a novel idea 
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for which we have overcome some logistical challenges. By having the successful 
integration of such a scaffold within our device, we open the possibility of testing a variety 
of scaffold designs within that designated space, particularly to determine the best design 
for generating a nerve-like structure within the device. Once this type of structure is 
developed within the device, we can then use the device to study other aspects of nerve 
growth, such as regeneration or myelination, within a controlled, but more structurally 
relevant growth system than others available.  
Second, it is the ultimate goal to grow spinal cord neurons, DRG neurons, and skin cells 
within the same device to create a biologically relevant stimulation and release model. 
The device was designed with that goal in mind and, therefore, it would be an obvious 
next step to incorporate other cells into the device. Once incorporated, we would study 
how the cells interact, what type of innervation may occur, and how the presence of 
certain cell types within the system may influence stimulation, release, and possibly the 
progression of injury response. 
8.2.4 Single Cell Peptide Profiling 
Although I didn’t discuss it within this dissertation, I would like to address the potential 
importance of and use for single cell peptide profiling within the sensory system. Primary 
sensory neurons are divided into subtypes based on morphology and protein expression, 
and these subtypes can be related to functionality [1-6]. Within the DRG are various types 
of sensory neurons, classified by size, myelination state, immunohistochemical staining, 
and physiological response to stimulants. There are multiple studies characterizing 
subpopulations of DRG sensory neurons, which has become increasingly complex [1-7]. 
Historical characterizations loosely conform to basic categories: 1) large and medium 
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diameter low-threshold mechanoreceptors, which express heavy-chain neurofilament 
(NF)200 and the neurotrophin receptors trkA, trkC, and p75NTR; 2) small diameter 
unmyelinated polymodal nociceptors or thermoreceptors that constitutively synthesize 
CGRP and express trkA; and 3) small diameter unmyelinated polymodal nociceptors 
which bind lectin Griffonia simplicifolia isoelectin B4 (IB4), with some overlap between 
CGRP positive neurons and both NF200 and IB4 populations [1-7].  
However, recent efforts have used single cell transcriptomics to distinguish between DRG 
neuronal subtypes with unprecedented detail [7]. While it is encouraging that further 
information and classifications have been discovered about sensory neuron subtypes, the 
influx of transcriptomic data lead us to wonder what the actual peptide content of these 
cells might be, and if we could differentiate between cellular subtypes using mass 
spectrometry. Theoretically, we should be able to distinguish between cell subtypes using 
peptide profiles with the same, if not increased, detail as the transcriptomic studies.  
There are many approaches to single cell peptidomics [8]. Single-cell peptide studies 
require a highly sensitive approach that can characterize analytes on a subcellular level, 
such as matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-
MSI). The Sweedler lab has already used MALDI-MSI to probe the chemical 
heterogeneity of DRG slices and to compare the chemical profile of these slices to 
surrounding structures [9] as well as used single cell MALDI-MS profiling to characterize 
cellular subpopulations [10]. These initial proof of concept studies utilized cells and 
cellular subpopulations that contained a relatively high abundance of peptides which were 
easily distinguished from each other, such as Aplysia californica and pancreatic islet cells.  
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Throughout my graduate career, the idea of using single cell peptide profiling to 
differentiate between sensory neuronal subtypes was compelling. I performed various 
studies but found it difficult to detect expected neuropeptides within the DRG cells. During 
this time, a post-doctoral researcher in our lab, Dr. Thanh Do, took up the project and was 
able to use peptide profiling to differentiate subtypes of sensory neurons [11]. This work 
is extremely promising. However, we did not compare the mass spectrometric subtypes 
that were obtained in our study to the current biological/morphological subtypes in use 
today. Therefore, it is a logical next step for our lab to use immunofluorescent and 
morphological measurements to complement mass spectrometry peptide profiling results 
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